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In everyday life, consumers are exposed to a wide variety of chemicals used in 
personal care products (PCPs). The use of chemicals in PCPs raises questions with 
consumers, such as: “If I use this product, what do I apply to my skin?”, “Will the 
product or its components be taken up?”, “Is this harmful for me or my children?”, 
or “Is it okay to use a lot of this product?”. These questions are understandable 
DQG MXVWLÀHG DV FHUWDLQ LQJUHGLHQWV RI 3&3V DUH DVVRFLDWHGZLWK RU VXVSHFWHG
of adverse health effects, such as endocrine disruption (1-3), allergic contact 
dermatitis (4, 5), neurotoxicity (7, 8) and an increased risk of breast cancer (9). 
To establish a high level of protection of human health and the environment, 
legislation was implemented by the European Union. In 2006, the Registration, 
Evaluation, Authorisation and Restriction of Chemicals (REACH) directive entered 
into force (11). Manufacturers are responsible to provide the evidence that 
chemicals produced and placed on the market are safe. Registration of these 
chemicals is the main aspect of the REACH system. If a chemical, imported or 
manufactured in a quantity of 10 tonnes or more per year, is registered, a complete 
human and environmental risk assessment is required. This introduction presents 
the general concept of human health risk assessment and discusses current 
SULQFLSOHV DQG SUDFWLFHV RI HDFK VHSDUDWH VWHS KD]DUG LGHQWLÀFDWLRQ KD]DUG
characterization, exposure assessment, and risk characterization. Subsequently, 
more detailed insight is given into one aspect of human health risk assessment, 
namely consumer exposure assessment and its current practices, as lead-in to 
the objectives of this thesis. At the end of this introduction, the design and outline 
of the thesis are described. 
Risk assessment 
Human health risk assessment of consumer products consists of four steps (Figure 
1.1) (6, 12, 13). Risk assessors make a distinction between threshold and non-
threshold substances (14). Threshold substances have a “threshold” below which 
adverse health effects are not observed. In contrast, exposure to non-threshold 
substances could lead to an adverse health effect even at the lowest dose.
+D]DUGLGHQWLÀFDWLRQ
7KHÀUVWVWHSKD]DUGLGHQWLÀFDWLRQLQYROYHVWKHLGHQWLÀFDWLRQRIWKHLQWULQVLFWR[LF
properties of a substance and the determination of whether these properties can 
cause adverse health effects in humans (e.g., diseases, development of tumours, 
reproductive effects, or death). The toxicokinetic and toxicodynamic properties 
RIDVXEVWDQFHDUHNH\FRPSRQHQWVLQKD]DUGLGHQWLÀFDWLRQ+D]DUGDQGULVNDUH
often mixed up, but are actually two different concepts. A toxic substance may 
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be hazardous and able to cause adverse health effects, but as long as no or no 
UHOHYDQWH[SRVXUHRFFXUVLWGRHVQRWSRVHDVLJQLÀFDQWKHDOWKULVN
Hazard characterization
The second step, dose-response assessment or hazard characterization, is the 
estimation of the relation between dose or level of exposure to a substance and 
the occurrence and severity of an adverse health effect. The majority of the studies 
used for this purpose are animal experiments, but data from observational human 
studies are being used as well. Because animals and humans are different and 
humans differ from one another, uncertainty factors are taken into account in the 
assessment of a human health risk. Both animal experiments and epidemiological 
studies are used to identify a starting point for human health risk assessment. 
7KHLGHQWLÀHGGRVHLVUHIHUUHGWRDVWKH5HIHUHQFH3RLQW53RU3RLQWRI'HSDUWXUH
(PoD) (6, 15)7KHSUHIHUUHGZD\WRGHÀQHDQ53IRUQRQJHQRWR[LFDVZHOODVIRU
genotoxic substances is the Benchmark Dose concept (BMD) (16). The BMD is 
a dose level, derived from the estimated dose-response curve, associated with 
DVSHFLÀHGFKDQJHLQUHVSRQVHWKH%HQFKPDUN5HVSRQVH%057KH6FLHQWLÀF
committee of the European Food Safety Authority (EFSA) proposes that the default 
value for BMR should be 5% for continuous data and 10% for quantal data derived 
IURP DQLPDO VWXGLHV 7KH %0'/ WKH ORZHVW FRQÀGHQFH ERXQG RI WKH %0' LV
normally used as the RP (15). Previously, the No-Observed-Adverse-Effect-Level 
(NOAEL) was often used, which is the highest dose tested that does not show a 
relevant adverse effect compared to a control group. However, in comparison with 
the BMD, the NOAEL has some limitations (15). First, the NOAEL approach does not 
HUMAN HEALTH RISK ASSESSMENT 
1. Hazard identification 
3. Exposure assessment 
4. Risk characterization 2. Hazard characterization  
Figure 1.1 Steps in human health risk assessment (6, 12, 13). 
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incorporate all experimental data available, as it only considers the effects of the 
doses tested, making the outcome dependent on the design of the experiment (i.e. 
the spacing between the doses tested). In the BMD approach, experimental data 
DUHÀWWHGWRDVHWRIGRVHUHVSRQVHPRGHOV7KHEHVWÀWZLOOOHDGWRWKHFDOFXODWLRQ
of a BMD and BMDL, taking into account all data available. This also leads to 
the possibility of interpolation between doses. Secondly, the NOAEL is sometimes 
interpreted as a “no effect” dose, leading to the false assumption that there is no 
observed effect of the dose tested. However, the effect might be too small to be 
detected in a particular study. As a consequence, the size of the possible effect at 
the selected NOAEL remains unknown. In the BMD approach, the size of the effect 
is known as it is set in advance as the benchmark response (critical effect size). 
7KLUGD12$(/YDOXHLVQRWSUHVHQWHGZLWKDFRQÀGHQFHLQWHUYDOPDNLQJLWGLIÀFXOW
WRDVVHVVXQFHUWDLQW\LQWKHFDOFXODWHGYDOXH$FRQÀGHQFHLQWHUYDOLVLQFOXGHGLQ
the BMD approach, which allows accounting for uncertainty especially as a result 
of limited or scattered data.
 
Exposure assessment
The third step, exposure assessment, is the process of measuring or estimating 
the magnitude, frequency, and duration of human exposure. The concept of 
consumer exposure assessment will be discussed separately below, as this topic 
is the main interest of this thesis. 
Risk characterization
7RJHWKHUWKHÀUVWWKUHHVWHSVRIWKHULVNDVVHVVPHQWSURFHVVOHDGWRWKHIRXUWK
DQGÀQDOVWHSULVNFKDUDFWHUL]DWLRQ5LVNFKDUDFWHUL]DWLRQLVWKHHVWLPDWLRQRIWKH
incidence and severity of the adverse effect likely to occur in a human population, 
taking into account all information collected during the previous steps. In the 
registration process of chemicals under REACH, risk is characterized using the risk 
FKDUDFWHUL]DWLRQUDWLR5&5)RUWKUHVKROGFKHPLFDOVWKLVUDWLRLVGHÀQHGDVWKH
UDWLRRIH[SRVXUHWRWKHGHULYHGQRHIIHFWOHYHO'1(/,IDFKHPLFDOLVFODVVLÀHG
without a threshold, the RCR is calculated as the ratio of exposure to the derived 
minimal effect level (DMEL). The DNEL is considered to be an overall NOAEL for a 
given exposure (route, duration, frequency), accounting for uncertainty/variability 
in these data and the human population exposed (17). If the exposure is smaller 
than the DNEL value, the risk is controlled. In case of exposure smaller than the 
DMEL value, exposure is controlled to a risk level of low concern (18). The margin 
RIH[SRVXUH02( LVDOVRXVHGWRFKDUDFWHUL]HULVN7KH02(LVGHÀQHGDVWKH
ratio of the NOAEL or BMDL for the critical effect to the theoretical, predicted, 
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1or estimated exposure dose or concentration (19). Depending on the chosen accepted risk in the BMD approach (e.g., 5 or 10%), a MOE of 10,000 or more 
is considered of low concern from a public health point of view (19, 20). The 
6FLHQWLÀF&RPPLWWHHRQ&RQVXPHU6DIHW\6&&6XVHVWKHPDUJLQRIVDIHW\0R6
to characterize risk of a cosmetic ingredient (21). The MoS value is calculated by 
dividing the lowest NOAEL value by the estimated systemic exposure dosage and 
is used to extrapolate from test animals to humans. A substance is considered 
safe when the MoS value is at least above 100 (21). In the absence of compound-
VSHFLÀF WR[LFRORJLFDO GDWD WKH 7KUHVKROG RI 7R[LFRORJLFDO &RQFHUQ 77& PLJKW
be an alternative method to characterize the risk. The TTC concept incorporates 
information on potential exposure and is based on chemical structure and the 
toxicity data of structurally related chemicals (22). TTC values have also been 
derived for inhalation exposure to PCPs (23). Although accepted in science, the 
SCCS does not support the use of TTC values for the risk characterization of 
cosmetic ingredients at this moment. First, existing databases used to derive TCC 
values need further development and validation (21).
The last part of a risk characterization consists of an uncertainty analysis to 
identify the parameters that are the main sources of uncertainty or to demonstrate 
that the overall risk assessment is adequate. As the level of the uncertainty 
assessment depends on the purpose of the risk assessment, a stepwise approach 
was proposed by the European Chemical Agency (ECHA) (24)$WWKHÀUVWOHYHOWKH
uncertainties are discussed qualitatively, whereas at the higher levels they are 
discussed quantitatively using deterministic and probabilistic approaches. 
Consumer exposure assessment
Exposure assessment is an essential part of human health risk assessment for 
PCPs, as a substance in a PCP can only pose a risk if a consumer is actually being 
exposed. Consumer exposure assessment describes and analyses concentrations 
RIFKHPLFDOVWRZKLFKLQGLYLGXDOVDUHH[SRVHGLQWKHLUSULYDWHOLIHVSHFLÀFDOO\(25-
27). Following REACH registration, this is based on three underlying questions:
1. What is the composition of a PCP?
2. What is realistic use and exposure scenario? 
3. Is the substance taken up by the body and will it become available in the 
systemic circulation?
Chapter 1
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Composition of PCPs
According to the EU regulation on cosmetic products, manufacturers of cosmetics 
need to list all ingredients added to the product during the manufacturing process 
on the product label (28). The compound with the highest concentration in the 
SURGXFW LV OLVWHGÀUVWEXWVRPH LQJUHGLHQWVDUHQRWZHOOGHVFULEHGRUQRW OLVWHG
at all (e.g., certain additives). The exact amounts of compounds present in PCPs 
are not listed on the ingredient labels either, leaving a knowledge gap in exposure 
assessment. In the literature, the presence of a wide variety of compounds in 
PCPs has been reported, such as emollients or solvents (29-31), fragrances (30, 
32) and preservatives (33-35). 
Exposure scenario
An exposure scenario includes a combination of facts, assumptions, and inferences 
WKDWGHÀQHDGLVFUHWHVLWXDWLRQLQZKLFKH[SRVXUHPD\RFFXU7KHVHPD\EHWKH
sources and time frame of exposure, the exposed population, microenvironment(s), 
and activities. Scenarios are often created to aid exposure assessors in estimating 
exposure (36). When performing consumer exposure assessment, one has to 
take into account the types of products in which the substance is present, the 
usage characteristics of the products, the circumstances and conditions of the 
exposure events, and the most likely relevant exposure routes (25, 27). Several 
researchers investigated the usage patterns of consumers regarding PCPs. 
7KHVHVWXGLHVRIWHQUHÁHFWDVSHFLÀFJURXSRUVXESRSXODWLRQVXFKDVFKLOGUHQRU
adults in distinct parts of the world (37, 38). Furthermore, these studies focus on 
particular products (39-41) and on detailed aspects of the usage pattern, such as 
the frequency of product use and the quantity used per application. Next to these, 
other aspects of the usage pattern are important as well, e.g., the area of the 
body where a PCP is applied or the use of several products simultaneously. The 
ODWWHUOHDGVWRDJJUHJDWHH[SRVXUHGHÀQHGDVH[SRVXUHWRRQHVLQJOHFKHPLFDOYLD
all exposure routes and from different sources (42, 43). In Europe and the USA, 
databases have been assembled that contain information on exposure factors 
(44, 45). In exposure assessment, the required information, such as usage 
frequency or amount of PCP applied, can be collected from these databases.
Uptake - Dermal absorption
As the majority of PCPs is applied to the skin, dermal absorption is considered to be 
the primary route of uptake. The epidermis acts as a barrier, preventing excessive 
water loss from the body and protecting the body to the uptake of exogenous 
substances. The properties of the stratum corneum (SC), the top layer of the 
General Introduction
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1epidermis, determine how fast a substance penetrates the skin. The structure of the SC resembles a construction of bricks (corneocytes) in mortar (lipids) (46, 
47). Exogenous substances penetrate the skin by diffusion using three routes: 
transcellular, intercellular, and transappendageal (through sweat and sebaceous 
glands and hair follicles). The chemical properties of a substance determine its 
ability to penetrate the skin and at what speed. As healthy skin is hydrated, water-
soluble and small molecules will penetrate easily using the transcellular pathway. 
In contrast, lipophilic molecules will primarily use the intercellular (lipid) pathway. 
They will encounter resistance, as the space between the corneocytes is limited. 
The structure of the SC differs from one region of the body to another: the skin on 
the feet, for instance, is much thicker than the skin in the axilla which tends to slow 
down uptake. The thickness of the SC is a factor governing the rate of uptake of 
substances. If the skin is damaged due to physical or chemical stressors, uptake 
of exogenous substances might be enhanced. 
Uptake - Inhalation
Next to dermal absorption, ingredients of PCPs can enter the body via inhalation, 
especially if spray products are used causing substances to evaporate. Water 
solubility and reactivity will determine if an inhaled substance interacts with 
respiratory tract tissues and subsequently delay or prevent inhalation uptake 
(48). Water-soluble substances can diffuse in the mucosa lining the respiratory 
tract and may not reach the alveoli (i.e. wash-in wash-out effect) (49, 50). Reactive 
substances can interact with components of the mucus tissue, causing the 
concentration in the respiratory tract to drop rapidly leaving only a small fraction 
that reaches the blood (48). Especially with substances of low water-solubility and 
low reactivity, gas exchange between the blood and the inhaled air takes place in 
the alveoli. The exchange rate mainly depends on the likelihood of a substance to 
SDUWLWLRQIURPLQKDOHGDLUWREORRGGHVFULEHGE\WKHEORRGDLUSDUWLWLRQFRHIÀFLHQW
After inhalation exposure to aerosols, the amount and location of deposition are 
mainly determined by residence time, particle size and concentration, water-
solubility of the substance in the aerosol, airway geometry, and respiratory 
parameters (13, 51). The smallest aerosols penetrate deep into the airways and 
can reach the alveoli where they may be taken up into the blood, although alveolar 
marcophages can discard the aerosols before they are absorbed (13).
Uptake - Ingestion
Although less likely, ingestion is a pathway that may lead to internal exposure to 
PCPs as well (e.g., ingestion of lipstick). Substances may be taken up throughout 
Chapter 1
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the entire gastro-intestinal (GI) tract. The exact location of absorption is determined 
by physico-chemical properties of the substance, such as pKa and lipid-solubility. 
The fraction of the ingested dose that reaches the systemic circulation depends 
on the amount absorbed by the GI epithelial cells. Furthermore, substances in GI 
FHOOVFDQXQGHUJRELRWUDQVIRUPDWLRQRUEHHOLPLQDWHGE\WKHOLYHULHWKHÀUVWSDVV
effect) before reaching the systemic circulation. 
Current practice 
Guidance on how to perform consumer exposure assessment is provided by 
ECHA, who uses the REACH legislation as a legal background (52). At the moment, 
consumer exposure assessment is performed using a tiered approach (i.e., a 
VWHSZLVHSURFHGXUHVWDUWLQJZLWKVLPSOHFDOFXODWLRQVWKDWDUHUHÀQHGVWHSE\VWHS
(25). The lowest tiers (tier 0 and 1) are based on conservative default parameter 
values and provide a realistic but worst-case exposure estimate. Higher tier 
exposure estimates are based on more detailed and realistic parameters (52). 
Even though measured data are preferred over modelled data, the collection of 
GLUHFWH[SRVXUHPHDVXUHPHQWVLVGLIÀFXOWDQGWKHDYDLODELOLW\RIVSHFLÀFH[SRVXUH
GHWHUPLQDQWVHJIUHTXHQF\RIXVHVSHFLÀFXVHRISURGXFWLVOLPLWHG7KHUHIRUH
models are the main tool in the assessment of exposure (27, 53). Examples of 
consumer exposure models are ECETOC TRA and ConsExpo (54, 55). In a lower 
tier model, few input parameters with assigned default values are used to estimate 
exposure. In contrast, a wider range of parameters is incorporated when using a 
higher tier model. These parameters are not inserted as point values, but are 
incorporated as distributions in a probabilistic approach. Subsequently, Monte-
Carlo simulation is used to estimate exposure in a population. As consumers 
are exposed to multiple PCPs via different routes, the estimation of aggregate 
exposure is an important part in consumer exposure modelling under REACH. 
The easiest way, which could be applied in a tier 1 approach, is by adding up 
DOO H[SRVXUHV LGHQWLÀHG (27). In this process, the assumption is made that the 
same individuals use all of the products containing the chemical simultaneously, 
which leads to an unrealistic high exposure estimation. To obtain a more realistic 
HVWLPDWLRQRIDJJUHJDWHH[SRVXUHUHÀQHPHQWLQKLJKHUWLHUPRGHOVLVSURSRVHG
for example by assigning weights to different exposures (27). ECHA as well as SCCS 
stress the importance for aggregate exposure in consumer exposure assessment, 
but provide only models for lower tier aggregate exposure assessment (21, 52). 
Currently, higher tier models do not have the ability to aggregate exposure. Thus, 
more data are needed on the determinants of (aggregate) consumer exposure 
to PCPs to further develop consumer exposure models and improve the risk 
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1assessment for PCPs.   
Objectives 
To support improved risk assessment for PCPs, this thesis aims at obtaining 
better insight into consumer exposure to PCPs. To be more precise, the aim can 
be divided into three objectives:
1. To construct a database consisting of exposure factors related to the use 
of PCPs by Dutch consumers.
2. To investigate internal exposure to substances in PCPs after dermal 
administration of a single product and the combined use of two products 
(aggregate exposure). 
3. 7R UHÀQH DQG DSSO\ D SK\VLRORJLFDOO\ EDVHG SKDUPDFRNLQHWLF 3%3.
model to simulate aggregate consumer exposure to substances in PCPs. 
Figure 1.2 provides an overview of the objectives of this thesis and the three 
questions underlying consumer exposure assessment.
 CONSUMER EXPOSURE ASSESSMENT 
1. What is the composition of a PCP? 
Extensively reviewed in the literature; recently 
attention was paid to cyclic siloxanes (10)
2. What is realistic use and exposure scenario? 
Objective 1 of this thesis; results are reported in Ch 2   
3. Is the substance taken up by the body and will it 
become available in the systemic circulation?  
Objective 2 of this thesis; results are reported in Ch 5 
(methodology in Ch 3 and 4) 
Exposure modelling 
Objective 3 of this thesis; 
results are reported in Ch 6 
Figure 1.2 Overview of the objectives of this thesis and the three questions underlying 
consumer exposure assessment.
Design of the study and outline of this thesis
The studies described in this thesis were part of a research project “Estimation 
of realistic consumer exposure to substances from multiple sources and 
approaches to validation of exposure models”, funded by the European Chemical 
Industry Council Long Range Initiative (CEFIC-LRI). The project was a collaboration 
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between three partners: the Radboud university medical centre (Radboudumc), 
the National Institute for Public Health and the Environment (RIVM) and the Swiss 
Federal Institute of Technology (ETH Zurich).  
&RQVLGHULQJ WKH ÀUVW REMHFWLYH D ZHEEDVHG TXHVWLRQQDLUH ZDV GHYHORSHG WR
obtain person-oriented information regarding usage patterns and circumstances 
of use of 32 PCPs. In total, 516 men and women in the Netherlands completed 
the questionnaire and provided information on their PCP usage patterns and 
circumstances of use, which is presented in Chapter 2. PCPs usually consist 
of many different compounds, which complicates the analysis of different 
compounds and the interpretation of the results. Therefore, we focussed on two 
related compounds to investigate actual internal exposure to PCPs (objective 2). 
7KHVXEVWDQFHVRIFKRLFHKDGWRIXOÀOWKHIROORZLQJFULWHULD
x Used in multiple products, so that aggregation of exposure was an issue
x Almost exclusively present in a broad range of PCPs
x Safe when administered to the skin of human volunteers
x Known amount of substance in products
x Detectable in a non-invasive biological matrix (i.e., end-exhaled air)
x Availability of a calibrated (human) PBPK model
x Stakeholder interest, including societal and political relevance
Based on these criteria, two cyclic siloxanes, i.e. octamethylcyclotetrasiloxane 
(D4; CAS number 556-67-2) and decamethylcyclopentasiloxane (D5; CAS number 
541-02-6), were selected for the determination of the internal dose. D4 and D5 
are common ingredients of PCPs and the primary route of exposure to D4/D5 for 
consumers is the use of PCPs (56)%RWKWKH6FLHQWLÀF&RPPLWWHHRQ&RQVXPHU
Safety in Europe and the Cosmetic Ingredient Review Expert Panel in the US 
concluded that cyclic siloxanes are safe with regard to the current practices of use 
and their concentrations in PCPs (57, 58). Furthermore, end-exhaled air analysis 
is a feasible non-invasive method to determine the internal concentration of these 
substances, as exhaled air is a major excretion route in humans. The high vapour 
SUHVVXUHDQG ORZEORRGDLU SDUWLWLRQ FRHIÀFLHQWPDNH F\FOLF VLOR[DQHV H[FHOOHQW
candidates for end-exhaled air analysis. Also, several calibrated PBPK models 
were proposed to estimate internal exposure to D4/D5 resulting from dermal 
absorption as well as inhalation uptake (59-61). 
In general and consumer exposure assessment, the use of end-exhaled air analysis 
is limited. While searching the literature, it appeared that practical guidance on the 
actual use of breath analysis is missing. Therefore, a literature review, presented in 
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1Chapter 3, was written to describe current practices and increase raise awareness for end-exhaled air analysis as an adequate method of exposure assessment and 
to provide practical guidance for fellow exposure scientists and toxicologists. In our 
laboratory, a sensitive analytical method (Chapter 4) was developed to quantify 
D4 and D5 in end-exhaled air using thermal desorption gas chromatography mass 
spectrometry (TD-GC-MS). After obtaining ethical approval, 15 men and women 
were exposed to D4 and D5 in different media (pure substance, night cream, 
deodorant or a combination of the latter two) in a laboratory setting to assess 
internal exposure. The results of this study are presented in Chapter 5. Next, the 
LQWHQWLRQZDVWRXVHWKHUHVXOWVRIWKLVKXPDQH[SRVXUHVWXG\WRUHÀQHDQH[LVWLQJ
PBPK model and predict aggregate dermal exposure to PCPs. However, the results 
showed that inhalation and not dermal absorption of cyclic siloxanes was the 
most important route of uptake. Since dermal uptake data were therefore not 
available to construct a PBPK model, the focus was changed to inhalation uptake 
of cyclic siloxanes and an additional human exposure study was performed. In a 
ÀHOGVWXG\KHDOWK\YROXQWHHUVZHUHREVHUYHGLQWKHLUEDWKURRPDWKRPHGXULQJ
the application of a deodorant containing D5 to collect realistic exposure data. 
Subsequently, a linear regression model was constructed and an existing PBPK 
PRGHOZDVUHÀQHGDQGDSSOLHGWRSUHGLFWLQWHUQDOH[SRVXUH&KDSWHU$JHQHUDO
GLVFXVVLRQ RI RXU ÀQGLQJV DQG IXWXUH SHUVSHFWLYHV IRU UHVHDUFK RQ H[SRVXUH
assessment for PCPs are included in Chapter 7. 
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Abstract
Complete information regarding the use of personal care products (PCPs) by 
consumers is limited, but such information is crucial for realistic consumer 
H[SRVXUH DVVHVVPHQW 7R ÀOO WKLV JDS D GDWDEDVH ZDV FUHDWHG ZLWK SHUVRQ
oriented information regarding usage patterns and circumstances of use for 32 
different PCPs. Out of 2700 potential participants from the Netherlands, 516 
men and women completed a digital questionnaire. The prevalence of use varied 
by gender, age, level of education and skin type. A high frequency of use was 
observed for some products (e.g. lip care products), while toothpaste, deodorant 
and day cream were generally used once or twice a day. The frequency of use 
for other PCPs varied over a wide range. The amounts of use varied largely 
between and within different product groups. Body lotion, sunscreen and after 
sun lotion were often applied on adjacent body parts. The majority of PCPs were 
applied in the morning, but some products, such as night cream and after sun, 
were predominantly applied in the evening or night. As expected, the participants 
used several PCPs simultaneously. The database yields important personalized 
exposure factors which can be used in aggregate consumer exposure assessment 
for substances that are components of PCPs. 
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Introduction
In daily life, many people use numerous personal care products (PCPs), such 
as deodorant, facial moisturizer or night cream on a regular basis (1). PCPs 
are carefully prepared using intricate recipes and a variety of substances with 
diverse functions. These substances include active ingredients, but also solvents, 
preservatives and additives, some of which are suspected to affect the health of 
the consumer, e.g. phthalates, parabens or antimicrobials (triclosan/triclocarban), 
which may have endocrine disrupting properties (2-4). UV absorbers in sunscreens, 
such as dibenzoylmethanes and benzophenones, as well as fragrances and 
preservative agents in cosmetics, may initiate allergic or photo-allergic contact 
dermatitis (5, 6). Other PCPs contain heavy metals, such as mercury or cadmium 
that may lead to neurotoxicity (7-9). Consumers are exposed to these substances 
in small amounts through various PCPs, via multiple routes including inhalation, 
dermal absorption and ingestion. 
In order to assess potential health risks for consumers, it is necessary to conduct 
aggregate exposure assessments considering the simultaneous exposure to a 
substance from all possible sources and routes (10, 11). A common approach 
is to aggregate deterministic worst-case assessments for all sources and routes, 
which results in highly unrealistic, but conservative, exposure levels. Therefore, 
UHÀQHPHQWRIWKHVHXQUHDOLVWLFH[SRVXUHOHYHOVZLOORIWHQEHQHHGHG)RUDJJUHJDWH
H[SRVXUHWKHPRVWHIIHFWLYHUHÀQHPHQWLVWRWDNHLQWRDFFRXQWFRXVHDQGQRQ
use of products in a person-oriented approach (12). In order to do so, individual 
exposure factors, such as frequency and amount of use of single products, as 
ZHOODVVSHFLÀFLQIRUPDWLRQDERXWWKHFLUFXPVWDQFHVRIXVHDUHQHHGHG(13). In 
a series of three studies, Loretz and co-workers investigated the distribution of 
the frequency and amount of use of several cosmetics in a US female population 
of regular users (14-16). Wu and colleagues collected information on the usage 
patterns of 30 types of PCPs in Californian households (1). Special attention was 
paid to the distribution of the frequency of use of the investigated products. Hall 
and co-workers also provided distributions of daily amounts of use for several 
cosmetic products in Europe, including body lotion, facial moisturiser, hair styling 
products, hand cream, liquid foundation, mouthwash, shampoo, shower gel and 
toothpaste (17, 18)7KH6FLHQWLÀF&RPPLWWHHRQ&RQVXPHU6DIHW\XVHGWKHGDWD
collected by Hall and co-workers to provide exposure data for some cosmetic 
products in their 7th notes of guidance (19).
All of these studies mainly focused on the frequency and amount of PCP use, but 
none addressed both the circumstances and patterns of individual product use. 
Circumstances of use are for example the presence of ventilation or the location 
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of application (indoors/outdoors). Inhalation exposure will be relatively low when 
a product is used in a ventilated area. Therefore, the aim of the current study 
was to create a database containing information regarding the circumstances and 
patterns of individual PCP use. It provides important information on product use for 
different age and gender groups and can be used to calculate aggregate consumer 
exposure to various substances in PCPs, by incorporating the information on both 
product co-use and the circumstances of use. 
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Methods
Study population
We randomly selected one large (>100,000 inhabitants) and one small (<20,000 
inhabitants) municipality in every province of the Netherlands for a total of 24 
municipalities. These were requested to draw a random sample of inhabitants 
between 18 and 70 years of age from their population administration. Each large 
municipality provided 150 addresses and each small municipality 75 addresses, 
leading to a total of 2700 addresses of potential participants. We sent invitation 
letters for the study to all of these addresses, including an internet address linking 
to a digital questionnaire in November 2011. In early January 2012, a reminder 
was sent. We also offered the opportunity to complete the questionnaire on paper 
instead of through the internet. 
Data collection
We developed a web-based questionnaire to assess the use patterns and 
circumstances of PCPs. This questionnaire contained general questions regarding 
demographics, lifestyle and skin type. The detailed usage patterns of 32 types 
of PCPs were assessed using questions regarding the frequency of use and the 
amount of product used per application. We used photographs to visualize the 
amount of product used in the following product categories: general hygiene (e.g. 
deodorant), shaving products, hair care, skin care and tanning products. The 
photographs contained three images displaying an increasing amount of product 
(Figure 2.1). We recorded the weight of the amount of product shown in each of 
the images. This information was used to transform the categorical data provided 
by the respondents (e.g. an amount equal to picture A or an amount between 
pictures A and B) into numerical values (e.g. 2.5 g) for actual exposure calculation. 
Figure 2.1 Example of a photograph used to assess the amount of product (e.g. make-up 
remover) used per application.
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For the following PCPs the visual display of amounts was not meaningful: deodorant 
spray, perfume or eau de toilette, aftershave spray, hair spray, eye shadow, 
mascara, eye pencil, eyebrow pencil, lip pencil, lipstick, lip balm and nail polish. 
For these products, we developed alternative questions to describe the amounts 
used such as: “how often did you spray?” (spray products), “where exactly did you 
apply the product?” (eye shadow, eye pencil and lip pencil), “how many layers did 
you apply?” (mascara, eyebrow pencil, lip pencil, lipstick, lip balm and nail polish). 
A small experimental study was performed and the mean amounts used were 
calculated by weighing before and after application of the product. 
In addition, the questionnaire contained questions regarding the type and brand 
of the product, the application area on the body, the time of day a product was 
used (e.g. morning or evening), the location of use (indoors or outdoors) and the 
presence of ventilation. All of the questions concerned use within the past six 
months, except for the questions regarding tanning products, which covered the 
SDVW\HDUWRPLQLPL]HVHDVRQDOLQÁXHQFHV
Data analysis
Frequency tables were used to describe the prevalence of PCP use. This variable 
was analyzed by gender (male, female), age group (18-39, 40-54, 55-71), level of 
education (low, intermediate, high), skin type (dry/sensitive skin, oily/combined 
skin, normal skin), skin colour (Northern European, Southern European) and 
lifestyle (non-smoking/no use of alcohol, smoking/use of alcohol) using Chi-
square tests. The frequency of use, amount of use, application area on the body, 
time of application, location of use and the presence of ventilation were also 
analyzed by gender, age group and level of education using Chi-square tests. In 
DGGLWLRQWKHFRXVHRISURGXFWVZDVDQDO\]HGXVLQJ&RKHQ·VNDSSDZKLFKUHÁHFWV
the level of agreement corrected for agreement by chance between the use of two 
products. The brand loyalty of the respondents was described by the proportion of 
UHVSRQGHQWVXVLQJDVSHFLÀFEUDQGSHUSURGXFW'DWDZHUHDQDO\]HGXVLQJ6366
version 18.0. Differences with a p-value of less than 0.05 were considered to be 
VWDWLVWLFDOO\VLJQLÀFDQWXQOHVVQRWHGRWKHUZLVH
Results
The results presented below give a general overview; more detailed information is 
available as Supplementary material. 
Demographics
In total, 516 out of the 2700 potential participants completed the questionnaire 
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and 27 invitation letters were returned to sender. Therefore, the minimum 
adjusted response rate was 19.3%. A small proportion of the respondents did 
not provide information on the demographic variables. Among the ones who did, 
210 respondents (41.0%) were male and 302 respondents (59.0%) were female. 
We constructed three age groups: young (18-39), middle aged (40-54) and senior 
(55-71). These groups contained 21.6%, 36.9% and 41.5% of the respondents, 
respectively. Furthermore, the respondents were divided into three groups based 
on the level of education: low (24.2%), intermediate (38.6%) and high (37.2%), 
GHÀQHGDVWKHFRPSOHWLRQRIVL[WKURXJKWHQ\HDUVHOHYHQWKURXJKIRXUWHHQ\HDUV
DQGÀIWHHQ\HDUVRUPRUHRIHGXFDWLRQ$GGLWLRQDOO\WKHSDUDPHWHUVNLQW\SHZDV
divided into three groups: dry/sensitive skin, oily/combined skin and normal skin 
for future detailed exposure assessment. Male respondents mostly reported to 
have normal skin (68.0%), whereas 21.5% and 10.5% had a dry/sensitive or 
oily/combined skin, respectively. The proportion of women in the three groups 
was evenly distributed, being 32.6%, 35.5%, 31.9% in the dry/sensitive skin, 
oily/combined skin and normal skin group, respectively. Only eight respondents 
had an Asian skin colour and no respondents had a Negroid skin. Therefore, the 
parameter skin colour was divided into two groups: Northern European (69.3%) 
versus Southern European (30.7%).
Prevalence of use
7KHSUHYDOHQFHRIXVHZDVGHÀQHGDVWKHSURSRUWLRQRIXVHUVWKDWUHSRUWHGWKH
use of a PCP at least once in the past six months. Table 2.1 shows an overview of 
the percentages of users per product. 
Although the percentages of users for most general hygiene products were high, 
approximately 10% of the respondents reported not to have used deodorant or 
toothpaste in the last six months. Of the hair care products, shampoo was used 
by 96.7% of the respondents while conditioner was used by 33.5%. The majority 
of the respondents who used conditioner used a rinse off product (84.4%), while 
others used a leave on product (6.4%) or a combination of both (9.2%). The 
percentages of female users were higher (p<0.05) compared to the percentages 
of male users for all PCPs studied, except for shaving products (Figure 2.2). For 
most products, the percentage of users in the age group 18-39 (young) was higher 
compared to the percentages of users in the older age groups (data not shown). 
However, hair dye was most often used by middle aged and low/intermediately 
HGXFDWHGUHVSRQGHQWV,QDGGLWLRQWKHOHYHORIHGXFDWLRQLQÁXHQFHGWKHXVHRI
several other PCPs. More users with a high level of education used aftershave 
(32.8%) compared to users with an intermediate or low level of education (25.1% 
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Table 2.1. General overview of the percentages of users by product and gender based on 
all respondents (N=516).
Product Number of 
users 
(N=516) 
% of users % of male 
users 
(N=210) 
% of female 
users 
(N=302) 
General 
hygiene 
Deodorant 470 91.1 86.7 94.7 
Perfume or Eau de 
toilette 
326 63.2 34.3 83.8 
Shower gel 411 79.7 71.0 85.8 
Bathing foam/oil 121 23.4 18.1 27.2 
Toothpaste 461 89.3 77.6 97.7 
Shaving 
products 
Shaving 
foam/gel/oil/soap 
185 35.9 53.3 23.5 
Aftershave 133 25.8 61.0 1.0 
Hair care  Shampoo 499 96.7 92.9 99.7 
Conditioner 173 33.5 9.5 50.7 
Hairspray 159 30.8 3.3 50.0 
Other  
(gel, lotion, foam, wax) 
258 50.0 28.1 65.9 
Hair dye 175 33.9 3.3 55.6 
Skin care  Body lotion 264 51.2 21.4 72.2 
Hand cream 273 52.9 28.6 69.5 
Day cream 268 51.9 11.9 80.5 
Night cream 147 28.5 3.3 46.0 
Facial cleaning lotion or 
tonic 
140 27.1 2.9 44.4 
Cosmetics  Foundation 99 19.2 0.5 32.5 
Make-up remover 130 25.2 0.5 42.7 
Powder or rouge 105 20.3 0.5 34.4 
Eye shadow 154 29.8 0 50.7 
Mascara 187 36.2 0 61.6 
Eye pencil 160 31.0 0 52.6 
Eyebrow pencil 80 15.5 0 26.5 
Lip pencil 24 4.7 0 7.9 
Lipstick or lip gloss 170 32.9 0.5 55.6 
Lip balm 173 33.5 10.5 50.0 
Nail care Nail polish 155 30.0 0 51.0 
Nail polish remover 145 28.1 0 47.7 
Tanning 
products 
Bronzers 32 6.2 0.5 10.3 
Sunscreen 368 71.3 60.5 79.1 
After sun 228 44.2 37.6 49.3 
DQGUHVSHFWLYHO\S7KHVHÀJXUHVZHUHDQGIRU
shaving foam/gel/oil/soap and 81.3%, 69.3% and 59.2% for sunscreen products.
Frequency of use
The frequency of use of the products with a similar range (< 1 time per week, 1-2 
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WLPHVSHUZHHNWLPHVSHUZHHNWLPHVSHUZHHNWLPHSHUGD\
times per day) is summarized in Figure 2.3. The distributions of the frequency of 
use for all PCPs studied are provided in Supplementary material S1. The majority 
of users (>50%) clearly indicated to use deodorant, day cream, night cream, make-
up remover, mascara, eye pencil and eye brow pencil once a day. The frequency of 
use of the other products was much more diverse and a predominant frequency 
of use could not be assessed. 
Toothpaste (not shown in Figure 2.3), was generally used once (22.9%) or twice 
(67.1%) per day, with women belonging slightly more often to the latter category. 
+DLUG\HZDVPRVWO\XVHGHYHU\ÀYHWRWHQZHHNVZKLOHWKHPDMRULW\RI
users (64.7%) applied nail polish less than once a month (data not shown). We 
observed a higher frequency of use for all skin care products, except for body lotion, 
among women (1 time per day) compared to men (< 1 time per week, p<0.05). 
The young age group used shaving foam/gel/oil/soap less frequently compared 
to the senior age group, i.e. 1 time per week and 1 time per day, respectively. This 
GLIIHUHQFH LQ IUHTXHQF\RIXVHZDVVWDWLVWLFDOO\VLJQLÀFDQW7DEOHVKRZV WKH
frequency of use for tanning products. We observed a large variability in the use of 
bronzers, sunscreen and after sun ranging from only one to more than 100 days 
in the past year. 
Table 2.2 Frequency of use for bronzers, sunscreen and after sun.
 Number of days of use in the past year  
% of users 
Product  1 
day 
2-4 
days 
5-7 
days 
8-14 
days 
15-21 
days 
22-30 
days 
31-60 
days 
61-100 
days 
>100 
days 
Tanning 
products 
Bronzers 
(N=32) 
0 18.8 21.9 15.6 15.6 12.5 15.6 0 0 
Sunscreen 
(N=364) 
2.2 12.9 18.7 21.4 17.9 14.6 7.7 2.2 2.5 
After sun 
(N=226) 
5.3 15.9 20.4 22.1 17.3 10.6 5.3 2.2 0.9 
Amount of use
Table 2.3 shows the mean amounts of use of the PCPs studied per application 
and per day. For some products, we were unable to determine the amount applied 
by weighing before and after application due to very small differences (e.g. for eye 
shadow). 
We were unable to determine the amounts used by weighing the products.
The distributions of the amount of use for all PCPs studied are provided in 
Supplementary material S2. In general, the amounts used differed between and 
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Table 2.3 Amount of use per application for all PCPs studied.
Product Mean 
amount per 
application 
Mean 
amount 
per day 
Range of 
amount per 
day 
General hygiene Deodorant Cream (g) 1.0 1.0 0.8-8.9  
Roller (g) 0.2 0.2  0.1-0.2  
Stick (g) 0.1 0.1  0.04-0.1  
Spray (g) 0.4 0.4  0.06-0.1  
Perfume or Eau de toilette (g) 0.1 0.1  0.04-0.07  
Shower gel (g) 6.3 4.5  0.7-10.7  
Bathing foam (g) 8.1 1.2  0.1-2.1  
Bathing oil (ml) 3.3 0.5  0.1-0.9  
Toothpaste (g) 1.1 2.2  0.8-4.0  
Shaving products Shaving foam (g) 3.1 1.3  0.3-3.4  
Shaving gel (g) 4.0 1.7  0.3-3.8  
Shaving oil (ml) 1.0 0.4  0.3-2.6  
Shaving soap NDa ND ND 
Aftershave Lotion/balm/gel (ml) 1.3l 0.6  0.3-2.6  
Spray (g) 0.08 0.03  0.03-0.04  
Hair care  Shampoo (g) 4.8 2.4  0.5-7.5  
Conditioner (g) 4.9 2.1  0.4-6.4  
Hairspray (g) 0.9 0.4  0.3-0.6  
Other  Hair foam (g) 3.5 1.5  0.3-3.4  
Hair gel (g) 1.7 1.0  0.3-4.3  
Hair lotion (ml) 1.8 1.0 l 0.4-3.4  
Hair wax (g) 1.3 0.6  0.3-3.2  
Hair dye ND ND ND 
Skin care  Body lotion (g) 8.5 3.6  0.4-21.4  
Hand cream (g) 0.5 0.4  0.08-0.9  
Day cream (g) 0.4 0.4  0.1-1.1  
Night cream (g) 0.4 0.3  0.09-0.9  
Facial cleaning lotion or tonic (ml) 1.6 1.1 l 0.5-4.3  
Cosmetics  Foundation (g)  0.3 0.2  0.06-0.6  
Make- up remover (g) 1.8 1.5  0.7-7.6  
Powder or rouge (mg) 5.9 4.2  2.1-21.4  
Eye shadow ND ND ND 
Mascara (mg) 9.6 8.2  5.1-15.3  
Eye pencil (mg) 0.3 0.3  0.2-0.3  
Eyebrow pencil (mg) 0.3 0.3  0.2-0.4  
Lip pencil (mg) 0.8 0.4  0.3-0.6  
Lipstick or lip gloss (mg) 5.2 4.1  1.7-5.1  
Lip balm (mg) 12.0 8.6  3.6-10.7  
Nail care Nail polish (g) 0.3  0.04  0.03-0.1  
Nail polish remover (ml) 2.0  0.3  0.1-0.9  
Tanning products Bronzers (g) 5.8  0.3  0.06-2.9  
Sunscreen (g) 9.2  0.4  0.04-1.9  
After sun (g) 8.8  0.3  0.04-1.9  
aND = not determined.  
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within the product groups. Some products were used in a wide range of amounts, 
especially products that are usually applied in large quantities, such as body lotion 
or sunscreen. In general, men used smaller amounts of skin care products (i.e. 
body lotion, night cream and hand cream) and tanning products (i.e. sunscreen 
and after sun) per application compared to women. Female users applied more 
shaving foam compared to men, presumably because the shaving area for women 
LV XVXDOO\ ODUJHU WKDQ IRU PHQ 7KHVH GLIIHUHQFHV ZHUH VWDWLVWLFDOO\ VLJQLÀFDQW
Almost no differences in product amounts used were found between the age 
groups. Only the amount of eye shadow applied by younger and middle aged users 
was higher compared to senior users (p<0.05). We hardly observed an effect of 
educational level on the amount of use, except that users with a high level of 
education applied more eye pencil compared to users with an intermediate or low 
level of education. 
Application area 
Some PCPs were applied on a single part of the body, whereas others were 
applied on multiple body parts. The determination of the total exposure to PCPs 
LV LQÁXHQFHGE\VNLQSHUPHDELOLW\ZKLFKGLIIHUVEHWZHHQDQDWRPLFDO VLWHV 7KH
scrotum, forehead, axilla, scalp, back and extremities are sites in general order of 
decreasing permeability (Klaassen, 2001). Therefore, the most frequently exposed 
parts of the body were examined regarding the use of body lotion, sunscreen and 
after sun of which relatively large amounts were used (Figure 2.4). 
Approximately 70-80% of the users applied sunscreen and 65-80% of the users 
applied after sun on all parts of their body exposed to sunlight on a summer day. 
Moreover, most users (75-90%) applied body lotion on the upper and lower arms 
and legs. The percentage of male users applying body lotion on their head and 
face was higher compared to the percentage of female users. The majority of users 
applied body lotion, sunscreen and after sun on adjacent body parts. For example, 
95.2% of the users who applied body lotion on their lower arms also applied body 
lotion on their upper arms, while 90.0% of the users that applied sunscreen on 
their neck also applied sunscreen on their shoulders. Furthermore, most male 
users applied shaving foam on their head and face (93.5%), whereas most female 
users applied this product on their axillae (78.3%), pubic area (68.1%) and lower 
legs (84.1%). More young users compared to middle aged and senior users used 
shaving foam on their axillae, pubic area, upper legs and lower legs (p<0.05). 
Time of application
Only a small proportion of users reported to use PCPs after midnight. We assumed 
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Figure 2.4 Application of body lotion, sunscreen and after sun on different parts of the 
body. The application of these products was not restricted to one body part. 
that these users go to sleep after twelve o’clock in the evening. Therefore, we 
combined the users applying a product in the evening and the users applying a 
product at night into a single group. Figure 2.5 shows a summary of the application 
WLPHRIWKH3&3VVWXGLHG7KLVÀJXUHLQGLFDWHVWKDWWKHPDMRULW\RISURGXFWVZHUH
SUHGRPLQDQWO\DSSOLHGLQWKHPRUQLQJ+RZHYHUVRPHVSHFLÀFSURGXFWVVXFKDV
bathing foam/oil, night cream, facial cleaning lotion or tonic, make-up remover, 
nail polish remover and after sun were mostly used during the evening or night. 
Other products, such as hand cream, lip balm and lip stick, did not have a restricted 
time of application, but were used during the entire day. 
Location of use and the presence of ventilation
Most users (between 89.7% and 99.7%) applied deodorant spray, hair spray, nail 
polish and nail polish remover indoors. Of these users, approximately 65-75% 
DSSOLHGWKHSURGXFWVLQDYHQWLODWHGDUHDZKLFKZDVGHÀQHGDVWKHSUHVHQFHRI
natural or mechanical ventilation. No meaningful differences were observed for 
gender, age groups, level of education and skin type. 
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Co-use
The usage patterns of all 32 different PCPs were also investigated. Overall, the 
respondents used an average number of thirteen products (range 0-28). The 
average number of products used was seventeen (range 3-28) among women and 
seven (range 2-20) among men. The respondents in the young age group used 
16 products on average, whereas 14 and 11 products were used by respondents 
in the middle age group and the senior age group, respectively. Table 2.4 shows 
the Cohen’s kappa values with a p<0.05 for co-use of the PCPs studied, with the 
moderately to highly positive (kappa>0.40) and negative (kappa<-0.40) values 
presented in bold. The table shows that the respondents used several products at 
the same time. For example, 93.5% of all users who applied nail polish also used 
nail polish remover (kappa=0.95), and 82.5% of all users who applied eye shadow 
also used mascara (kappa=0.62). Being a predominantly male product, the use 
of aftershave was negatively associated with the use of day cream (kappa=-0.40), 
night cream (kappa=-0.30), mascara (kappa=-0.40) and several other hair care, 
skin care, nail care and cosmetic products. The use of most products within the 
hair care, skin care or cosmetic products groups was correlated. For instance, 
day cream was quite often used by the same people that used night cream 
(kappa=0.49) and the use of powder was highly likely among people who used 
foundation (kappa=0.67). However, not all products that seem to be associated 
were used simultaneously. Out of 499 respondents using shampoo, only 173 
(34.7%) used conditioner as well (kappa=0.03). 
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Discussion
,QWKLVVWXG\ZHFUHDWHGDGDWDEDVHFRQWDLQLQJVSHFLÀFLQIRUPDWLRQUHJDUGLQJWKH
usage patterns and circumstances of use of 32 personal care products (PCPs). 
This database includes the prevalence of use, frequency of use, amount of use, 
application area on the body, time of application (i.e. time of day), the presence or 
absence of room ventilation, the co-use of PCPs and the brand loyalty of the users. 
To the best of our knowledge, no similar studies that include circumstances of use 
KDYHEHHQSXEOLVKHGSUHYLRXVO\7KLV LV WKHÀUVWFRPSUHKHQVLYHVWXG\SURYLGLQJ
this information for a single population on an individual level. 
Strength and weaknesses 
Response rate
Web-based questionnaires are easy to administer and have several advantages, 
such as immediate checks for incomplete or implausible answers and hiding of 
non-relevant follow-up questions. In contrast, the response rates in web-based 
questionnaires are generally lower compared to postal questionnaires, as safety 
DQGFRQÀGHQWLDOO\LVVXHVPD\SOD\DUROH(20). The overall response rate to our web-
based questionnaire was 19.3%, which is similar to some population-based studies 
(21, 22), but relatively low compared to others (23-25). Nearly immediately after 
sending the invitations for this study to potential participants, we were contacted 
by some people who were unable to access the questionnaire via the URL that 
was provided in the printed invitation letter. Therefore, we sent these respondents 
an email with a direct link to the website that hosted the questionnaire. However, 
this issue may have had a negative impact on the response rate, as it is unlikely 
WKDWDOOUHVSRQGHQWVZKRH[SHULHQFHGGLIÀFXOWLHVFRQWDFWHGXV
Representativeness
We believe that the usage patterns and circumstances of use of PCPs collected in 
this study are fairly representative for the Dutch adult population, as we started 
with a random sample of Dutch citizens living throughout the entire country and 
we have no indications for selective non-response. In addition, most results 
seem to be logic and are generally as expected. However, the highly educated 
respondents (37.2%) may be slightly overrepresented compared to the Dutch 
general population. In 2010, the Dutch adult population (age 24-64) consisted 
for 33% of highly educated people (26). Consumer behaviour (i.e. usage of PCPs) 
LV LQÁXHQFHGE\ SHUVRQDO VRFLRFXOWXUDO DQGPDUNHWLQJ YDULDEOHV (27, 28). The 
latter two issues make it hard to generalize our results to other populations, 
such as in Southern Europe or other continents. However, the format of our web-
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based questionnaire is universal. After translation, the questionnaire could be 
implemented in other European countries or elsewhere in order to assess usage 
patterns and circumstances of PCPs use. 
Recall issues
The respondents were asked to recall their use of most PCPs during the previous 
six months, and their use of tanning products during the previous year. These 
UHODWLYHO\ORQJWLPHSHULRGVPDGHLWGLIÀFXOWIRUWKHUHVSRQGHQWVWRUHFDOOWKHLUXVH
exactly, but take into account variability in use of PCPs. Furthermore, by using a 
TXHVWLRQQDLUHDORQH LWZDVGLIÀFXOW WRDVVHVVSUHFLVHDPRXQWVRI WKHSURGXFWV
that were used per application. Weighing a PCP before and after application is a 
more accurate method to assess the precise amount of product used (29), but 
this is impractical with large survey-based studies and puts an additional burden 
on the respondents. In nutritional research, photographs are often used to assess 
the amount of food consumed (30). This method results in a representative 
assessment (31, 32). Therefore, a similar strategy with photographic aids was 
used to assess the amount of product used per application. 
:HDVVXPHGWKDWWKHXVDJHSDWWHUQVRIFRQVXPHUVDUHLQÁXHQFHGE\VNLQW\SH
For example, someone with dry/sensitive skin would likely apply more body 
lotion than someone with normal or oily/combined skin. However, the question 
UHODWHGWRWKLVWRSLFZDVQRWIRUPXODWHGVSHFLÀFHQRXJKLQWKHTXHVWLRQQDLUH7KH
questionnaire referred to general skin type, but this should have been divided 
LQWRVSHFLÀFSDUWVRIWKHERG\)RUH[DPSOHLQRQHLQGLYLGXDOIDFLDOVNLQPLJKWEH
FODVVLÀHGDVVHQVLWLYHVNLQZKHUHDVWKHUHVWRIWKHERG\PLJKWEHFODVVLÀHGDV
normal skin. Therefore, the results by skin type should be interpreted with caution.
Exposure assessment
The distributions of the frequency of use and the amount of use per product and 
by gender presented in the Supplementary material provide an excellent basis for 
exposure assessment to PCPs. In addition, extra exposure information regarding 
OHYHORIHGXFDWLRQVNLQ W\SHRUVNLQFRORXUFRXOGEHEHQHÀFLDOZKHQDVSHFLÀF
population requires attention. Also, the circumstances of use, such as the time 
of application, the location of use or the presence of ventilation could provide 
additional useful information. Because we assessed product use over the past 
six months, no information was given about peak exposures. In general, however, 
time-weighted averages make for more balanced exposure assessment. 
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5HÁHFWLRQRQWKHOLWHUDWXUH
Prevalence of use
7KHSUHYDOHQFHRI3&3VXVHZDVLQÁXHQFHGE\GHPRJUDSKLFIDFWRUVVXFKDVJHQGHU
and age. Within all product categories (with the exception of shaving products), 
the percentage of female respondents was higher than that of male respondents. 
Recently, Wu et al. (1) collected information regarding usage patterns of personal 
care products in California households and reported similar results. However, the 
prevalence of use of shaving foam/gel/oil was not investigated. Furthermore, only 
female participants received questions regarding the use of cosmetics (i.e. make-
up products), and only male participants were questioned regarding the use of 
DIWHUVKDYH,QWKHFXUUHQWVWXG\ZHGLGQRWPDNHVXFKDSUHGHÀQHGDVVXPSWLRQ
that only women use cosmetic products and only men use aftershave. Such an 
assumption can cause information to be missed, as men may use cosmetics 
professionally (e.g. actors) and male cosmetic use is also becoming more accepted 
in society. Indeed, some of our male respondents (0.5%) reported using make-up 
products (foundation, make-up remover and powder or rouge).
Frequency of use
In general, the frequency of use of the PCPs studied varied widely. This variation 
was also observed by Wu et al. (1). In a series of studies reported by Loretz et al. 
(14-16) exposure data were collected for cosmetic products and the daily use rates 
of several PCPs were reported, including facial cleanser, hair conditioner and eye 
shadow. However, for these studies only female respondents who regularly used 
two or more test products were recruited. As a random population sample was 
included in the current study, it was not possible to compare our results with these 
previous reports. 
Amount of use
The European cosmetics manufacturers, acting within the trade organisation 
Colipa, modelled the exposure of European consumers to several cosmetics 
products (17, 18). In these studies, Hall et al. assessed the amount applied per 
day, whereas Loretz et al. (14-16) reported on the amount applied per application. 
Table 2.5 gives an overview of the amount of use per application or per day for the 
current study and the studies described by Loretz and Hall. 
In the current study, the mean amounts of shampoo and conditioner applied per 
application were 4.8 and 4.9 g, respectively. The corresponding mean amounts 
applied per day were 2.4 and 2.1 g. In contrast, Loretz et al. (15, 16) reported 
values that were more than twice these amounts (11.8 and 13.1 g per application 
for shampoo and conditioner, respectively). Hall et al. also reported at least a 
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twofold higher amount for the application of shampoo (application per day being 
6.0 g) (18). Similar differences were observed with respect to the amounts of 
shower gel, hand cream, day cream and lip stick used. On the other hand, the 
amount of body lotion per application was 8.5 g in the current study, whereas 
Loretz et al. (14) reported only 4.4 g. Per day, the amount of body lotion applied 
was 4.5 g in the study by Hall and colleagues, which is more or less similar to our 
ÀQGLQJVJ7KHUHSRUWHGDPRXQWVRIIRXQGDWLRQDQGWRRWKSDVWHLQWKHFXUUHQW
study were equal to the amounts presented in the Colipa study (17, 18). 
Co-use
In contrast to Wu et al. (1), Cohen’s kappa values were calculated to evaluate 
the combined use of several PCPs. In addition, the percentages of respondents 
using one product and a second product were calculated. A high percentage of 
respondents (70–95%) used a combination of two skin care products, for example, 
day cream and night cream. A similar usage pattern was observed by Wu et al., 
who reported a moderate correlation between the amounts of shampoo and hair 
conditioner used (R=0.43). In our study, however, only 34.7% of the respondents 
ZKRXVHG VKDPSRR DOVR XVHG FRQGLWLRQHUZKLFK OHG WR D NDSSD FRHIÀFLHQW RI
0.03.
The differences regarding prevalence of use, frequency of use, amount of use 
and co-use between our study and the studies described in the literature may 
be explained by the different populations studied. However, the literature was 
QRWVXIÀFLHQWO\GHWDLOHGRQDJHJHQGHURU OHYHORIHGXFDWLRQWRSURSHUO\DVVHVV
the differences and similarities. Another explanation may be the variability in 
the methods of data collection. Telephone interviews were used by Wu et al. (1), 
whereas Hall et al. (17, 18) used existing databases, such as the ETCD (European 
Toiletries and Cosmetics Database). The information in that database is provided 
by volunteers via a postal survey. Volunteers included in the study by Loretz et al. 
(14-16) used products of which the weight was recorded at the beginning and at 
the end of the study. In addition, these volunteers recorded daily use information 
in a diary. 
In conclusion, the current study provides valuable information on the individual 
usage patterns and circumstances of PCP use by Dutch adults that may partly 
be extrapolated to other populations. A database was created that will guide the 
next step in consumer exposure modelling of PCPs as well as aggregate exposure 
assessment for substances that are components of PCPs. 
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eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 >
 3
 ti
m
es
 p
er
 d
ay
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H
ai
r c
ar
e 
± H
ai
r l
ot
io
n 
                             L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 >
 3
 ti
m
es
 p
er
 d
ay
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H
ai
r c
ar
e 
± H
ai
r f
oa
m
 
                              L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 >
 3
 ti
m
es
 p
er
 d
ay
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H
ai
r c
ar
e 
± H
ai
r w
ax
 
                              L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 >
 3
 ti
m
es
 p
er
 d
ay
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H
ai
r c
ar
e 
± H
ai
r d
ye
 
                              L
eg
en
d:
 
1 
= 
1 
tim
e 
in
 th
e 
la
st
 s
ix
 m
on
th
s;
 2
 =
 2
-3
 ti
m
es
 in
 th
e 
la
st
 s
ix
 m
on
th
s;
  
3 
= 
4-
5 
tim
es
 in
 th
e 
la
st
 s
ix
 m
on
th
s 
(a
pp
ro
xi
m
at
el
y 
ev
er
y 
5-
6 
si
x 
w
ee
ks
); 
4 
= 
> 
5 
tim
es
 in
 th
e 
la
st
 s
ix
 m
on
th
s 
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S
ki
n 
ca
re
 ± 
Bo
dy
 lo
tio
n 
                              L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 >
 3
 ti
m
es
 p
er
 d
ay
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64
S
ki
n 
ca
re
 ± 
H
an
d 
cr
ea
m
 
                              L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 4
-5
 ti
m
es
 p
er
 d
ay
;  
8 
= 
> 
5 
tim
es
 p
er
 d
ay
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S
ki
n 
ca
re
 ± 
D
ay
 c
re
am
 
                              L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 >
 3
 ti
m
es
 p
er
 d
ay
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S
ki
n 
ca
re
 ± 
N
ig
ht
 c
re
am
 
                             L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 >
 3
 ti
m
es
 p
er
 d
ay
 
Usage patterns of personal care products
2
67
S
ki
n 
ca
re
 ± 
Fa
ci
al
 c
le
an
in
g 
lo
tio
n 
or
 to
ni
c 
                              L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 >
 3
 ti
m
es
 p
er
 d
ay
 
Chapter 2
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C
os
m
et
ic
s 
± F
ou
nd
at
io
n 
                              L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 >
 3
 ti
m
es
 p
er
 d
ay
 
Usage patterns of personal care products
2
69
C
os
m
et
ic
s 
± M
ak
e-
up
 re
m
ov
er
 
                              L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 >
 3
 ti
m
es
 p
er
 d
ay
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C
os
m
et
ic
s 
± P
ow
de
r o
r r
ou
ge
 
                              L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 >
 3
 ti
m
es
 p
er
 d
ay
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C
os
m
et
ic
s 
± E
ye
 s
ha
do
w
 
                           L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 >
 3
 ti
m
es
 p
er
 d
ay
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72
C
os
m
et
ic
s 
± M
as
ca
ra
 
                                 
 
Le
ge
nd
: 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 >
 3
 ti
m
es
 p
er
 d
ay
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C
os
m
et
ic
s 
± E
ye
 p
en
ci
l 
                              L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 >
 3
 ti
m
es
 p
er
 d
ay
 
Chapter 2
74
C
os
m
et
ic
s 
± E
ye
br
ow
 p
en
ci
l 
                             L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 >
 3
 ti
m
es
 p
er
 d
ay
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C
os
m
et
ic
s 
± L
ip
 p
en
ci
l 
                                 
 
Le
ge
nd
: 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 4
-5
 ti
m
es
 p
er
 d
ay
;  
8 
= 
> 
5 
tim
es
 p
er
 d
ay
 
Chapter 2
76
C
os
m
et
ic
s 
± L
ip
st
ic
k 
or
 li
p 
gl
os
s 
                              L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 4
-5
 ti
m
es
 p
er
 d
ay
;  
8 
= 
> 
5 
tim
es
 p
er
 d
ay
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C
os
m
et
ic
s 
± L
ip
 b
al
m
 
                              L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r w
ee
k;
 2
 =
 1
-2
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 3
-4
 ti
m
es
 p
er
 w
ee
k;
 4
 =
 5
-6
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 1
 ti
m
e 
pe
r d
ay
; 6
 =
 2
-3
 ti
m
es
 p
er
 d
ay
; 7
 =
 4
-5
 ti
m
es
 p
er
 d
ay
;  
8 
= 
> 
5 
tim
es
 p
er
 d
ay
 
Chapter 2
78
N
ai
l c
ar
e 
± N
ai
l p
ol
is
h 
(a
pp
lic
at
io
n 
on
 h
an
ds
) 
                              L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r m
on
th
; 2
 =
 <
 1
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 1
 ti
m
e 
pe
r w
ee
k;
 4
 =
 2
-3
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 >
 3
 ti
m
es
 p
er
 w
ee
k 
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N
ai
l c
ar
e 
± N
ai
l p
ol
is
h 
(a
pp
lic
at
io
n 
on
 fe
et
) 
                              L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r m
on
th
; 2
 =
 <
 1
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 1
 ti
m
e 
pe
r w
ee
k;
 4
 =
 2
-3
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 >
 3
 ti
m
es
 p
er
 w
ee
k 
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80
N
ai
l c
ar
e 
± N
ai
l p
ol
is
h 
re
m
ov
er
 
                              L
eg
en
d:
 
1 
= 
< 
1 
tim
e 
pe
r m
on
th
; 2
 =
 <
 1
 ti
m
es
 p
er
 w
ee
k;
 3
 =
 1
 ti
m
e 
pe
r w
ee
k;
 4
 =
 2
-3
 ti
m
es
 p
er
 w
ee
k;
 5
 =
 >
 3
 ti
m
es
 p
er
 w
ee
k 
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Ta
nn
in
g 
pr
od
uc
ts
 ± 
Br
on
ze
rs
 
                             L
eg
en
d:
 
1 
= 
1 
da
y;
 2
 =
 2
-4
 d
ay
s;
 3
 =
 5
-7
 d
ay
s;
 4
 =
 8
-1
4 
da
ys
; 5
 =
 1
5-
21
 d
ay
s;
 6
 =
 2
2-
30
 d
ay
s;
 7
 =
 3
1-
60
 d
ay
s;
 8
 =
 6
1 
= 
10
0 
da
ys
; 9
 =
 >
 1
00
 d
ay
s 
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82
Ta
nn
in
g 
pr
od
uc
ts
 ± 
S
un
sc
re
en
 
                              L
eg
en
d:
 
1 
= 
1 
da
y;
 2
 =
 2
-4
 d
ay
s;
 3
 =
 5
-7
 d
ay
s;
 4
 =
 8
-1
4 
da
ys
; 5
 =
 1
5-
21
 d
ay
s;
 6
 =
 2
2-
30
 d
ay
s;
 7
 =
 3
1-
60
 d
ay
s;
 8
 =
 6
1 
= 
10
0 
da
ys
; 9
 =
 >
 1
00
 d
ay
s 
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Ta
nn
in
g 
pr
od
uc
ts
 ± 
A
fte
r s
un
 
                              L
eg
en
d:
 
1 
= 
1 
da
y;
 2
 =
 2
-4
 d
ay
s;
 3
 =
 5
-7
 d
ay
s;
 4
 =
 8
-1
4 
da
ys
; 5
 =
 1
5-
21
 d
ay
s;
 6
 =
 2
2-
30
 d
ay
s;
 7
 =
 3
1-
60
 d
ay
s;
 8
 =
 6
1 
= 
10
0 
da
ys
; 9
 =
 >
 1
00
 d
ay
s 
Chapter 2
84
S2 D
is
tr
ib
ut
io
ns
 o
f t
he
 a
m
ou
nt
 o
f u
se
 fo
r 
al
l P
CP
s 
st
ud
ie
d 
ar
e 
sh
ow
n 
be
lo
w
. S
ep
ar
at
e 
di
st
rib
ut
io
ns
 a
re
 p
re
se
nt
ed
 fo
r 
m
al
e 
an
d 
fe
m
al
e 
PC
P 
us
er
s.
 
O
n 
th
e 
y-
ax
is
, t
he
 n
um
be
r 
of
 m
al
e 
or
 fe
m
al
e 
us
er
s 
is
 d
ep
ic
te
d.
 O
n 
th
e 
x-
ax
is
, t
he
 c
at
eg
or
ie
s 
of
 t
he
 a
m
ou
nt
 o
f u
se
 a
re
 s
ho
w
n,
 i.
e.
 1
 t
hr
ou
gh
 7
, 
FR
UU
HV
SR
QG
LQ
J
Z
LWK
D
U
DQ
JH
R
I



WR






J
UD
P
V
7
KH
H
[D
FW
F
OD
VV
LÀ
FD
WLR
Q
RI
WK
H
FD
WH
JR
ULH
V
IR
U
WK
H
VS
HF
LÀ
F
3&
3
LV
S
UH
VH
QW
HG
LQ
WK
H
le
ge
nd
 b
el
ow
 e
ac
h 
gr
ap
h.
 In
 a
dd
iti
on
, a
 n
or
m
al
 d
is
tr
ib
ut
io
n 
w
as
 p
lo
tt
ed
 in
 t
he
 g
ra
ph
s.
 N
ot
 a
ll 
PC
Ps
 s
tu
di
ed
 w
er
e 
us
ed
 b
y 
m
en
. T
he
re
fo
re
, n
o 
di
st
rib
ut
io
ns
 o
f t
he
 a
m
ou
nt
 o
f u
se
 a
m
on
g 
m
en
 c
ou
ld
 b
e 
m
ad
e 
fo
r e
ye
 s
ha
do
w
, m
as
ca
ra
 a
nd
 li
p 
pe
nc
il.
 
G
en
er
al
 h
yg
ie
ne
 ± 
D
eo
do
ra
nt
 c
re
am
 
                             
Le
ge
nd
: 
1 
= 
0-
0.
59
 g
; 2
 =
 0
.5
9-
1.
45
 g
; 3
 =
 1
.4
5-
1.
98
 g
; 4
 =
 1
.9
8-
3.
90
 g
; 5
 =
 3
.9
0-
7.
21
 g
; 6
 =
 7
.2
1-
10
.5
2 
g;
 7
 =
 1
0.
52
-3
1.
55
 g
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G
en
er
al
 h
yg
ie
ne
 ± 
D
eo
do
ra
nt
 ro
lle
r o
r s
tic
k 
                               
 
Le
ge
nd
: 
If 
ro
lle
r: 
1 
= 
0.
02
5-
0.
14
1 
g;
 2
 =
 0
.0
61
-0
.2
92
 g
; 3
 =
 0
.1
48
-0
.2
90
 g
; 4
 =
 0
.3
83
-0
.5
46
 g
; 5
 =
 1
.3
11
-1
.4
74
 g
 
If 
st
ic
k:
 1
 =
 0
.0
04
-0
.0
70
 g
; 2
 =
 0
.0
61
-0
.0
95
 g
; 3
 =
 0
.0
74
-0
.1
12
 g
; 4
 =
 0
.1
74
-0
.2
20
 g
; 5
 =
 0
.5
68
-0
.6
15
 g
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G
en
er
al
 h
yg
ie
ne
 ± 
D
eo
do
ra
nt
 s
pr
ay
 
                                
 
Le
ge
nd
: 
1 
= 
0.
26
0-
0.
45
3 
g;
 2
 =
 0
.2
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Abstract
We discuss the use of exhaled air analysis in exposure assessment and provide 
practical guidance for analytical chemists. First, overview of published literature 
reviews is provided and the basic principle of end-exhaled air analysis described. 
:HHODERUDWHRQVDPSOHFROOHFWLRQDQGVXEVWDQFHVSHFLÀFSURSHUWLHVQHHGHGWR
assess the added value of exhaled air analysis. Subsequently, we characterize 
situations in which the use of exhaled air analysis could be useful, and provide 
evidence to demonstrate that exhaled air sampling is a good alternative to 
collection of blood or urine samples. Widespread use of exhaled air analysis is 
currently hampered by a lack of background and guidance values. Nevertheless, 
the method has great potential to be used widely. We, therefore, see many 
opportunities for breath sampling, particularly in populations that require a 
method of sample collection that is less invasive than the collection of blood or 
urine.
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Introduction
Exhaled air is primarily made up of nitrogen, oxygen, carbon dioxide, water 
vapor and traces of volatile organic compounds (VOC). This matrix represents 
a potentially valuable source for diagnostics and exposure assessment (1). It is 
an easy to use, rapid, and person-friendly non-invasive way to obtain biological 
samples (2-5). Compared to blood and urine, exhaled air is more easily accessible 
and its collection will cause less discomfort and embarrassment for the subjects. 
The samples collected do not need any pre-treatment prior to analysis, which 
VLPSOLÀHVWKHDQDO\WLFDOSURFHGXUHFRPSDUHGWRWKHDQDO\VLVRIPRVWERG\ÁXLGV
'HVSLWHWKHVHEHQHÀWV WKHQXPEHURIVWXGLHVWKDWUHSRUWRQWKHXVHRIEUHDWK
analysis as a human biological monitoring (HBM) approach is still limited. 
Traditionally, blood and urine are the most frequently used matrices (6). When 
searching PubMed using “human biomonitoring” or “human biological monitoring”, 
combined with “exhaled air” or “blood” or “urine”, only 2% of the HBM studies 
describe the use of exhaled air as a sampling medium. The majority of abstracts 
describe the use of blood (50%), urine (33%) or both (17%). 
The current status of breath sampling procedures, breath collection devices 
and sample-enrichment methodologies in exhaled breath analysis for exposure 
assessment was recently described by Alonso and Sanchez (1). They also 
summarized the practical applications of exposure analysis in the past two 
decades. However, they did not provide guidance on the use of breath analysis 
in HBM for exposure assessment. This review discusses the use of exhaled air 
analysis in HBM and provides practical guidance for analytical chemists interested 
in the use of exhaled air analysis for exposure assessment. The main focus of this 
review is on biomarkers of exposure. Biomarkers of effect have been reviewed 
extensively elsewhere (3-5, 7).    
Published reviews 
7ZRPDMRUVFLHQWLÀFÀHOGVRIDSSOLFDWLRQFDQEHGLVWLQJXLVKHG WKHGHWHFWLRQRI
VOC as biomarkers of disease (diagnostic applications) and as biomarkers of 
exposure (exposure assessments). In 2007, Amorim and Cardeal reviewed the 
use of exhaled air for biomarker analysis of occupational and environmental 
exposure to chemical agents (2). Recently, Alonso and Sanchez described the 
current status of sampling procedures, collection devices and sample-enrichment 
methodologies in exhaled air analysis used for exposure assessment (1). They 
summarized the practical applications of exhaled air analysis in exposure analysis 
LQ WKH SDVW WZR GHFDGHV DQG FDWHJRUL]HG WKHP LQWR ÀYH ÀHOGV  H[SRVXUH
simulations in controlled chambers; (2) swimming and domestic water activities; 
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(3) services related to mechanical vehicles; (4) solvents and volatile compounds 
in the workplace and (5) active and passive smoking.
Several authors reviewed the role of exhaled air analysis in diagnostics research 
practice (3-5, 7). Cao and Duan, as well as Buszewski and co-workers, provided an 
overview of markers in exhaled air for certain disease conditions, such as oxidative 
stress, lung diseases, and metabolic and gastroenteric disorders (3, 4). Smith and 
FROOHDJXHVZHUHWKHÀUVWWRJLYHDQRYHUYLHZRIWKHOHYHOVRIPDUNHUVLQH[KDOHGDLU
in the healthy population as a reference framework to recognize abnormal levels 
that might be related to disease (8). In a broader perspective, de Lacy Costello 
and co-workers reported all VOCs emanating from the human body (volatolome). 
,QWRWDO92&VZHUHLGHQWLÀHGRIZKLFKLQH[KDOHGDLU2WKHU92&VZHUH
found in saliva, blood, breast milk, skin secretions, urine and faeces (9). Recently, 
Buszewski and co-workers gave an overview on the developments in breath 
analysis applied to diagnosis of disease using high-quality analytical instruments 
(10). Several techniques, such as gas chromatography mass spectrometry (GC-
06VHOHFWHGLRQÁRZWXEH066,)706SURWRQWUDQVIHUUHDFWLRQ0637506
and electric noses are used in medical diagnosis. In addition, Navas and co-
workers evaluated the advantages and limitations of photoacoustic spectrometry 
for the determination of markers in exhaled air (11). 
 
Physiological principle
(QGH[KDOHGDLULVGHÀQHGDVDQDOLTXRWRIWKHDOYHRODUIUDFWLRQLHWKHDLUYROXPH
in the gas exchange region of the lungs that has been in equilibrium with blood). 
Exhaled air is a mixture of air from the alveolar volume and dead space volume, 
often referred to as ‘mixed exhaled air’. The principle of the determination of 
92&HOLPLQDWLRQXVLQJHQGH[KDOHGDLUZLOOEHEULHÁ\LQWURGXFHG2QHRIWKHÀUVW
to describe the basic concept of elimination by lung ventilation was Farhi, who 
assumed that the concentration of a compound in the ambient environment is 
negligible (12). We adjusted this concept, as we think that it is more realistic to 
assume a background level for compounds in ambient air. Under steady state 
conditions, the rate at which a substance enters the lungs via venous blood 
equals the amount of substance leaving the lungs via in- or exhalation (CA-Cin) and 
via arterial blood per unit time, as described by:
ܳ஼ ൈܥ௏ ൌ  ஺ܸ ൈ ሺܥ஺ െܥ௜௡ሻ ൅ܳ஼ ൈܥ௔௥௧     (1)
Where QC is the cardiac output, CV is the venous blood concentration, VA is the 
ventilation rate, CA is the alveolar air concentration, Cin the concentration in 
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inhaled air and Cart is the arterial blood concentration. 
7KHDUWHULDOEORRGFRQFHQWUDWLRQLVSURSRUWLRQDOWRWKHEORRGDLUSDUWLWLRQFRHIÀFLHQW
(PB), assuming a diffusion equilibrium between arterial blood and alveolar air 
leaving the lungs:
ܥ௔௥௧ ൌ ܥ஺ ൈ  ஻ܲ     (2)
Equations 1 and 2 can be combined to describe the alveolar concentration (13, 
14): 
ܥ஺ ൌ 
ሺொ಴ൈ஼ೇሻାሺ௏ಲൈ஼೔೙ሻ
௏ಲାொ೎ൈ௉ಳ
    (3)
:KHQPHDVXULQJ VXEVWDQFHVZLWK D ORZ EORRGDLU SDUWLWLRQ FRHIÀFLHQW 3B
WKHFRQFHQWUDWLRQLQYHQRXVEORRGLVSULPDULO\LQÁXHQFHGE\WKHYHQWLODWLRQUDWH
and the cardiac output. Such variation in these parameters leads to inter- and 
intra-individual differences (15). In contrast, for substances with a high blood:air 
SDUWLWLRQFRHIÀFLHQW3B>10), the venous blood concentration is less affected by 
changes in ventilation rate and cardiac output. 
Sample collection techniques
In principal, three techniques are available for collection of breath samples: 
rebreathing, mixed exhaled air and end-exhaled air. For rebreathing, a study 
VXEMHFWLVDVNHGWREUHDWKHIRUVHYHUDOPLQXWHVLQWRDÁH[LEOHFRQWDLQHUXVXDOO\
DSODVWLFEDJPDGHRI7HGODUSRO\YLQ\OÁXRULGH$IWHUUHSHDWHGEUHDWKVZLWKRXW
inhaling fresh air, the concentration in the bag will approach a level approaching 
the alveolar air concentration that is in equilibrium with the blood concentration. 
Compared to other materials, Tedlar has a low background emission of pollutants 
and shows negligible surface interactions with VOC analytes, keeping these stable 
during a longer storage period, even up to one week (16). 
Mixed-exhaled air samples include both air that has been in contact with the 
alveoli and  the air volume from the region of the airways without gas exchange 
GHDGVSDFHYROXPH7KHÀUVWDLUYROXPHHTXLOLEUDWHVZLWKEORRGEXWWKHVHFRQG
does not, which results in a ‘mixed’ sample consisting of diluted alveolar air. The 
easiest way to collect such a sample is by asking a subject to exhale into a plastic 
bag. Without accurate data on the ratio of dead space to alveolar volume of the 
test person, it is not possible to relate the amount determined in a mixed-exhaled 
air volume to an alveolar air concentration. 
Of an end-exhaled air sample only the last part consists of air that has been in 
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equilibrium with blood. Over the years, several devices were developed to collect 
this fraction of exhaled air (Figure 3.1). 
Figure 3.1 Three devices designed for the collection of exhaled air, glass pipette (A), plastic 
Tedlar bag (B) and rigid plastic Bio-VOC container (C).
Using a glass pipette of 100-200 mL, the subject is asked to exhale and continue 
WKLVH[SLUDWLRQXQWLOWKHHQG:KHQWKHÁRZDSSURDFKHV]HURWKHVDPSOHFROOHFWLRQ
is completed. The last part of the exhaled air is captured in the pipette. After 
sample collection the pipette is closed on both sides with screw-caps equipped 
with a septum. Needles are pierced through these septa and nitrogen is used 
to transfer the substances of interest to a suitable adsorbent (17). A stainless 
VWHHOFDQLVWHUZDVÀWWHGZLWKDGLVSRVDEOHPRXWKSLHFHE\WKH86(QYLURQPHQWDO
Protection Agency in the 1990’s (18). The subject was asked to exhale normally, 
while discarding the dead space portion of air. Next, the subject put the mouthpiece 
in his or her mouth and opened the canister valve to collect one litre of the lungs’ 
expiratory reserve. The UK Health and Safety Laboratory used this principle to 
develop the Bio-VOC breath sampler (19, 20). When a subject exhales into the Bio-
92&PRVWDLUZLOOÁRZWKURXJKDQGRQO\WKHODVWSDUWDQDOLTXRWRIDSSUR[LPDWHO\
P/ LV FROOHFWHG $ RQHZD\ YDOYH SURKLELWV DPELHQW DLU IURP ÁRZLQJ EDFN
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into the Bio-VOC, preventing the sample from becoming diluted with ambient air 
or causing potential contamination. After sample collection a screw-in plunger is 
used to transfer the sampled VOCs to a sorbent tube. Over the years, adsorbent 
WXEHVÀOOHGZLWK7(1$;DQGPXOWLEHGVRUEHQWWXEHVKDYHEHHQGHYHORSHG(21). The 
advantage of the use of TENAX is that the high humidity of the exhaled air does not 
interfere with the process of absorption of VOCs (21). However, in the presence of 
radicals or other reactive compounds, artefacts and possible misinterpretation of 
the results may occur (22). 
Detection of substances in exhaled air
As the internal dose integrates the contribution from all routes of exposure, 
LQKDODWLRQH[SRVXUHGHUPDOXSWDNHDQGLQJHVWLRQRIVXEVWDQFHVDUHUHÁHFWHGLQ
H[KDOHGDLU7RGHWHFWDVXEVWDQFHLQH[KDOHGEUHDWKYRODWLOLW\PXVWEHVXIÀFLHQWO\
high (i.e. >0.3 Pa). Figure 3.2 lists the vapor pressures of a range of VOCs which 
have been previously investigated in human exposure studies by means of exhaled 
breath. The exact values are also listed in Table 1 of the Supplementary Material. 
7KH EORRGDLU SDUWLWLRQ FRHIÀFLHQW 3E VKRXOG SUHIHUDEO\ EH VPDOO LH  
Table 3.1), which increases the ability of a substance to partition from blood to 
air. However, substances with a Pb of up to 2500-3000, such as methanol and 
ethanol, have been detected successfully in exhaled air as well (23-25). 
7KHGDWDSUHVHQWHGRQYDSRUSUHVVXUHDQGEORRGDLUSDUWLWLRQFRHIÀFLHQWLQ)LJXUH
DQG7DEOHDUHH[WHQVLYHEXWQRWFRPSOHWH ,QERWKWKHWDEOHDQGÀJXUH
we provide an overview of volatile substances that have been investigated in 
literature by exhaled air analysis. These data are intended to provide a framework 
to support a well informed discussion whether or not to use exhaled air analysis. 
We would like to point out that the origin (e.g., in vitro or in vivo) of these data for 
the use in for example PBPK modeling should be considered carefully. 
%HVLGH YDSRU SUHVVXUH DQG EORRGDLU SDUWLWLRQ FRHIÀFLHQW ZDWHU VROXELOLW\ LV
important. Water-soluble chemicals may become dissolved in the mucous 
membrane lining the respiratory tract. This results in lower uptake compared 
to what would be expected based on blood:air partitioning (26, 27). This so-
called wash-in wash-out effect requires standardized sample collection and an 
adjustment (i.e. adding additional compartments for bronchioles, mucosa and 
alveoli) for this effect should be considered when modeling the data. Mörk and 
Johanson developed a PBPK model which explains the toxicokinetics of acetone 
DQG HYDOXDWHV WKH LQÁXHQFH RI WKH ZDVKLQ ZDVKRXW HIIHFW  ,Q WKH LQLWLDO
model, the respiratory tract was represented by an inert tube. Acetone was only 
exchanging between alveolar air and arterial blood. Subsequently, the model was 
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Table 3.1 %ORRGDLUSDUWLWLRQFRHIÀFLHQWVRIVXEVWDQFHVVWXGLHGE\PHDQVRIHQGH[KDOHG
air analysis.
Substance CAS 
number 
Blood:air partition coefficient (mean 
± sd) 
Reference 
Pentane 109-66-0 0.38 ± 0.08 (68) 
Decamethylcyclopentasiloxane 541-02-6 0.41 ± 0.13 (69) 
Sevoflurane 28523-86-6 0.68 ± 0.02 (70) 
n-Hexane 110-54-3 0.80 ± 0.08 (68) 
Octamethylcyclotetrasiloxane 556-57-2 0.96 (71) 
Vinyl Chloride  75-01-4 1.16 (72) 
1,3-Butadiene 106-99-0 1.22 ± 0.30 (73) 
Carbon tetrachloride  56-23-5 2.4 (25) 
Halothane 151-67-7 2.57 ± 0.15 (70) 
1,1,1-Trichloroethane 71-55-6 3.3 (25) 
Mercury (vapor) 7439-97-6 4.20 (74) 
Decane 124-18-5 5.28 
5.0 
(75, 76) 
Chloroform  67-66-3 6.85 ± 0.51 
10.07 ± 0.70 
10.30 
(24, 77, 78) 
Dichloromethane 75-09-2 7 to 12 (79) 
Cis-1,2-dichloroethene 156-59-2 9.2 (25) 
Naphthalene 91-20-3 10.3 (80) 
Perchloroethylene  127-18-4 10.3 ± 1.1 (77) 
Trichloroethene  79-01-6 9.5 (25) 
Benzene 71-43-2 7.8 ± 1.1 
8.19 
(24, 25, 77, 
81) 
Methyl tertiary-butyl ether  1634-04-4 11.7 (95% CI 11.3-12.1) (82) 
Toluene 108-88-3 15.6 ± 1.7 (24, 25, 81) 
m-Xylene 108-38-3 26.4 ± 0.9 
32.5 ± 1.6 
(25, 77, 81) 
Bromodichloromethane 75-27-4 26.6 ± 1.4 (78) 
Ethylbenzene 100-41-4 28.4 ± 1.7 (25, 81) 
o-Xylene 95-47-6 31.1 ± 2.3 
34.9 ± 1.7 
(25, 77, 81) 
p-Xylene 106-42-3 37.6 ± 3.5 
44.7 ± 1.9 
(25, 77, 81) 
Dibromochloromethane  124-48-1 52.7 ± 1.2 
49.2 ± 2.3 
(77, 78) 
Styrene 100-42-5 51.9 ± 2.0 
52 
(24, 25, 81) 
Bromoform  75-25-2 103 ± 8.8 (78) 
Acetone 67-64-1 245 ± 32 
330 
(24, 25, 81) 
Ethanol 64-17-5 1 756 
2 516 
(23, 24) 
Methanol 67-56-1 2 100 
2 874 
(24, 25) 
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extended to account for the wash-in wash-out effect by dividing the arterial blood 
compartment of the inert tube model into four parts (bronchioles, mucosa, alveoli 
and arterial blood). In the extended model, acetone exchanged between air in 
the bronchioles and the mucosa, and between mucosa and arterial blood. The 
observed acetone concentration in end-exhaled air over time was much better 
described by the wash-in wash-out model compared to the initial inert tube model. 
7KH GHWHFWLRQ RI FHUWDLQ FRPSRXQGV GRHV QRW QHFHVVDULO\ UHÁHFW H[RJHQRXV
exposure, as many volatile compounds are detected in the breath of healthy 
human volunteers as a result of endogenous formation (9). For some substances, 
such as acetone and isoprene, the biochemical mechanisms for their formation 
well understood (3, 28), but for others it is still unknown. Wang and colleagues 
investigated the source of endogenous formation of common trace volatile 
compounds and concluded that some were generated systemically (acetone, 
methanol and isoprene), whereas others were largely generated in the mouth 
(ammonia, ethanol and hydrogen cyanide) or generated systemically as well as 
orally (propanol and acetaldehyde) (29). In this study, the source of formaldehyde 
formation was uncertain, as the background levels in ambient air are often higher 
than the formaldehyde levels in exhaled air. The authors stated, however, that 
formaldehyde in exhaled air is primarily generated systemically. 
$WORZFRQFHQWUDWLRQVRIDVXEVWDQFHLQHQGH[KDOHGDLULWLVGLIÀFXOWWRGHWHUPLQH
whether the compound is formed endogenously or is the result of exogenous 
exposure. Phillips and colleagues introduced the concept of the alveolar gradient, 
ZKLFKLVGHÀQHGDVWKHDEXQGDQFHLQH[KDOHGDLUPLQXVWKHDEXQGDQFHLQURRP
air (30). When the concentration of a compound in room air is higher than the 
concentration of the compound in exhaled air, the compound is most likely of 
exogenous origin. In addition, Pleil and colleagues argued that the alveolar 
gradient approach may not go far enough in clinical settings as it does not account 
for previous exposures before the patient or subject arrives at the clinic (31). 
Good practices
The collection of breath samples is non-invasive. It does not cause much discomfort 
or embarrassment, and it can be repeated without becoming much of a burden. 
Almost every person, including a young child, can provide an exhaled air sample 
as long as he or she understands the instruction for sample collection (5, 32). 
A few minutes before the start of the sample collection, instructions should be 
provided to the study subject. In addition, it is useful to clarify the instructions by 
demonstrating the collection procedure. The collection of blood can be a burden, 
especially when repeated samples are required. Since an end-exhaled air sample 
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UHÁHFWVWKHDUWHULDOEORRGFRQFHQWUDWLRQRIDVXEVWDQFHHQGH[KDOHGDLUDQDO\VLV
can be used as a substitute for the collection of blood samples. 
When humans are exposed to VOC, the elimination of these substances can be 
monitored by end-exhaled air analysis in repeated samples collected at different 
points in time. Figure 3.3 shows the concentration of the cyclic siloxane D5 
(decamethylcyclopentasiloxane) observed in end-exhaled air following dermal 
application of a personal care product (33). In this study, end-exhaled air analysis 
was used as a non-invasive biomonitoring tool. 
The fact that several samples needed to be collected in a short period of time, 
made the choice for end-exhaled air analysis preferable. Exhaled air collected 
LPPHGLDWHO\ IROORZLQJ FHVVDWLRQRIH[SRVXUH UHÁHFWVSULPDULO\ UHFHQWH[SRVXUH
to that substance. Samples collected during no or low exposure periods may, 
GHSHQGLQJ RQ WKH SURSHUWLHV RI WKH VXEVWDQFH DOVR UHÁHFW H[FUHWLRQ IURP
compartments that act like a sink, such as adipose tissue for lipophilic substances. 
The measured values are representative for exposure over a longer period of time, 
depending on the elimination half-life of the substance from long-term storage 
compartments, and can be modeled using physiologically-based pharmacokinetic 
(PBPK) models (32). Some volatile substances with fast kinetics or rapid excretion 
can easily be missed if sample collection is postponed until too long after cessation 
Figure 3.3 The concentration-time course of decamethylcyclopentasiloxane (D5) observed 
in end-exhaled air following dermal application of a personal care product. 
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RI H[SRVXUH ([FUHWLRQSDWWHUQVDUH LQÁXHQFHGE\SK\VLFDO H[HUFLVH ,QGLYLGXDOV
with a high physical workload have increased ventilation rates and cardiac output, 
which enhance the uptake during exposure but also accelerate excretion following 
cessation of exposure (34, 35). Such physiological parameters can be included in 
an appropriate PBPK model to improve accuracy of internal exposure estimates 
(27). 
$OYHRODU DLU FRQFHQWUDWLRQV UHÁHFW DUWHULDO EORRG FRQFHQWUDWLRQV DQG WKXV WKH
systemic internal dose. A fraction (approximately 15% of the cardiac output) of 
this blood volume perfuses the brain before reaching other internal organs (36) 
and before biotransformation, which primarily occurs in the liver. This means that 
measurement of end-exhaled air is of particular value for those substances for 
which the parent and not the product of biotransformation is the critical (toxic) 
species involved in potentially adverse effects. This is the case for most small VOC 
that can pass the blood-brain barrier and have an effect on the central nervous 
system (37).
Table 3.2 shows some examples of studies that present a good correlation 
between the concentrations of a compound measured in exhaled air and blood 
or urine, indicating that the collection of exhaled air provides an interesting 
alternative in HBM. The correlation between exhaled air and blood and urine is 
LQÁXHQFHGE\ LQWHULQGLYLGXDOYDULDWLRQLQELRPDUNHU OHYHOVVXFKDVYDULDELOLW\ LQ
metabolism or differences in half-life of the substance (38). Another factor which 
LQÁXHQFHVWKHFRUUHODWLRQEHWZHHQEUHDWKEORRGDQGEUHDWKXULQHLVWKHIDFWWKDW
the concentration of many volatile compounds declines rapidly after the end of 
H[SRVXUHPDNLQJ WKHGHWHFWLRQ LQH[KDOHGEUHDWKGLIÀFXOW7KHUHIRUHVDPSOLQJ
time is of great importance. 
Table 3.2 Correlation between alveolar air concentrations and levels in blood or urine of 
several compounds studied during occupational and environmental exposure.  
Compound Correlation Reference 
Styrene  r=0.76 (blood)  (40) 
n-Hexane  r=0.74 (urine) (83) 
Benzene  r=0.95 (urine)  
r=0.86 (blood) 
(84)  
(85) 
Toluene r=0.75 (blood) (86) 
Tetrachloroethylene r=0.61 (urine) (39) 
Chloroform r=0.92 (urine) (87) 
1,3-Butadiene r=0.87 (blood) (85) 
2,5-Dimethylfuran r=0.89 (blood) (85) 
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In an exposure study on tetrachloroethylene (PCE) among dry-clean workers, 
McKernan and colleagues demonstrated that PCE concentrations in blood, 
ambient air (8 h time-weighted average) and exhaled air were highly correlated 
(39). However, the authors still propose blood as the most appropriate medium 
for a quick biological index to assess PCE body burden, as they rated the sample 
analysis as labor-intensive. The same day post-shift exhaled breath sample is a 
good alternative if the invasive nature of blood collection makes recruitment of 
ZRUNHUVPRUHGLIÀFXOW
Some authors reported a good correlation between the concentration of a 
compound in ambient air and the concentration of the same compound in exhaled 
DLU3HUVRQDODLUVDPSOLQJRQO\UHÁHFWVLQKDODWLRQXSWDNHZKHUHDVH[KDOHG
DLUOHYHOVUHÁHFWDOOURXWHVRIXSWDNH3RJDUHYDQGFROOHDJXHVGHPRQVWUDWHGWKDW
during short-term exposure to mercury vapor the determination of mercury in 
exhaled air is a more suitable biomarker for recent exposure than urinary mercury 
(41). Scheepers and co-workers found no correlation between benzene, toluene 
en xylene (BTX) levels measured in personal air samples and exhaled air samples 
of Turkish school children. In contrast, the authors demonstrated that levels of 
BTX in exhaled air were explained by known determinants of exposure, such as 
smoking and use of consumer products. This was not the case when taking the 
results of 24h diffusive sampling in the breathing zone as dependent exposure 
estimates (32). This shows that the presence of substances in exhaled air is a 
useful indicator for previous exposure.  
 
Framework for interpretation
Some studies provide background values for biomarkers in end-exhaled air in 
small numbers of subjects from the general population (Table 3.3). These values 
UHÁHFWDEDVHOLQH LQYROXQWHHUVZKRZHUHQRWNQRZLQJO\H[SRVHGDQGRUDVNHG
to stay clear of known sources of residential or occupational exposure. These 
EDFNJURXQG YDOXHV DUH QRW À[HG EXW DUH SDUW RI D GLVWULEXWLRQ UHÁHFWLQJ LQWHU
individual variability in the population. On the other hand, guidance values were 
established as health-based threshold limit values to protect workers from adverse 
health effects. In the United States, the American Conference of Governmental 
Industrial Hygienist (ACGIH) have developed biological exposure indices (BEIs) 
(42). Review committees evaluated published and peer-reviewed literature in 
YDULRXVVFLHQWLÀFÀHOGVHJHSLGHPLRORJ\WR[LFRORJ\DQGRFFXSDWLRQDOPHGLFLQH
Based on available information the ACGIH BEI committee established the level of 
exposure that a worker will protect from long-term adverse health effects (43). 
In Germany, the Deutsche Forschungsgemeinschaft has developed biological 
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WROHUDQFHYDOXHV%$7VZKLFKDUHGHULYHGXVLQJVFLHQWLÀFGDWDWKDWDUHEDVHGRQD
quantitative relationship between exposure concentration and body burden (44). 
The BEIs, as well as the BAT values are applied to workers. Most guidance values 
are available for urine and blood, whereas only few biological guidance values 
have been established for exhaled air (Table 3.4). Therefore, additional guidance 
values regarding end-exhaled air need to be derived. This can be done using the 
DSSURDFKRIWKH%LRPRQLWRULQJ(TXLYDOHQW%(GHÀQHGDVWKHFRQFHQWUDWLRQRID
chemical or metabolite in a biological medium that is consistent with an existing 
exposure guidance value such as a tolerable daily intake (TDI) or reference dose 
(RfD) (42, 45). 
Recently, Verner and colleagues used a PBPK model to propose a biological 
guidance value for occupational exposure to styrene in end-exhaled air of 0.3 ppm, 
15 minutes after the end of the work shift (46). When deriving background and 
guidance values, the occurrence of endogenously formed VOC and the wash-in 
wash-out effect are aspects to take into account. Inter individual differences may 
Table 3.3 Background values of exogenous and endogenous substances present in exhaled 
air of healthy volunteers. Table continues until the next page.
Substance CAS 
number 
Background 
value (ng/L) 
N Reference 
population 
Reference 
Benzene 71-43-2 8 65 Male and 
female 
volunteers from 
Belgium, 
Denmark, 
Germany, 
Sweden, the 
Netherlands 
and the United 
Kingdom. 
(88) 
 Chloroform 67-66-3 0.1 60 
Tetrachloroethylene 127-18-4 0.2 54 
Trichloroethylene 79-01-6 0.1 54 
Octamethylcyclotetrasiloxane 
(D4) 
556-57-2 3.5 3 Female 
volunteers from 
the 
Netherlands. 
(33) 
Decamethylcyclopentasiloxane 
(D5) 
541-02-6 4.0 3 Male and 
female 
volunteers from 
the 
Netherlands. 
(33) 
Ammonia 7664-41-7 833 * 103 30 Male and 
female 
volunteers from 
the United 
Kingdom 
 
(8) 
 Acetone 67-64-1 477 * 103 30 
Methanol 67-56-1 461 * 103 30 
Ethanol 64-17-5 112 * 103 30 
Isoprene 78-79-5 106 * 103 30 
Propanol 71-23-8 18 * 103 30 
Acetaldehyde 75-07-0 22 * 103 30 
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OHDGWRGLIIHUHQFHVLQHQGRJHQRXVO\SURGXFHGYRODWLOHFRPSRXQGV:LWKRXWVSHFLÀF
exposure some people exhale these compounds. The formation of endogenous 
substances may interfere and confound the interpretation of guidance values. The 
lack of background and guidance values hampers a broader implementation and 
more frequent utilization of end-exhaled air as a non-invasive biological medium.
Future perspectives 
7KHFROOHFWLRQRIHQGH[KDOHGDLUXVLQJULJLGFRQWDLQHUVRUÁH[LEOHEDJVLVDVLPSOH
and non-invasive way to obtain a sample for biomarker analysis. Subjects can 
easily collect samples themselves, as a collection device can be sent to the study 
subjects accompanied by written instructions. After sample collection is completed, 
the material can be returned to the laboratory for subsequent analysis. Sample 
collection by self-administration may be useful, for example, in the aftermath of a 
FKHPLFDOLQFLGHQWDVHQGH[KDOHGDLUPD\SURYLGHDQHIÀFLHQWDQGHIIHFWLYH
source of exposure data. Beside self-administration, on-line sampling and real-
time analysis could be of additional value, as these methods provide direct 
information of the systemic dose. This may be useful in clinical settings when 
people are admitted to hospital after inhalation of volatile neurotoxic fumigants 
(48). In occupational settings, tasks resulting in enhanced exposure may be 
LGHQWLÀHGDQG LPPHGLDWH IHHGEDFN WR WKHPDQDJHPHQWDQG WKHZRUNHUV FRXOG
be provided after the implementation of exposure reducing measures. Real-time 
analysis requires mobile analytical equipment, such as a portable GC-MS system, 
which are commercially available nowadays. 
In addition to traditional applications in diagnostics and in occupational or 
HQYLURQPHQWDOH[SRVXUHDVVHVVPHQWQHZUHVHDUFKÀHOGVPD\EHQHÀWIURPWKLV
method, for example, exposure assessment in consumers. Aggregate exposure in 
the general population comprises the simultaneous exposure to a substance from 
all possible sources and routes of uptake (49, 50). The best-known application 
of exhaled air analysis is the determination of alcohol blood levels in drivers of 
Table 3.4. Established and proposed biological guidance values for exhaled air.
Substance CAS 
number 
Sampling Time Biological exposure index 
(μg/L*) 
Reference 
Carbon monoxide 630-08-0 End of shift 20 000 (43) 
Methylchloroform  71-55-6 Prior to last shift of 
workweek 
40 000  (43) 
Perchloroethylene 127-18-4 Prior to shift 3 000 (43) 
Styrene 100-42-5 15 min after the end of 
shift 
300  (46) 
* ppm converted to μg/L. 
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road vehicles. However, not only alcohol affects a driver’s capabilities. The use 
of other drugs may have similar consequences. Beck and colleagues (51-53) 
GHYHORSHGDPHWKRGWRGHWHFWDPSKHWDPLQHVDQGƄ9-tetrahydrocannabinol (THC) 
in exhaled air. Another new application related to security issues is currently 
being explored, such as early collection and analysis of exhaled air samples 
for benzene, toluene and xylene during triage following chemical-, biological- 
and radionuclear-incidents (CBRN-incidents) (54, 55). In addition, Amann and 
colleagues introduced the concept of ‘the human volatilome’, the measurement 
of volatile organic compounds in exhaled air, skin emanations, urine, feces and 
saliva (56).  
Conclusion
The merits of breath analysis as a non-invasive biomonitoring tool have been 
ZLGHO\DFNQRZOHGJHGLQWKHVFLHQWLÀFOLWHUDWXUH+RZHYHUWKHQXPEHURIVWXGLHV
using breath analysis for HBM is still lagging behind compared to more traditional 
PHWKRGV:HEHOLHYHWKDWUHVHDUFKHUVPD\EHFDXJKWLQDÀ[HGPLQGVHWOLQNLQJ
ELRPRQLWRULQJRQO\WRDQDO\VLVRIERG\ÁXLGVVXFKDVEORRGDQGXULQH7KHPHULWV
of breath analysis should be further disseminated to reveal its potential as an 
alternative biological matrix for HBM. Additional research is needed to explore 
novel opportunities for the application of biomarkers in exhaled air, to develop 
standardized protocols for sample collection and analysis, and to establish more 
guidance values. This will boost the future implementation of breath analysis as 
a time-resolved, non-invasive technique to study occupational and environmental 
exposures.
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Supplementary material
Table SI 1. Substances studied by means of end-exhaled air analysis and their vapor 
pressures.
Substance CAS number Vapor pressure at 25 °C (Pa) Reference 
Mercury 7439-97-6 0.3  (57) 
Naphthalene 91-20-3 11 (58) 
Octamethylcyclotetrasiloxane 556-57-2 13 (59) 
Decamethylcyclopentasiloxane 541-02-6 25 (59) 
Decane 124-18-5 191 (60) 
1,4-Dichlorobenzene  106-46-7 232 (60) 
1,3,5-Trimethylbenzene 108-67-8 331 (60) 
Bromoform  75-25-2 720 (61) 
Styrene 100-42-5 841 (62) 
o-Xylene 95-47-6 881 (60) 
m-Xylene 108-38-3 1 103 (63) 
p-Xylene 106-42-3 1 178a (63) 
Ethylbenzene 100-41-4 1 280 (60) 
Bromodichloromethane  75-27-4 2 270 (63) 
Perchloroethylene  127-18-4 2 466 (63) 
Toluene  108-88-3 3 786 (60) 
2,5-Dimethylfuran 625-86-5 6 404 (64) 
Ethanol 64-17-5 7 906 (60) 
Trichloroethene  79-01-6 9 199 (61) 
Benzene 71-43-2 13 330 (63) 
Carbon tetrachloride 56-23-5 15 332 (61) 
1,1,1-Trichloroethane  71-55-6 16 532 (61) 
Methanol 67-56-1 16 932 (61) 
n-Hexane 110-54-3 20 398 (60) 
Chloroform  67-66-3 26 265 (61) 
Sevoflurane 28523-86-6 26 664 (65) 
Acetone 67-64-1 30 797 (66) 
Methyl tertiary-butyl ether  1634-04-4 33 330 (60) 
Halothane 151-67-7 40 263  (60) 
Carbon disulfide  75-15-0 47 863  (67) 
Dichloromethane 75-09-2 57 995  (60) 
Pentane 109-66-0 68 528  (60) 
1,3-Butadiene 106-99-0 281 263 (60) 
Vinyl chloride  75-01-4 397 301  (60) 
Methyl chloride 74-87-3 573 286  (60) 
Ethane 74-84-0 4 194 188  (60) 
Carbon monoxide  630-08-0 20 664 967 105  (67) 
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Abstract
Octamethylcyclotetrasiloxane (D4) and decamethylpentasiloxane (D5) are used 
as ingredients for personal care products (PCPs). Due to the use of these PCPs, 
consumers are daily exposed to D4 and D5. A sensitive analytical method was 
developed for analysis of D4 and D5 in end-exhaled air by thermal desorption gas 
chromatography mass spectrometry (TD-GC-MS), to determine the internal dose 
for consumer exposure assessment. Fifteen consumers provided end-exhaled air 
samples, that were collected using Bio-VOC breath samplers and subsequently 
transferred to automatic thermal desorption (ATD) tubes. Prior to use, the ATD 
tubes were conditioned for a minimum of 4 hours at 350 °C. The TD unit and 
auto sampler were coupled to a GC-MS using electron ionization (EI). Calibration 
was performed using 0-10 ng/μL solutions of D4/D5 and 13C-labelled D4/D5 as 
internal standards. The ions monitored were m/z 281 for D4, 355 for D5, 285 
for 13C-labelled D4 and 360 for 13C-labelled D5. The addition of internal standard 
UHGXFHGWKHFRHIÀFLHQWRIYDULDWLRQIURPWRIRU'DQGIURP
WRIRU'7KHOLPLWRITXDQWLÀFDWLRQZDVQJ/HQGH[KDOHGDLUIRU'
and 1.4 ng/L end-exhaled air for D5. With this method, cyclic siloxanes (D4 and 
'FDQEHTXDQWLÀHGLQHQGH[KDOHGDLUDWFRQFHQWUDWLRQVDVORZDVEDFNJURXQG
levels observed in the general population.
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Introduction
On a daily basis, consumers are exposed to cyclic siloxanes, such as 
octamethylcyclotetrasiloxane (D4) and decamethylcyclopentasiloxane (D5) via 
the use of personal care products (PCPs) (1, 2). These substances are added to 
PCPs as emollient or solvent (3, 4). Some PCPs are used with a high frequency 
(e.g. deodorant or day cream once a day) (5). Often multiple products are used 
simultaneously, leading to aggregate exposure (i.e. simultaneous exposure to the 
same substance from all possible sources and routes) (6, 7). For example, D4 
or D5 present in a deodorant or day cream could be inhaled when applying the 
product and could be dermally absorbed as the product stays on the skin during 
the day.
The widely investigated toxicity of D4 and D5 has recently been reviewed by the 
6FLHQWLÀF&RPPLWWHHRQ&RQVXPHU6DIHW\6&&6RIWKH(XURSHDQ8QLRQDQG
the Cosmetic Ingredient Review (CIR) expert panel in the US (3). Both committees 
state that the use of D4 and D5 in PCPs represents a minimal human health risk. 
However, data to assess the potential health risks of aggregate exposure were not 
available and therefore not included in the assessment. 
The majority of D4 and D5 that becomes systemically available, either through 
inhalation or dermal absorption, is eliminated by exhalation of the parent 
compound (8). A small fraction is metabolised and excreted in urine (9, 10). D4 
DQG'ZHUHTXDQWLÀHGXVLQJ*&06LQGLIIHUHQWELRORJLFDOPHGLDVXFKDVEORRG
and urine (11-13). Their vapour pressures (Table 4.1) and low blood:air partition 
FRHIÀFLHQWVPDNHWKHPVXLWDEOHIRUGHWHFWLRQLQHQGH[KDOHGDLU
Table 4.1 Chemical structure and some physical chemical properties of D4 and D5.
 D4 D5 
Chemical structure 
 
 
Molecular weight 296.6  370.8  
Vapour pressure (Pa, at 25 °C) 138 (14) 25 (14) 
Blood:air partition coefficient  0.96 (15) 0.41 (8) 
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Plotzke and co-workers studied 13C-D4 and 13C-D5 concentrations in exhaled 
air (16, 17). Tedlar bags were used for sample collection and the substances of 
interest were trapped on Tenax adsorbent tubes, desorbed with pure hexane and 
analysed by GC-MS. Recently, Pieri and colleagues determined the presence of 
linear and cyclic volatile methyl siloxanes (D3 to D6) in indoor air using TD-GC-MS 
7RRXUNQRZOHGJHRXUPHWKRGLVWKHÀUVWGHVFULELQJWKHXVHRI7'*&06DV
an analytical technique to quantify native cyclic siloxanes in end-exhaled air.  
The concept of sampling volatile organic compounds (VOCs) in end-exhaled air 
LVEULHÁ\LQWURGXFHGEHORZ7KHEDVLFFRQFHSWGHVFULEHGE\)DUKLKDVEHHQ
adjusted as we assume that VOCs are present in ambient air, leading to inhalation 
of the substance. Under steady state conditions, the amount of VOC entering the 
lung via venous blood equals the difference between the amount of VOC entering 
and leaving the lung via in- or exhalation (CA  - Cin) and the amount of VOC leaving 
via arterial blood and can be described according to the following mass balance 
(Equation 1):
ܳ஼ ൈܥ௏ ൌ  ஺ܸ ൈሺܥ஺ െ ܥ௜௡ሻ ൅ܳ஼ ൈܥ௔௥௧     (1)
Where QC is the cardiac output (L/min), CV is the venous blood concentration 
(ng/L), VA is the ventilation rate (L/min), CA is the alveolar concentration during 
exhalation (ng/L), Cin the concentration in inhaled air (ng/L) and Cart is the arterial 
blood concentration (ng/L). 
7KHDUWHULDOEORRGFRQFHQWUDWLRQLVGHSHQGLQJRQWKHEORRGDLUSDUWLWLRQFRHIÀFLHQW
(PB), assuming diffusion equilibrium between arterial blood leaving the lung and 
alveolar air leaving the lung (Equation 2):
ܥ௔௥௧ ൌ ܥ஺ ൈ  ஻ܲ     (2)
Subsequently, both equations 1 and 2 can be combined to describe the alveolar 
concentration (Equation 3). The alveolar concentration (CA) is proportional to the 
concentration of the VOC in mixed venous blood (CV ) and the concentration of the 
VOC present in inhaled air (CinZKLFKLVDVVRFLDWHGZLWKWKHVXEVWDQFHVSHFLÀF
EORRGDLUSDUWLWLRQFRHIÀFLHQWPB ), alveolar ventilation (VA) and cardiac output (QC) 
(19, 20). 
ܥ஺ ൌ 
ሺொ಴ൈ஼ೇሻାሺ௏ಲൈ஼೔೙ሻ
௏ಲାொ಴ൈ௉ಳ
    (3)
:KHQ PHDVXULQJ 92&V ZLWK D ORZ EORRGDLU SDUWLWLRQ FRHIÀFLHQW 3B WKH
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FRQFHQWUDWLRQLQYHQRXVEORRGLVSULPDULO\LQÁXHQFHGE\WKHYHQWLODWLRQUDWHDQG
cardiac output. As a consequence, slight variations in these parameters will 
lead to inter- and intra individual differences (21). In contrast, for VOCs with a 
KLJK EORRGDLU SDUWLWLRQ FRHIÀFLHQW 3B>10), the venous blood concentration is 
less affected by changes in ventilation rate and cardiac output. Water-soluble 
compounds may become dissolved in the mucous membrane lining the respiratory 
tract during inhalation and exhalation (i.e. the wash-in wash-out effect). This 
results in a lower uptake of the hydrophilic solvent compared to what would be 
expected based on blood:air partitioning (22, 23). The wash-in wash-out effect 
requires standardization of the sample collection procedure and an adjustment 
for this effect should be considered when modelling the data. 
The collection of samples of end-exhaled air, using canisters, bags or glass 
tubes, is non-invasive and because of easy accessibility repeated samples can 
be obtained in a short time period without causing much of a burden to the study 
subject (24, 25). This makes exhaled air analysis attractive for kinetic studies.
7KHDLPRIWKLVVWXG\ZDVWRTXDQWLI\'DQG'LQHQGH[KDOHGDLUDVLWUHÁHFWVWKH
blood concentration and therefore internal exposure to D4 and D5. This method 
was used in a human exposure study focused on the dermal uptake of D4 and D5 
as a pure substance and as a constituent of cream or deodorant.
Materials and methods
Chemicals
Octamethylcyclotetrasiloxane (98% D4; CAS 556-67-2) and 
decamethylcyclopentasiloxane (97% D5; CAS 541-02-6) were obtained from 
Sigma-Aldrich (St. Louis, MO, United States). 13C-labelled D4 and 13C-labelled 
D5, used as internal standards, were purchased from Dow Corning (Midland, 
MI, United States). Methanol (99.9%; CAS 67-56-1) supplied by Boom (Meppel, 
the Netherlands) was used to dissolve 13C-labelled D4 or D5 and unlabelled D4 
or D5 for the preparation of standards. Bio-VOC breath samplers were obtained 
from Markes International (Llantrisant, United Kingdom) and automatic thermal 
GHVRUSWLRQ $7'µ [µ VWDLQOHVV VWHHO WXEHVÀOOHGZLWK&DUERJUDSK7'
60/80 and Carbograph 1 TD 60/80 were obtained from Camsco (Houston, TX, 
United States).
Standard preparation
We prepared a stock solution of 10 μg/μL of D4 and D5 in methanol. From this 
solution standards were prepared of 10, 5, 2, 1, 0.5 and 0.1 ng/μL. 13C-labelled 
D4 and 13C-labelled D5 were diluted with 10 ml of methanol to a stock of 1 μg/
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μL. Both stock solutions were further diluted and combined to a working solution 
of 5 ng/μL. 
Sample collection and preparation
Prior to use, the ATD tubes were conditioned at least four hours at 350 °C 
using a multi tube conditioner (TC-20, Markes International, Llantrisant, United 
Kingdom). End-exhaled breath samples were collected using Bio-VOC breath 
samplers. The participants were instructed to inhale normally, to place the Bio-
VOC breath sampler into their mouth and to exhale fully at normal speed into the 
sampler. Immediately following sample collection, the substances of interest were 
transferred to an ATD tube using the syringe (plunger). The ATD tubes were capped 
with Swagelock-caps and stored until analysis at ambient temperature for less 
than 24 h. Subsequently, 2.5 ng 13C-labelled D4 and D5 in 0.5 μL methanol was 
loaded on the ATD tubes using a loading rig (Markes International, Llantrisant, 
United Kingdom). The ATD tube was connected to the loading rig, the internal 
VWDQGDUG VROXWLRQZDV LQMHFWHG XVLQJ D V\ULQJH DQG WKH WXEHZDV ÁXVKHGZLWK
KHOLXP/LQGH*DV6FKLHGDP7KH1HWKHUODQGVDWDÁRZRIPOPLQIRU
three minutes to remove the methanol.
&DOLEUDWLRQSURFHGXUHDQGTXDQWLÀFDWLRQ
&DOLEUDWLRQDQGTXDQWLÀFDWLRQZDVFDUULHGRXWE\ VSLNLQJ VHYHQ$7' WXEHV LQD
concentration range between 0 and 10 ng/μL D4 and D5. A conditioned ATD tube 
was connected to the loading rig. Next, the standards were loaded on the tubes 
XVLQJDV\ULQJHDQGÁXVKLQJWKHWXEHZLWKKHOLXPDWDÁRZRIPOPLQIRU
three minutes to remove the methanol. Subsequently, this procedure was repeated 
for loading of the internal standards. Linear calibration curves were constructed 
by plotting the quotient of the peak area of the analytes of interest and the 
corresponding labelled internal standards versus the standard concentrations. 
The calibration curves routinely had r2 IRUERWKVXEVWDQFHV
Analysis
The samples were analysed by use of thermal desorption gas chromatography 
mass spectrometry (TD-GC-MS). The instrument consisted of a thermal desorption 
unit and auto sampler (Unity 2 and Ultra 2, Markes) coupled to a gas chromatograph 
PDVVVSHFWURPHWHU )RFXVDQG ,647KHUPR6FLHQWLÀF ,QWHUVFLHQFH%UHGD7KH
Netherlands). Electron impact ionisation was used. The ATD tubes were inserted 
in the auto sampler and subsequently desorbed at 275 °C for 15 minutes, using 
DVSOLW ÁRZRIPOPLQ6DPSOHVZHUH WUDSSHGDW &E\XVLQJDJHQHUDO
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purpose hydrophobic trap (U-T2GPH-2S). A 30 m Rxi-5 MS (0.25 mm i.d., 0.5 μm 
ÀOPWKLFNQHVV5HVWHNZDVXVHGDVDQDQDO\WLFDOFROXPQ+HOLXPZDVXVHGDV
carrier gas. The GC oven temperature was programmed as follows: hold for 5 min 
at 50 °C; 10 °C/min to 150 °C; 30 °C/min to 250 °C, hold for 2 min. The transfer 
line was kept at 250 °C and the ion source at 250 °C. We ran in full scan mode 
and the ions monitored were m/z 281 for D4, 355 for D5, 285 for 13C-labelled D4 
and 360 for 13C-labelled D5, respectively. The dwell time was set at 0.4 sec.  
Biological monitoring
To demonstrate the applicability of the method for quantifying values at a low 
range, we collected end-exhaled air samples (142 mL) in duplicate from 15 
consumers exposed to PCPs (regular use) and from the same consumers after 
they refrained from the use of PCPs for 24 hours. Regular use was described as 
the use of PCPs by our volunteers as they would normally do without restrictions.  
Results and discussion
Prevention of contamination
The ubiquitous presence of cyclic siloxanes and their unique chemistry makes 
their analysis at trace levels challenging (26). Several measures were taken to 
prevent contamination of the analytical process: 
x D4 and D5 are present in a wide variety of PCPs, such as hand creams and 
deodorants. All researchers, lab technicians and instrument operators 
refrained from the use of these products prior (24 h) and during the 
experimental and analytical work. 
x All calibration and internal standard solutions were prepared in glass 
jars with metal lined screw caps in order to prevent contamination of the 
solutions due to contact with plastic (possible silicon containing) screw 
caps. 
x 7KHLQLWLDOSUHVVXUHUHJXODWRUUHJXODWLQJKHOLXPÁRZZDVUHSODFHGE\D
pressure regulator with a complete iron inner lining. 
x All parts of the TD-GC-MS system that contained silicon were replaced by 
silicon free alternatives (e.g., septa). 
Before the start of every analysis the system was checked with an empty tube, 
which did not contain a sorbent, to verify that the system was not a source of 
background contamination (Figure 4.1a+b). 
Conditioning
ATD tubes, conditioned by the supplier with nitrogen, appeared to contain 
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substantial amounts of D4 and D5 upon arrival. Helium 4.5 was used to condition 
the ATD tubes, but the D4 and D5 levels present on the tubes did not decrease. To 
LPSURYHWKHSUHFOHDQLQJHIÀFLHQF\KHOLXPZDVUHSODFHGE\KHOLXPRIVXSHULRU
quality (helium 5.0). Despite extensive conditioning we were unable to completely 
remove all D4 and D5. Conditioning was considered satisfactory if the residual 
background level for both substances was present on the tubes, corresponded 
to <69 pg/tube for D4 and <47 pg/tube for D5. As the analytical system itself 
ZDVQRWDVRXUFHRIFRQWDPLQDWLRQZHVXJJHVWWKDW'DQG'ZHUHGLIÀFXOWWR
remove completely as they originated from the adsorbent material in the tubes. 
We accounted for this problem by analyzing each individual conditioned tube and 
subtracting the peak areas of the analytes on the tube prior to sample collection 
IURP WKHSHDNDUHDVREVHUYHG LQ WKH ÀQDO DQDO\VLV RI D WXEH ORDGHGZLWKHQG
exhaled air.
4XDQWLÀFDWLRQOLPLW
7KHOLPLWRITXDQWLÀFDWLRQ/24ZDVGHWHUPLQHGWREHWKHFRQFHQWUDWLRQDWZKLFK
WKHUHSHDWDELOLW\KDVDFRHIÀFLHQWRIYDULDWLRQRI)LJXUH7KH/24ZDV
2.1 ng/L end-exhaled air (0.3 ng/tube) for D4 and 1.4 ng/L end-exhaled air (0.2 
ng/tube) for D5. 
A 
B 
Figure 4.1 Extracted ion chromatogram of D4 (A) and D5 (B) after analysis of the TD-GC-MS 
system without the presence of samples loaded with D4 and D5.
A
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Repeatability of the method
This method shows well resolved peaks without interference (Figure 4.3a+b). 
Repeatability for both substances improved due to the addition of an internal 
VWDQGDUG 7KH FRHIÀFLHQW RI YDULDWLRQ GHFUHDVHG IURP  WR  IRU '
DQGIURPWRIRU'2YHUDSHULRGRIÀYHPRQWKVWKHVORSHRIWKH
FDOLEUDWLRQ FXUYHV VKRZHGD VPDOO YDULDWLRQ DV WKH FRHIÀFLHQW RI YDULDWLRQZDV
7.0% for D4 and 10.4% for D5. To take this variation in account, in each series of 
samples standards were analysed. The inter- and intraday variations were similar 
for both substances (Table 4.2). 
%UHDNWKURXJKDQGFROOHFWLRQHIÀFLHQF\
With this experimental set-up it was unlikely that breakthrough of D4 and D5 would 
occur as the concentrations present in the end-exhaled air samples were rather 
low. The siloxanes collected using the Bio-VOC breath sampler were transferred to 
WKH$7'WXEHVZLWKDPHDQHIÀFLHQF\RI
Figure 4.2 7KHFRHIÀFLHQWRIYDULDWLRQYHUVXVWKH'DQG'FRQFHQWUDWLRQLQHQGH[KDOHG
air.
Table 4.2 ,QWHUDQGLQWUDGD\YDULDELOLW\H[SUHVVHGDVFRHIÀFLHQWRIYDULDWLRQ
 Inter-day Intra-day 
Concentration (ng/tube) N D4 (%)  D5 (%) N D4 (%)  D5(%)  
1 17 22.7 15.9 5 25.4 22.4 
5 16 8.8 12.8 6 9.5 12.5 
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Figure 4.3 A TD-GC-MS chromatogram and the EI-mass spectra of D4 (A) and D5 (B), 
analysis of a sample provided by a volunteer who was exposed to PCPs on a regular basis.
The presence of water in end-exhaled air samples
In a recent article by Guallar-Hoyas and co-workers (27) it was suggested that the 
presence of water in breath samples, when thermally desorbed, could damage the 
stationary phase of the GC column and lead to the production of cyclic siloxanes 
due to hydrolysis. As a consequence the retention times and separations were 
not reproducible across analytical campaigns. We believe that the presence of 
water in our end-exhaled air samples did not interfere with the stationary phase. 
The method presented in this paper has been used to assess the D4 and D5 
content of approximately 1,300 end-exhaled air samples obtained in various 
experiments. The samples have been analyzed between March and August 2013 
and the retention times were stable during this period. Furthermore, when loading 
the internal standard, the tube was purged with helium for 3 minutes and directly 
A
B
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at the start of the TD-GC-MS program, the tube was dry-purged for 1 minute to 
remove excess water.
Results of biological monitoring
Table 4.3 shows the results of end-exhaled air samples, collected from 15 
volunteers who were using PCPs (regular use) and from the same consumers 
who refrained from the use of PCPs for 24 h. The cyclic siloxanes investigated 
were indicated on the ingredient labels of the PCPs used by the volunteers. All 
samples were collected in duplicate. The mean concentration in end-exhaled air 
ranged from 2 to 45 ng/L for D4 and from 2 to 44 ng/L for D5 following regular 
use of PCPs. The mean concentration of the cyclic siloxanes in end-exhaled air of 
consumers who did not apply any PCPs for 24 hours was below 4 ng/L for D4 and 
below 9 ng/L for D5. When volunteers refrained from the use of PCPs 24 h prior to 
sample collection, the mean D4 and D5 concentration in end-exhaled air was, in 
most cases, similar or lower compared to the mean concentration measured after 
regular use of PCPs. Table 3 shows one exception (volunteer nr. 8), which may be 
explained by inhalation exposure to ambient sources of D4 and D5 while using 
SXEOLFWUDQVSRUWDWLRQWRRXUODERUDWRU\$VLJQLÀFDQWdifference was found between 
the D4 concentration in end-exhaled air of volunteers who did not use personal 
care products for 24-hours and of the same volunteers who regularly used PCPs 
(P=0.009). For D5 also a difference was found, but failed to reached the 5% level 
RIVLJQLÀFDQFH3 SUREDEO\EHFDXVHRIWKHVPDOOVDPSOHVL]H
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D4 (ng/L) Regular use of PCPs No use of PCPs for 24 h prior to sample collection 
 First sample Second sample First sample Second sample 
1 2.1 4.3 2.8 3.8 
2 7.7 6.4 <2.1 <2.1 
3 9.1 20.0 <2.1 2.9 
4 2.7* 10.8 <2.1 4.0 
5 2.4 3.9 2.5 <2.1 
6 2.1 3.3 <2.1 <2.1 
7 3.4 5.2 <2.1 <2.1 
8 2.4 <2.1 8.7* <2.1 
9 3.8* 13.1 <2.1 <2.1 
10 <2.1 2.5 3.1 <2.1 
11 18.0 5.6 <2.1 <2.1 
12 11.2* 43.5 <2.1 <2.1 
13 10.9 2.2 <2.1 <2.1 
14 2.3 3.4 2.2 <2.1 
15 86.4 3.1* <2.1 <2.1 
 
D5 (ng/L) Regular use of PCPs No use of PCPs for 24 h prior to sample collection 
 First sample Second sample First sample Second sample 
1 2.9 3.4 5.2 1.8 
2 9.2 3.9 <1.4 <1.4 
3 23.2 13.3 3.3 <1.4 
4 1.4 1.8 5.8 2.0 
5 2.0 1.7 <1.4 3.3 
6 2.7 3.0 <1.4 <1.4 
7 17.0* 37.3 1.9 2.8 
8 3.7 1.9 <1.4* 18.5 
9 4.9* 83.8 <1.4 <1.4 
10 <1.4 4.7 <1.4 1.8 
11 3.2 <1.4 <1.4 <1.4 
12 10.4 55.9 <1.4 <1.4 
13 3.0 <1.4 <1.4 1.7 
14 6.8 2.1 <1.4 <1.4 
15 34.1 1.6* <1.4 <1.4 
* = Note that there is a rather large difference between the two samples collected. The lowest value is 
probably not representing the D4 or D5 concentration in alveolar air, as the volunteer did not exhale 
completely. The value is representing the D4 or D5 concentration present in air which consists of a 
combination of air present in the death space of the lungs and in the alveoli.  
Table 4.3 Mean concentrations of D4 and D5 in end-exhaled air collected from human 
volunteers who used PCPs and from the same study participants not using PCPs for 24 h 
prior to sample collection.
Conclusion
Analysis of end-exhaled air represents a new and promising non-invasive approach 
in the use of D4 and D5 as chemical markers of cyclic siloxanes in consumer 
and environmental exposure assessment. Cyclic siloxanes (D4 and D5) can be 
TXDQWLÀHGLQHQGH[KDOHGDLUDWFRQFHQWUDWLRQOHYHOVDVORZDVEDFNJURXQGOHYHOV
REVHUYHG LQ WKH JHQHUDO SRSXODWLRQ 7R RXU NQRZOHGJH WKLV LV WKH ÀUVWPHWKRG
describing the use of TD-GC-MS as an analytical technique to quantify cyclic 
siloxanes in end-exhaled air. 
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Abstract
Consumers who use personal care products (PCPs) are internally exposed to some 
of the organic components present of which some may be detected in exhaled 
air when eliminated. The aim of this study was the quantitative determination 
of octamethylcyclotetrasiloxane (D4) and decamethylcyclopentasiloxane (D5) in 
end-exhaled air to study dermal absorption of substances in PCPs. We exposed 
WKH IRUHDUPRIÀIWHHQKHDOWK\YROXQWHHUV IRUPLQXWHV WRSXUH'RU'DQG
to commercial products containing D4 and D5. Inhalation uptake was kept to 
DPLQLPXP E\ NHHSLQJ WKH IRUHDUP LQ D ÁRZ FDELQHW GXULQJ GHUPDO H[SRVXUH
DQGVXSSO\LQJÀOWHUHGDLUWRWKHEUHDWKLQJ]RQHRIWKHYROXQWHHUGXULQJWKHSRVW
exposure period. End-exhaled air was collected using a breath sampler (Bio-VOC), 
transferred to carbograph multi-bed adsorbent tubes and analyzed by thermal 
desorption gas chromatography mass spectrometry (TD-GC-MS). In the end-
exhaled air of non-exposed volunteers background concentrations of D4 (0.8-
3.5 ng/L) and D5 (0.8-4.0 ng/L) were observed. After exposing the volunteers, 
the level of D4 and D5 in end-exhaled air did not or barely exceed background 
concentrations. At t=90 minutes, a sharp increase of the D4/D5 concentration in 
end-exhaled air was observed, which we attributed to inhalation of the substances 
during a toilet visit without using inhalation protection devices. When this visit was 
taken out of the protocol, the sharp increase disappeared. Overall, the results of 
our study indicate that dermal absorption of D4 and D5 contributes only marginally 
to internal exposure following dermal applications. As in our study inhalation is the 
primary route of entry for these compounds, we conclude that its risk assessment 
should focus on this particular exposure route.
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Introduction 
Consumers use personal care products (PCPs) to clean, refresh and decorate 
their bodies. Some products are used on a daily basis, whereas others are 
used less frequently (1, 2). When multiple products are used simultaneously, 
consumers may be exposed to the same substance through different sources 
and routes, also referred to as aggregate exposure (3, 4). Cyclic siloxanes, such 
as octamethylcyclotetrasiloxane (D4) and decamethylcyclopentasiloxane (D5), 
are added to PCPs as emollients or solvents (5, 6) in many different products 
throughout the world (7-10). D5 and to a lesser extent D6 were observed to be 
the predominant substances, whereas D4 was found in smaller amounts. The 
use of PCPs is the primary source of exposure to cyclic siloxanes (11). Therefore, 
WKH 6FLHQWLÀF &RPPLWWHH RQ &RQVXPHU 6DIHW\ LQ (XURSH DQG WKH &RVPHWLF
Ingredient Review Expert Panel in the US assessed the health implications of the 
use of cyclic siloxanes processed in PCPs (5, 6). Both committees concluded that 
cyclic siloxanes are safe with regard to the present practices of use and their 
concentrations in PCPs. 
7KHVXEVWDQFHVSHFLÀFSURSHUWLHVRI'DQG'HJKLJKYDSRUSUHVVXUHDQG
the fact that PCPs are mainly applied to the skin, point towards inhalation and 
dermal uptake as the dominant determinants of the internal dose.  The retention 
of inhaled labeled D4 was 5-6%, when rats were exposed to single and multiple 
dosages of 14C-D4 (7, 70, 700 ppm) (12). A physiologically based pharmacokinetic 
(PBPK) model was developed and successfully described the data presented 
above (13). The PBPK model was extended with a pharmacodynamic model for 
hepatic enzyme induction by D4 (14) and used to describe the tissue dosimetry, 
plasma concentration, and clearance in the rat following inhalation, dermal, oral, 
and intra venous exposure (15). Furthermore, 12 healthy volunteers inhaled 122 
J/'UHVXOWLQJLQDPHDQLQWDNHRIPJ
When male and female rats were exposed to single or repeated doses of 7 or 160 
ppm 14C-D5, lung retention was rather low (4-5% for single exposure and 8-10% for 
repeated exposures) (17). Reddy and co-workers developed an inhalation PBPK 
model, using human and rat exposure data (18. An additional compartment  was 
added to describe the presence of D5 bound to blood proteins, indicating that not 
all D5 is freely available for biotransformation and elimination. 
Zarebra and co-workers investigated the dermal absorption of neat D4 in human 
skin, using the human skin/nude mouse model (19). Under semi-occluded 
conditions, only 1.1% of the applied dose was absorbed while a large fraction of 
D4 (95%) evaporated from the skin. A PBPK model was developed to determine 
the dermal uptake of D4 and D5 after application of these substances to the 
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skin of axilla of human volunteers (20). The percentages of the applied dose that 
reached the systemic circulation were calculated to be 0.12% and 0.30% for D4 in 
men and women, respectively, and 0.05% for D5 in both sexes. In a study on the in 
vitro and in vivo dermal absorption of 14C-D4 and 14C-D5, the majority of the applied 
substances volatilized before being absorbed (21). Only small percentages of the 
applied dose were absorbed (0.5% D4 and 0.04% D5 in vitro and <1.0% D4 and 
0.2% D5 in vivo). Despite these low absorption fractions, dermal exposure cannot 
EHFRQVLGHUHGLQVLJQLÀFDQWDVGHUPDODSSOLFDWLRQRI3&3VLVWKHSULPDU\VRXUFHRI
consumer exposure (Health Canada 2008) and the applied products contain large 
quantities of D4/D5 (7-10). 
Assuming dermal absorption fractions of 0.5% for D4 and 0.04% for D5, Dudzina 
and co-workers calculated theoretical maximum internal doses after dermal 
application of PCPs that amount to 0.054 and 0.49 mg/capita/day, respectively, 
in a European population (7). Furthermore, the internal doses of D4 and D5 were 
determined in blood and exhaled air after dermal application of 13C-labelled D4 
and D5 to the axilla of human volunteers (22, 23). The average D4 concentrations 
ranged from 0.57 to 5.67 ng/g in blood and corresponded to values in exhaled air 
of 111 ng/L (women) and 30 ng/L (men). The D5 levels ranged from 0.61 to 1.41 
ng/g in blood and from 347 to 2,315 ng/L in exhaled air. Plotzke and colleagues 
(22, 23) investigated the internal dose after a single application of D4 or D5, 
but in reality consumers tend to use several products simultaneously, leading to 
aggregate exposure. 
7KH FRQFHQWUDWLRQ RI D FRPSRQHQW LQ HQGH[KDOHG DLU UHÁHFWV WKH EORRG
concentration, which is considered to be the most reliable estimate of the internal 
dose for many substances (24). However, sampling of blood is invasive and should 
be limited to a minimal number of samples. In contrast, the collection of end-
exhaled air samples, using canisters, bags or glass tubes, is non-invasive. Because 
of easy accessibility repeated end-exhaled air samples can be obtained in a short 
period of time without causing much of a burden to the study participant (25). 
D4 and D5 are excellent candidates for detection in end-exhaled air, because 
RI WKHLU KLJK YDSRUSUHVVXUHDQG ORZEORRGDLU SDUWLWLRQ FRHIÀFLHQWV 7KHUHIRUH
we aimed to quantify the dermal uptake of D4 and D5 after dermal application 
of two PCPs (i.e. night cream and deodorant) and to subsequently investigate 
the internal consumer exposure to both D4 and D5 using end-exhaled air as a 
biological medium for sample collection. 
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Materials and Methods
Chemicals and test substances
Octamethylcyclotetrasiloxane (98% D4; CAS 556-67-2) and 
decamethylcyclopentasiloxane (97% D5; CAS 541-02-6) were obtained from 
Sigma-Aldrich (St. Louis, MO, United States). A commercially available night cream 
(50 mL) and deodorant (40 mL) were purchased from an online retailer. According 
to the manufacturer, the night cream contained approximately 25% of D5 and 
0.3% of D4. The deodorant contained approximately 30% D5 and 0.3% D4. 
13C-labelled D4 and 13C-labelled D5, used as internal standards, were purchased 
from Dow Corning (Midland, MI, United States). Methanol (99.9%; CAS 67-56-1) 
supplied by Boom (Meppel, the Netherlands) was used to dissolve 13C-labelled D4 
or D5 and unlabelled D4 or D5 for the preparation of standards. 
Study design 
Figure 5.1 provides an overview of the study design. We recruited 15 volunteers 
using information folders, bulletin boards and word of mouth. We included 
volunteers above 18 and not older than 70 years of age, with good general health. 
Volunteers were excluded from the study when they were using prescribed 
medication, were suffering from a skin disease (e.g. psoriasis or eczema) or 
worked occupationally with PCPs. Several animal studies showed that exposure to 
D4 may lead to a disruption of the reproductive cycle of a female rat (5). Therefore, 
'ZDVFODVVLÀHGDVDUHSURWR[LFVXEVWDQFH:HGHFLGHGWRH[FOXGHIHPDOH
volunteers who were pregnant or not taking birth control measures.
The volunteers participated in a series of experiments, during which the forearm 
was exposed to D4 or D5 as a pure substance or as ingredient of a PCP (i.e. 
night cream and deodorant) for one hour. When the substance was removed, 
WKHYROXQWHHUSURYLGHGVHYHUDOHQGH[KDOHGDLUVDPSOHVRYHUDWLPHSHULRGRIÀYH
hours to monitor the internal D4 or D5 concentration. A more detailed description 
of the experiments is provided below.  
Baseline
Before the start of the study, all volunteers (N=15) completed a questionnaire 
and a 24 h diary, which were used to assess their PCP usage pattern prior to the 
baseline experiment. Subsequently, the volunteers visited our laboratory. During 
WKLV ÀUVW YLVLW ZH FROOHFWHG GXSOLFDWH VDPSOHV RI HQGH[KDOHG DLU WR VWXG\ WKH
baseline (normal) excretion of D4 and D5. At this point in the study, the volunteers 
were not restricted regarding their PCP use. 
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 Before the start of the study: 
x Completion of a questionnaire and a 24-hr diary  
Baseline experiment:  
x Spot sample of end-exhaled air in duplicate 
x No restriction on the use of PCPs 
Control experiment:  
x No dermal exposure to D4 or D5 
First dermal exposure experiment:  
x D5 as a pure substance 
Second dermal exposure experiment:  
x Night cream containing D4 and D5 
Third dermal exposure experiment:  
x Deodorant containing D4 and D5 
Fourth dermal exposure experiment:  
x Combination of night cream and deodorant containing D4 
and D5 
Fifth dermal exposure experiment:  
x D4 as a pure substance 
Inhalation exposure experiment:  
x Night cream containing D4 and D5 
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Figure 5.1. Overview of the study design.
Control experiments
To study the contribution of a background exposure to D4 and D5, we performed 
control experiments for some volunteers (N= 6). The experiment was executed as if 
it was an exposure experiment, but we did not administer D4 or D5 to the forearm 
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RI WKHYROXQWHHU ,QVWHDG'RU'ZDVDSSOLHG WRDQDUWLÀFLDODUP JUDGXDWHG
F\OLQGHUZUDSSHGZLWK ÀOWHU SDSHU SODFHG QH[W WR WKH DUP RI WKH YROXQWHHU WR
determine the presence of D4 and D5 in end-exhaled air, without a dermal source. 
The participants were asked to refrain from the use of PCPs 24 hours prior to the 
start of the experiments. However, they were allowed to brush their teeth using 
toothpaste provided by us. According to the ingredients list, this toothpaste was 
free of D4 and D5.
Dermal exposure experiments
:HVWDUWHGDVHULHVRIÀYHH[SRVXUHH[SHULPHQWVLQZKLFKHDFKRIWKHYROXQWHHUV
was dermally exposed to D4 and/or D5 in the following different media: pure 
substance, night cream, deodorant (stick) or a combination of the latter two. 
Aiming for an accumulated exposure of approximately 15 mg of D4 or D5 per cm2, 
we applied an estimated dose of 2.5 mg of D4 or D5 per cm2 to the forearm every 
ten minutes over a total exposure period of one hour to create a surplus of D4 
and D5, and prevent back diffusion from the skin. We measured the surface area 
of the forearm of the volunteer to determine the amount of substance needed 
to achieve this total dose. The net applied dose was determined by weighing the 
applied substance before the start of the experiment and at the end, by recovering 
the residue from the arm. The content of D4 in night cream and deodorant was 
approximately two orders of magnitude lower than the content of D5, implying 
that the total accumulated dose of D4 after application of these products was 
approximately 0.15 mg per cm2. The resulting applied amount in the experiments 
with formulated D4 was too low to be detected after dermal absorption and 
WKHUHIRUHQRWIXUWKHUVWXGLHG7KLVSURWRFROGRHVQRWUHÁHFWW\SLFDOXVHRIDQLJKW
cream or deodorant. We calculated the minimum level of D4 and D5 in end-exhaled 
air needed for detection with our analytical method. Subsequently, we calculated 
the corresponding systemic dose of D4 and D5 and derived the required amount 
and surface area of the products required to achieve this systemic dose.
To prevent inhalation exposure, the participant was sitting with his or her forearm 
LQVLGHDÁRZFDELQHWLQRXUODERUDWRU\)LJXUH$7RPRQLWRUWKHDPELHQWDLU
concentration and potential inhalation during the exposure and post exposure 
period, the participant carried a head-set (Fenix Environmental, Umeå, Sweden) 
with two sampling heads that were placed in the breathing zone slightly above 
the nose (26). The sampling heads were equipped with mini ATD tubes loaded 
with Tenax TA (Fenix Environmental, Umeå, Sweden) that provided time-weighted 
average concentrations of D4 and D5 in ambient air during the exposure and post-
exposure periods.
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7RREWDLQDFOHDUNLQHWLFSURÀOHH[SRVXUHZDVFHDVHGDIWHURQHKRXUE\UHPRYLQJ
the residual substance using a spatula and washing the arm with water and 
VRDS ZLWKRXW''RQ WKH LQJUHGLHQW OLVW LQVLGH WKHÁRZFDELQHW 7RSUHYHQW
inhalation of D4 and D5 from ambient air after cessation of the exposure period, 
a fume hood was placed over the head of the participant (Figure 5.2B), which 
VXSSOLHGDFRQVWDQWGRZQVWUHDPÁRZRIÀOWHUHGDLU7KHIXPHKRRGZDVFXVWRP
PDGHXVLQJD0-XSLWHUDLUVWUHDPGHYLFHFRQQHFWHGWRD09HUVDÁR+HDGWRS
DQGHTXLSSHGZLWKWZR0$%(.35ÀOWHUV%LHVKHXYHO7HFKQLHN:LMFKHQ7KH
1HWKHUODQGV7KURXJKRXWWKHSRVWH[SRVXUHSHULRGÀYHKRXUVWKHYROXQWHHUZDV
VHDWHGEHKLQGDGHVNLQDQRIÀFHVSDFH(YHU\KRXUWKHSDUWLFLSDQWZDVDVNHGWR
visit the toilet to provide a urine sample, during which no attempt was made to 
prevent inhalation of ambient air. At some point during the exposure experiments 
to D5 as a pure substance, preliminary results showed a sharp increase in the 
HQGH[KDOHGDLUFRQFHQWUDWLRQGLUHFWO\DIWHUWKHÀUVWWRLOHWYLVLWLHDWWKHHQGRI
the 1 hr exposure period. After this discovery, this toilet visit was removed from 
the protocol. 
A 
B 
Figure 5.2 A: $SDUWLFLSDQWZLWKKLVORZHUDUPLQVLGHWKHÁRZFDELQHWGXULQJDGPLQLVWUDWLRQ
B: A participant after cessation of exposure with the fume hood placed over his head.
Inhalation experiments
Finally, we conducted exposure experiments without the prevention of inhalation, 
as the results of the previous experiments showed that inhalation instead of 
dermal uptake appeared to be the major route of exposure. The volunteer was 
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seated inside a toilet room of approximately 9 m3. Four grams of night cream were 
DSSOLHGWRWKHIRUHDUPRIWKHYROXQWHHU$IWHUÀYHPLQXWHVWKHQLJKWFUHDPZDV
removed and the forearm washed with water and soap. The volunteer remained 
seated for another ten minutes, thereafter inhalation exposure was terminated by 
PRYLQJWKHYROXQWHHUIURPWKHH[SRVXUHURRPWRWKHRIÀFHZKHUHWKHSDUWLFLSDQW
was seated underneath the fume hood. 
Sample collection
Before, during and after exposure, end-exhaled air was collected at predetermined 
intervals (Figure 5.3). The participants were asked to exhale completely into a 
GLVSRVDEOHFDUGERDUGPRXWKSLHFHWKDWZDVÀWWHGWRDP/%LR92&FRQWDLQHU
(Markes International, Llantrisant, United Kingdom). In total, 17 end-exhaled 
air samples were collected in duplicate, resulting in a total of 34 samples per 
person per experiment. The collection times of the samples differed between 
those exposure experiments using pure substance and those using a night cream 
or deodorant. We distributed the sampling times more evenly when applying a 
night cream or deodorant, as there might be delayed absorption due to a matrix 
effect. Immediately after collection of the sample, the organic compounds were 
WUDQVIHUUHGWRDµ[µ6WDLQOHVV6WHHOWXEHÀOOHGZLWK&DUERJUDSK7'
and Carbograph 1 TD 60/80 (CAMSCO, Houston TX, United States). 
We collected urine samples before the start and after the end of the exposure 
experiments to monitor the elimination of both D4 and D5 and their metabolites 
after dermal absorption of the applied products (Figure 5.3). In the post-exposure 
period, we asked the participants to visit the toilet every hour, leading to a 
minimum of 6 samples per volunteer per experiment. During the toilet visits, the 
volunteer was not placed underneath the fume hood. The urine samples were 
stored in Vacuettes (Greiner Bio-One, Alphen a/d Rijn, the Netherlands) at -20 °C. 
These results are not reported in the present paper.
Sample analysis
We prepared an internal standard solution of 5 ng/μL 13C-labelled D4/D5 in 
methanol, to quantify end-exhaled air samples. Prior to analysis, 2.5 ng of 
13C-labelled D4 /D5 (0.5 μL) was loaded on the ATD tubes using a loading rig 
(Markes International, Llantrisant, United Kingdom). The ATD tube was connected 
to the loading rig, the internal standard solution was injected via a syringe and the 
WXEHÁXVKHGZLWKKHOLXP/LQGH*DV6FKLHGDP7KH1HWKHUODQGVDWDÁRZRI
50 mL/min for three minutes to remove the methanol. 
The samples were analyzed using thermal desorption gas chromatography mass 
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spectrometry (TD-GC-MS). The analytical instrument consisted of a thermal 
desorption unit and an auto sampler (Unity 2 and Ultra 2, Markes) coupled to a 
gas chromatograph mass spectrometer (Focus and ISQ, Thermo) using electron 
impact ionization (EI). The ATD tubes were positioned in the auto sampler and 
subsequently desorbed at 275 °C for 15 minutes. The analytical column was a 
P5[L06PPLGPÀOPWKLFNQHVV5HVWHN7KHFDUULHUJDVZDV
helium 5.0. The GC oven temperature was 50 °C; hold 5 min; 10 °C/min to 150 
°C; 30 °C/min to 250 °C, hold 2 min. The transfer line was kept at 250 °C and 
the ion source at 250 °C. The ions monitored were m/z 281 for D4, 355 for D5, 
285 for 13C-labelled D4 and 360 for 13C-labelled D5, respectively. The dwell time 
was 0.4 sec. 
7KHOLPLWRITXDQWLÀFDWLRQ/24LQHQGH[KDOHGDLUZDVQJ/IRU'DQG
ng/L for D5. The calibration curve included seven standard solutions with a 
concentration range of 0-10 ng/μL. A more detailed description of the analytical 
method can be found elsewhere (27). The urine samples were stored for future 
analysis. 
Study approval
The study was approved by the Regional Committee on Research involving 
Human Subjects Arnhem-Nijmegen (registration number: 2011/131). Additional 
information on procedures used to ensure the safety of the volunteers can be 
found in Supplementary Information I. 
Results 
Baseline
:H LQFOXGHGSDUWLFLSDQWVZLWKDPHDQDJHRI \HDUV LQFOXGLQJ WHQ
women. Table 5.1 provides an overview of the median concentrations of D4 
and D5 measured in end-exhaled air of our volunteers during the baseline 
measurements. The raw data are presented in Supplementary Information II. The 
individual use patterns of PCPs during the 24 h prior to the baseline measurement 
were reported in a 24 h diary and are presented in Supplementary Information III. 
Table 5.1 Median baseline concentrations of D4 and D5 in end-exhaled air of all participants 
after normal use of PCPs. 
 Median (min ± max) 
Participants D4 (ng/L) D5 (ng/L) 
Men (N=5) 4.3 (2.7 ± 11.8) 2.3 (1.6 ± 27.1) 
Women (N=10) 7.0 (1.9 ± 44.8) 5.7 (2.1 ± 44.4) 
All (N=15) 6.6 (1.9 ± 44.8) 4.4 (1.6 ± 44.4) 
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Control experiments
Six volunteers participated in the control experiments. The mean D4 and D5 
concentrations in end-exhaled air and the mean time-weighted average D4 and 
D5 concentration in ambient air measured during the control experiments are 
presented in Figure 5.4. The detailed results for each volunteer are presented in 
Supplementary Information IV-V. The measured concentrations in end-exhaled air 
ranged from 0.8 to 3.5 ng/L (D4) and from 0.8 to 4.0 ng/L (D5). We considered 
this to be the background level. The mean time-weighted average ambient air 
concentrations of D4 were 4.8 μg/m3 during exposure and 1.3 μg/m3 during the 
post-exposure period. For D5 the concentrations were 1.3 μg/m3 during exposure 
and 4.3 μg/m3 post exposure. 
Dermal exposure experiments
Table 5.2 a-c provides an overview of the mean net amount of substance or product 
dermally applied and the resulting mean net dermally applied dose of D4 and D5. 
The raw data of each volunteer are presented in Supplementary Information VI. 
The net applied dose did not reach 15 mg/cm2, indicating that a residue was 
removed at the end of the exposure period (1 hr).
In total, 29 exposure experiments were performed, during which the volunteers 
were exposed to:
A. D5 as a pure substance (N=13)
B. D5 as a pure substance, without the toilet visit at t=90 minutes (N=3)
C. Night cream containing D4 and D5 (N=4) 
D. Deodorant containing D4 and D5 (N=1) 
E. Combination of night cream and deodorant (N=2) 
F. D4 as a pure substance, without the toilet visit at t=90 minutes (N=6). 
Figure 5.5 provides an overview of registered D4 and D5 patterns observed in 
end-exhaled air following exposure to different media (A-F). Results for each 
individual are presented in Supplementary Information VII-XII. In general, the D4 
DQG' FRQFHQWUDWLRQV LQ HQGH[KDOHG DLU VKRZHG D ÁXFWXDWLQJ SDWWHUQ ZKLFK
included increases and decreases in the concentrations during both the exposure 
and post-exposure period. The concentrations measured did not or only barely 
exceed the maximum background concentrations, which were determined during 
the control experiments. The peak levels of D4 in end-exhaled air of different 
individuals occurred during exposure and ranged from 7.5 to 280 ng/L. The peak 
levels of D5 in end-exhaled air occurring during both the exposure and the post-
Aggregate dermal exposure to cyclic siloxanes
5
175
Figure 5.40HDQ6''$DQG'%FRQFHQWUDWLRQV LQHQGH[KDOHGDLU QJ/DQG
mean time-weighted average D4 and D5 concentrations in ambient air (μg/m3) during 
control experiments (N=3 for each substance).
exposure periods ranged from 3.8 to 605 ng/L. 
Inhalation experiments
Figure 5.6 presents the mean D5 concentrations in end-exhaled air and the 
mean time-weighted average ambient air concentrations measured during the 
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inhalation experiments (N=3). The results for each volunteer separately are 
presented in Supplementary Information XIII. The highest concentration of D5 in 
HQGH[KDOHGDLUZDVPHDVXUHGGXULQJWKHVWD\LQWKHWRLOHWURRPEHWZHHQÀYHDQG
ten minutes after the application of night cream. This concentration ranged from 
1,000 to 1,500 ng/L. As no attempt was made to remove volatilized substance 
form the breathing zone, the time-weighted average ambient air concentration 
was approximately two to three times higher compared to the average ambient air 
concentration during the dermal exposure experiments (section 3.3). When the 
same experiment was performed inside the toilet room but without the application 
of night cream, the D5 concentration in end-exhaled air was approximately 4 
ng/L, which is similar to that in the control experiments. The D5 concentration in 
ambient air was approximately 16 μg/m3 (data not shown). 
Table 5.2 Overview of net amount of D5 applied using pure substance, a night cream 
and a deodorant (a), a combination of night cream and deodorant (b) and the resulting 
net applied dose D5. Overview of applied net amount of D4 pure substance (c) and the 
resulting net applied dose D4. Data are presented as mean (SD).
a. 
Applied D5 Exposed surface 
forearm (cm2) 
Amount (g) Dose (mg/cm2) 
D5 pure substance 
(N=13) 
805 (112) 4.8 (1.2) 5.9 (1.7) 
D5 pure substance 
(no toilet visit at t=90 
minutes) (N=3) 
822 (209) 6.1 (1.3) 7.5 (1.2) 
Night cream (N=4) 818 (83) 14.4 (5.5) 4.4 (1.6) 
Deodorant (N=1) 689 5.3 2.3 
b. 
Applied D5 Exposed surface 
forearm (cm2) 
Amount (g) Dose (mg/cm2) 
Deodorant Night 
cream 
Deodorant Night 
cream 
Deodorant Night 
cream 
Total 
Night cream and 
deodorant (N=2) 
795 (34) 781 (28) 16.6 (4.0) 9.0 (0.8) 5.3 (1.1) 3.4 
(0.1) 
8.7 
(1.2) 
c. 
Applied D4 Exposed surface 
forearm (cm2) 
Amount (g) Dose (mg/cm2) 
D4 pure substance 
(N=6) 
832 (147) 8.6 (1.4) 10.1 (1.9) 
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Figure 5.5 Mean D4 or D5 concentrations in end-exhaled air (ng/L) and mean time-
weighted average D4 or D5 concentrations in ambient air (μg/m3) after dermal exposure 
to D5 as a pure substance (N=13) (A), to D5 as a pure substance without the toilet visit at 
t=90 minutes (N=3) (B), a night cream (N=4) (C), a deodorant (N=1) (D), a combination of 
night cream and deodorant (N=2) (E) and D4 as a pure substance without the toilet visit at 
t=90 minutes (N=6) (F).
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Figure 5.6 0HDQ 6' ' FRQFHQWUDWLRQV LQ HQGH[KDOHG DLU QJ/ DQG PHDQ WLPH
weighted average D5 concentration in ambient air (μg/m3) during inhalation experiments 
(N=3). The arrow indicates the D5 concentration in ambient air during exposure.
Discussion
8VLQJ WKH H[SHULPHQWDO VHWXS GHVFULEHG LQ WKLV SDSHU ZH FRXOG QRW FRQÀUP
VLJQLÀFDQW GHUPDO XSWDNH RI ' DQG ' DIWHU WRSLFDO DSSOLFDWLRQ RI WKH QHDW
substance or PCPs on the skin of healthy volunteers. We were also able to 
investigate internal consumer exposure to both D4 and D5 present in PCPs after 
dermal exposure. 
Baseline
The results of the baseline measurements showed that some volunteers (i.e. 
volunteer 2, 4, 5, 11, 13 and 15) had a ratio of D4/D5 that exceeded unity. This 
is remarkable, since nowadays D5 is the primary siloxane ingredient used in 
SHUVRQDOFDUHSURGXFWVDQG'LVSKDVHGRXWLQVHYHUDOSURGXFWV6LPLODUÀQGLQJV
were reported by Hanssen and co-workers (28) who analyzed blood samples from 
94 postmenopausal women and 17 pregnant women and found that D4 was the 
dominant compound in plasma of both cohorts. The authors suggested that the 
lower dermal uptake and higher lipophilicity of D5 relative to D4 (log Kow = 8.03 
versus 6.49, respectively) (29) could explain the higher observed D4 plasma 
concentrations. 
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Dermal exposure experiments
We included 15 healthy volunteers to participate in the dermal exposure 
experiments. Our intention was to expose all volunteers according to the protocol 
presented in Figure 1. However, during the study preliminary results indicated that 
dermal absorption of the applied D4 and D5 was very low. For ethical reasons, we 
decided to discontinue the study. As a result, not all volunteers were exposed to 
every product leading to low numbers of exposed volunteers in some groups (e.g. 
N=1 for deodorant).
Dermal exposure ended after 60 minutes by removal of the applied substance 
from the skin surface using water and soap. Under normal circumstances a 
consumer will not remove a night cream or deodorant after one hour, extending 
the time that D4 and D5 is present on the skin and available for absorption. In 
theory, this means that we could have underestimated the total amount of D4 
and D5 absorbed through the skin. However, presumably the amounts applied 
by consumers are too low to be absorbed in quantities that could be detected 
with our analytical method. Due to the high vapor pressure of both substances 
the longer availability on the skin of both substances is not relevant, as both 
substances evaporate quickly.
Shortly after the end of exposure, the volunteer provided three end-exhaled air 
samples (t=65, t=70, and t=75 min). During these actions the forearm was kept 
LQVLGHWKHÁRZFDELQHW7KHVXUIDFHDLUYHORFLW\RIPVKDGOLWWOHLPSDFW
RQWKHHPLVVLRQRIVXEVWDQFHVSUHVHQWLQGLDSHUFUHDP+RZHYHULWGLGLQÁXHQFH
the emission of substances from a liquid fragrance (30). As the air velocity inside 
WKHÁRZFDELQHWZDVUHODWLYHO\ORZPVDQGWKHDSSOLHGDPRXQWVRI
neat D4 and D5 were large, we consider the losses to be negligible. 
Subsequently, the fume hood was placed over the head of the volunteer. Before 
the collection of the next end-exhaled air sample (t=90 min), the volunteer visited 
the toilet for the collection of a urine sample and was invited to remain seated 
XQGHUQHDWK D IXPHKRRG EHKLQG D GHVN LQ DQ RIÀFH VSDFH IRU WKH UHVW RI WKH
observation period. It was not feasible to use the fume hood during the toilet visit. 
Several graphs showed a sharp increase of the concentration of D5 in end-exhaled 
air at this time point (t=90 min). The mean D5 concentration in end-exhaled air 
at t=90 minutes was 69.6 ng/L with the toilet visit and 5.7 ng/L without the toilet 
visit (compare Figures 5A and 5B). The sharp increase in D5 concentration at 
t=90 minutes is most likely explained by inhalation of the substance during the 
toilet visit. The source is most likely evaporation of a residue from the treated 
skin surface (i.e. not completely removed or back-diffused from the skin to the 
air). At other time points during the experiments, we occasionally observed similar 
Chapter 5
180
unexpected and sudden increases of D4 and D5 concentrations and suggest 
that inhalation exposure is the most probable explanation in those cases. As 
the pattern showed similarities with the peak at t=90 minutes, we assume that 
unintended vapor releases may have contributed to these peaks, despite the fact 
WKDWWKHYROXQWHHUVZHUHSODFHGZLWKWKHLUIRUHDUPLQVLGHDÁRZFDELQHWH[SRVXUH
and underneath a fume hood (post exposure). 
The maximum concentration of D4 (7.5 - 280 ng/L) in end-exhaled air of different 
individuals occurred during the exposure period. The maximum concentration of 
D5 (3.8 - 605 ng/L) occurred during the exposure and post exposure period. These 
concentrations are well within the range of results earlier reported by Plotzke and 
colleagues (22, 23). They observed maximum concentrations of D4 in exhaled air 
ranging from 30 to 111 ng/L, after the application of 1.0 or 1.4 g of 13C-labelled 
D4 to the axillae, at 60 minutes after exposure. When applying similar quantities 
of 13C-labelled D5 to the axillae, the authors observed peak levels of D5 in end-
exhaled air between 15 and 60 minutes after exposure, ranging from 347 to 2,315 
ng/L. Plotzke and co-workers did not report measures to prevent inhalation during 
dermal application of 13C-labelled D4 (23). During the application of 13C-labelled 
D5 volunteers were instructed to breathe from a clean air source (22). The exact 
WLPHSRLQWDQGGXUDWLRQRIXVDJHRIWKHFOHDQDLUVRXUFHZDVQRWVSHFLÀHGQRUGLG
they determine concentrations of 13C-labelled D5 in ambient air. After application 
of the substance a large fraction evaporates and as no information is provided 
on the time point and method of cessation of exposure, evaporation may have 
continued. Due to this supposedly limited prevention of inhalation exposure and 
the fact that the peak concentrations D4 and D5 in end-exhaled air in both studies 
DUHVLPLODU WRRXUÀQGLQJVZHVXVSHFWWKDW WKHUHVXOWVUHSRUWHGE\3ORW]NHDQG
colleagues do not exclusively represent dermal absorption but most probably 
UHÁHFW WRWDO H[SRVXUH IURPERWK LQKDODWLRQDQGGHUPDO DEVRUSWLRQSDWKZD\V ,I
this is true, the dermal PBK model developed by Reddy and colleagues (20) was 
parameterized incorrectly because D4 and D5 concentrations in exhaled air by 
Plotzke and co-workers were attributed to the dermal uptake route only, whereas 
LQKDODWLRQSUREDEO\DOVRSOD\HGDVLJQLÀFDQWUROH
Ambient air concentrations
We provided the volunteers with a headset to assess potential inhalation exposure 
to D4 and D5 during the control and exposure experiments. A time-weighted 
average D4 or D5 concentration was measured in a laboratory environment 
during the exposure period. Next, the volunteer was instructed to remain seated 
XQGHUQHDWKDIXPHKRRGEHKLQGDGHVNLQDQRIÀFHVSDFHWKXVWKHWLPHZHLJKWHG
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DYHUDJH FRQFHQWUDWLRQ SRVW H[SRVXUH UHÁHFWV ÀOWHUHG DLU FRQFHQWUDWLRQV 7KH
UHVXOWV ÁXFWXDWHG EHWZHHQ WKH LQGLYLGXDO GHUPDO H[SRVXUH H[SHULPHQWV DQG
between the exposure and post-exposure periods within these experiments, but 
our results are within the range reported by previous studies that assessed normal 
background indoor concentrations of cyclic siloxanes (31-35). 
Dermal uptake versus inhalation exposure
Our results indicate that the dermal uptake route of D5 is much less important 
than previously assumed. We even hypothesize that the dermal uptake route 
PD\ EH LQVLJQLÀFDQW FRPSDUHG WR WKH LQKDODWLRQ URXWH 7R H[SORUH WKLV LVVXH
further, we applied the PBK model of Reddy and co-workers (20) to estimate the 
concentration of D5 in exhaled air after inhalation exposure only, ignoring the 
possible contribution of dermal uptake. In inhalation experiments (section 3.4), 
we measured the ambient D5 concentrations present in the toilet area before 
and during dermal exposure to a night cream. The mean D5 concentrations in 
ambient air were approximately 14 μg/m3 (pre-exposure) and 4,500 μg/m3 
(exposure). These concentrations served as input for the human PBK model, 
UHÁHFWLQJ DPLQLPXPDQGPD[LPXPH[SRVXUH VFHQDULR IRU WKH WRLOHW YLVLW 7KH
modeled exhaled air concentrations were approximately 10 ng/L and 3,200 ng/L, 
respectively, for these scenarios. The D5 concentrations measured in end-exhaled 
air at t=90 minutes varied between 10 and 600 ng/L and are thus within the 
range of these modeled exhaled air concentrations. These results indicate that 
the measured concentrations in exhaled air can be explained based on inhalation 
H[SRVXUHRQO\FRQÀUPLQJRXUK\SRWKHVLVWKDWGHUPDOXSWDNHSOD\VDPLQRUUROH
We conclude that risk assessment of D5 should focus on inhalation exposure 
since the contribution of dermal absorption of D5 to internal exposure is only 
marginal.
Conclusions
Overall, the results of our dermal exposure experiments using pure D5, pure 
D4, a night cream, a deodorant and a combination of the latter two indicate 
that concentrations of D4 and D5 eliminated in end-exhaled air cannot be 
discriminated from background levels observed following the non use of PCPs for 
24 hours. When applying PCPs, such as a night cream or deodorant containing 
cyclic siloxanes (D4/D5), inhalation and not dermal exposure is the primary 
pathway of uptake. Therefore, it is important to take inhalation exposure into 
account when performing aggregate exposure assessments to dermally applied 
D4, D5 or substances with physicochemical properties similar to these volatile 
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cyclic siloxanes.
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Supplementary Information
The following information is presented:
1. Study approval
2. The baseline concentrations of D4 and D5 in end-exhaled air after normal 
use of PCPs for all participants
3. Information obtained from 24-hour diaries
4. Control experiments (D4)
5. Control experiments (D5)
6. Overview of the amount of substance applied
7. Exposure to D5 as a pure substance
8. Exposure to D5 as a pure substance – no toilet visit at t=90 min
9. Exposure to night cream
10. Exposure to deodorant
11. Exposure to night cream and deodorant
12. Exposure to D4 as a pure substance
13. Inhalation experiments
14. References
SI 4-5, 7-12
Graphical representations of D4 and D5 concentrations in end-exhaled air and 
DPELHQWDLU QJ/DUHSORWWHGDJDLQVW WLPH6HSDUDWHÀJXUHVDUHSUHVHQWHG IRU
male (M) and female (F) volunteers. On the left y-axis the D4 or D5 concentration 
(ng/L) is shown. The black line in the graph represents the D4 or D5 concentration 
in end-exhaled air. The orange line in the graph represents the D4 or D5 
concentration in ambient air during the period of dermal administration (60 min) 
and the blue line represents the D5 concentration in ambient air during the post-
exposure period. 
SI 13
Graphical representations of D5 concentrations in end-exhaled air and ambient 
DLUQJ/DUHSORWWHGDJDLQVWWLPH6HSDUDWHÀJXUHVDUHSUHVHQWHGIRUPDOH0
and female (F) volunteers. On the left y-axis the D5 concentration (ng/L) is shown. 
The black line in the graph represents the D5 concentration in end-exhaled air. 
The orange line in the graph represents the D5 concentration in ambient air during 
dermal administration in the toilet area (5 min). The blue line represents the D5 
concentration in ambient air during the post-exposure period inside the toilet area 
and the green line represents the D5 concentration in ambient air during the post-
exposure period outside the toilet area.
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SI 1. Study approval
We ensured the safety of our volunteers as follows:
- The volunteers were had access to an independent physician, who was familiar 
with the study but not involved. 
- During the experiments, the volunteer’s well being was continuously monitored 
by the researcher.
'XULQJWKHHQWLUHSHULRGRIWKHH[SHULPHQWDWUDLQHGDQGFHUWLÀHGÀUVWUHVSRQGHU
was available on the study location. 
SI 2. The baseline concentrations of D4 and D5 in end-exhaled air after normal 
use of PCPs for all participants
Table 2.1 shows the baseline concentrations of D4 and D5 in end-exhaled air after 
normal use of PCPs for all volunteers. 
Table SI 2.1. The baseline concentrations of D4 and D5 in end-exhaled air after normal use 
of PCPs for all participants.
Gender Volunteer D4 (ng/L) D5 (ng/L) Ratio D4/D5 
Male (N=5) 4 6.7 1.6 4.3 
5 3.2 1.9 1.7 
6 2.7 2.8 1.0 
7 4.3 27.1 0.2 
11 11.8 2.3 5.2 
Female (N=10) 1 3.2 3.1 1.0 
2 7.0 6.6 1.1 
3 14.5 18.2 0.8 
8 1.9 2.8 0.7 
9 9.8 44.4 0.2 
10 ND*  4.7 ND 
12 27.4 33.2 0.8 
13 6.5 2.1 3.1 
14 2.8 4.4 0.6 
15 44.8 17.9 2.5 
* ND = due to a technical problem no value is available. 
SI 3. Information obtained from 24-hour diaries
Table 3.1 shows information on regular use of PCPs of our volunteers. The 
LQIRUPDWLRQZDV FROOHFWHG XVLQJKRXU GLDULHVZKLFK KDG WR EH ÀOOHG RXW 
hours before the baseline measurement. In the table information about the 
product used, the time of day, the amount and the exposed body parts is given. 
The amount of use was calculated by the method described by Biesterbos and co-
workers (Biesterbos et al. 2013).
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SI 4. Control experiments (D4)
V3 (F)
0 30 60 90 120 150 180 210 240 270 300 330 360
0.1
1
10
D4 in end-exhaled air
D4 in ambient air (exposure)
D4 in ambient air (post exposure)
Time (min)
D
4 
co
nc
en
tra
tio
n 
(n
g/
L)
V8 (F)
0 30 60 90 120 150 180 210 240 270 300 330 360
0.1
1
10
D4 in end-exhaled air
D4 in ambient air (exposure)
D4 in ambient air (post exposure)
Time (min)
D4
 c
on
ce
nt
ra
tio
n 
(n
g/
L)
Aggregate dermal exposure to cyclic siloxanes
5
201
V9 (F)
0 30 60 90 120 150 180 210 240 270 300 330 360
0.1
1
10
D4 in end-exhaled air
D4 in ambient air (exposure)
D4 in ambient air (post exposure)
Time (min)
D4
 c
on
ce
nt
ra
tio
n 
(n
g/
L)
Figure SI 4.1. The mean D4 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D4 concentration in ambient air (ng/L) during the control experiments of 
volunteer 3, 8 and 9.
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SI 5. Control experiments (D5)
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Figure SI 5.1. The mean D5 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D5 concentration in ambient air (ng/L) during the control experiments of 
volunteer 2, 5 and 14.
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SI 6. Overview of the amount of substance applied
Table 6.1-6.3 provides an overview of the exposed surface, the applied amount of 
substance and the resulting dose of D4 or D5. 
Table SI 6.1. The amount of D5 applied using a pure substance, a night cream and a 
deodorant.
Applied substance Volunteer Exposed surface 
forearm (cm2) 
Amount (g) Dose of D5 
(mg/cm2) 
D5 pure substance 1 689 4.85 7.0 
2 870 4.33 5.0 
3 771 3.01 3.9 
4 819 2.65 3.2 
5 934 5.02 5.4 
6 922 5.37 5.8 
7 949 5.25 5.5 
8 730 6.24 8.5 
9 749 3.96 5.3 
10 747 4.25 5.7 
13 937 4.46 5.8 
14 581 4.99 6.5 
15 763 7.33 9.6 
D5 pure substance (no 
toilet visit at t=90 min) 
7 949 5.85 6.2 
11 937 7.43 7.9 
12 581 4.90 8.4 
Night cream 3 771 6.27 2.0 
4 819 15.98 4.9 
5 934 18.78 5.1 
10 747 16.36 5.5 
Deodorant 1 689 5.27 2.3 
Table SI 6.2. The amount of D5 applied using a combination of night cream and deodorant.
Applied 
substance Volunteer 
Exposed surface 
forearm (cm2) 
Amount (g) Dose of D5 (mg/cm2) 
Deodorant Cream  Deodorant Cream Deodorant Cream Total 
Night 
cream & 
deodorant 
3 771 761 13.82 8.42 4.5 3.3 7.8 
4 819 800 19.42 9.48 6.0 3.5 9.5 
Table SI 6.3. The amount of D4 applied using a pure substance.
Applied 
substance 
Volunteer Exposed surface 
forearm (cm2) 
Amount (g) Dose of D4 
(mg/cm2) 
D4 pure 
substance 
2 870 7.21 8.3 
6 922 10.00 10.8 
7 949 9.73 10.3 
8 730 9.76 13.4 
11 937 8.09 8.6 
14 581 6.92 9.0 
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SI 7. Exposure to D5 as a pure substance
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Figure SI 7.1. The mean D5 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D5 concentration in ambient air (ng/L) after dermal exposure to D5 pure 
substance of volunteer 1 and 2.
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Figure SI 7.2. The mean D5 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D5 concentration in ambient air (ng/L) after dermal exposure to D5 pure 
substance of volunteer 3 and 4. Note: Due to a technical error no data for the time-weighted 
average D5 concentration in ambient air are presented for volunteer 4. 
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Figure SI 7.3. The mean D5 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D5 concentration in ambient air (ng/L) after dermal exposure to D5 pure 
substance of volunteer 5 and 6.
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Figure SI 7.4. The mean D5 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D5 concentration in ambient air (ng/L) after dermal exposure to D5 pure 
substance of volunteer 7 and 8.
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Figure SI 7.5. The mean D5 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D5 concentration in ambient air (ng/L) after dermal exposure to D5 pure 
substance of volunteer 9 and 10.
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Figure SI 7.6. The mean D5 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D5 concentration in ambient air (ng/L) after dermal exposure to D5 pure 
substance of volunteer 13 and 14.
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Figure SI 7.7. The mean D5 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D5 concentration in ambient air (ng/L) after dermal exposure to D5 pure 
substance of volunteer 15.
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SI 8. Exposure to D5 as a pure substance – no toilet visit at t=90 min
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Figure SI 8.1. The mean D5 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D5 concentration in ambient air (ng/L) after dermal exposure to D5 pure 
substance of volunteer 7 and 11.
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Figure SI 8.2. The mean D5 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D5 concentration in ambient air (ng/L) after dermal exposure to D5 pure 
substance of volunteer 12.
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SI 9. Exposure to night cream
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Figure SI 9.1. The mean D5 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D5 concentration in ambient air (ng/L) after dermal exposure to night 
cream of volunteer 3 and 4.
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Figure SI 9.2. The mean D5 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D5 concentration in ambient air (ng/L) after dermal exposure to night 
cream of volunteer 5 and 10.
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SI 10. Exposure to deodorant
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Figure SI 10.1. The mean D5 concentrations in end-exhaled air (ng/L) and the mean 
time-weighted average D5 concentration in ambient air (ng/L) after dermal exposure to 
deodorant of volunteer 1. 
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SI 11. Exposure to night cream and deodorant
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Figure SI 11.1. The mean D5 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D5 concentration in ambient air (ng/L) after dermal exposure to night 
cream and deodorant of volunteer 3 and 4.
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SI 12. Exposure to D4 as a pure substance
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Figure SI 12.1. The mean D4 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D4 concentration in ambient air (ng/L) after dermal exposure to D4 as a 
pure substance of volunteer 2 and 6.
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Figure SI 12.2. The mean D4 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D4 concentration in ambient air (ng/L) after dermal exposure to D4 as a 
pure substance of volunteer 7 and 8.
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Figure SI 12.3. The mean D4 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D4 concentration in ambient air (ng/L) after dermal exposure to D4 as a 
pure substance of volunteer 11 and 14.
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SI 13. Inhalation experiments
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Figure SI 13.1. The mean D5 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D5 concentration in ambient air (ng/L) during inhalation experiments of 
volunteer 4 and 12.
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Figure SI 13.2. The mean D5 concentrations in end-exhaled air (ng/L) and the mean time-
weighted average D5 concentration in ambient air (ng/L) during inhalation experiments of 
volunteer 15.
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Abstract
In consumer exposure assessment, with limited time and resources, models 
are often used in a tiered approach to predict the internal exposure to personal 
care products (PCPs). The aim of the present study was to identify whether 
environmental or personal variables are more important in predicting internal 
consumer exposure to decamethylcyclopentasiloxane (D5). Often added as an 
emollient or solvent, D5 is an important ingredient of PCPs. Thirty-four healthy 
volunteers applied a deodorant with known D5 content to their axillae in the 
bathroom of their residence. The D5 concentration in end-exhaled air served as 
a proxy for the alveolar air concentration. In addition, we determined the ambient 
D5 concentration, room air exchange rate, air temperature, relative humidity and 
volume of the bathroom. We also recorded personal variables, such as age, length 
and weight of the volunteers. These parameters served as input to construct a 
statistical linear regression model. We used this regression model, together with 
a physiologically based pharmacokinetic (PBPK) model and the time-weighted 
average ambient air concentration to predict the internal exposure to D5. The 
performance of these three prediction methods was evaluated by calculating 
the difference between the measured and predicted D5 concentration in end-
exhaled air. The statistical linear regression model performed best. We conclude 
that environmental variables are more important than personal variables for the 
prediction of internal exposure to D5. 
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Introduction 
Consumers use a wide variety of personal care products (PCPs). Depending 
on the type of product, the frequency of use can vary considerably (1, 2). PCPs 
consist of different ingredients, including active components and preservatives. 
Cyclic siloxanes, a class of chemicals consisting of circular structures with 
alternating Si and O atoms, are added to PCPs as emollients or solvents (3, 4). 
Decamethylcyclopentasiloxane (D5; CAS 541-02-6) is the most predominant 
compound in PCPs, while octamethylcyclotetrasiloxane (D4; CAS 293-51-6) and 
GRGHFDPHWK\OF\FORKH[DVLOR[DQH '&$6ZHUH LGHQWLÀHG WR D OHVVHU
extent (5-8). Based on the present practices of use and the concentrations of 
'DQG'LQ3&3VWKH6FLHQWLÀF&RPPLWWHHRQ&RQVXPHU6DIHW\LQ(XURSHDQG
the Cosmetic Ingredient Review Expert Panel in the US concluded that the use of 
PCPs containing cyclic siloxanes is safe (3, 4). 
Several researchers studied the indoor air concentrations of cyclic siloxanes 
(D3, D4, D5 and D6) (9-14) and concluded that because of PCP use, these 
FRQFHQWUDWLRQVDUHSULPDULO\LQÁXHQFHGE\WKHQXPEHURIRFFXSDQWVSUHVHQWLQD
room (11, 14). Tran and Kannan (12) calculated mean daily inhalation exposure 
doses of total siloxanes and found that D5 contributed to the relative highest daily 
exposure. 
To assess consumer risks, researchers and regulators are in need of tools and 
data that allow them to assess the exposure to PCP ingredients adequately (15). 
One option is to perform actual human exposure measurements, e.g. under 
realistic exposure conditions. However, measuring can be cumbersome because 
of ethical considerations, the high costs involved and the large time investment 
needed. As an alternative, risk assessors often use models to estimate consumer 
exposure to PCPs, e.g. in a tiered approach. Simple deterministic models are 
used in the lower tiers, while more sophisticated, realistic models are used in the 
KLJKHUWLHUV0RGHOVFRQVLVWRIGLIIHUHQWYDULDEOHVLQÁXHQFLQJFRQVXPHUH[SRVXUH
7KHVH YDULDEOHV FDQ EH URXJKO\ FODVVLÀHG LQWR WZR FDWHJRULHV LH YDULDEOHV
that characterize the exposed individual (personal variables) and variables that 
characterize the environment (environmental variables). Some models consist of 
only environmental variables or only personal variables, while others combine the 
two.  
With limited time and resources available in consumer risk assessment, we 
wondered if it would be better to invest in an accurate determination of the 
environmental or personal variables to predict consumer exposure to D5. 
Therefore, the aim of the present study was to investigate whether environmental 
or personal variables are more important to predict the concentration of D5 in 
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end-exhaled air – as a proxy for internal exposure to D5 – after realistic inhalation 
exposure to D5 as an ingredient of PCPs.
Materials and Methods
Chemicals and test substances
Decamethylcyclopentasiloxane (97% D5; CAS 541-02-6) was obtained from Sigma-
Aldrich (St. Louis, MO, United States) and a commercially available deodorant (40 
mL) was purchased from an online retailer. According to the manufacturer, the 
deodorant contained approximately 30% D5. 13C-labelled D5, used as internal 
standard, was purchased from Dow Corning (Midland, MI, United States). Methanol 
(99.9%; CAS 67-56-1) supplied by Boom (Meppel, the Netherlands) was used to 
dissolve 13C-labelled D5 and unlabelled D5 for the preparation of standards. 
Field study design
We recruited 34 volunteers using information folders and word of mouth. All 
volunteers included had to be over 18 years of age and in good general health. No 
other inclusion or exclusion criteria were applied. In the period February through 
May 2014, we visited the volunteers at their home and performed a small exposure 
study in their bathroom. To prevent possible contamination, the volunteers were 
asked to refrain from using personal care products 24 hours before the start of the 
study. The study itself lasted a total of 35 minutes and consisted of three periods: 
the pre-exposure period, the exposure period, and the post-exposure period. 
During the pre-exposure period, which lasted ten minutes, the volunteer was 
invited to take a seat inside the bathroom and the ambient D5 concentration was 
measured. At the end of the pre-exposure period, end-exhaled air samples were 
collected. Following, we asked the volunteer to apply deodorant underneath the 
axilla using the deodorant stick provided and to put on a long sleeved sweater. The 
volunteer was instructed to apply a “regular” amount of deodorant, as we intended 
to monitor realistic exposure scenarios. The deodorant stick was weighted before 
and after the experiment to determine the actual amount applied. At the end 
of the exposure period of ten minutes, the volunteer left the bathroom and was 
invited to take a seat in another “non-contaminated” room (e.g., the living room) 
for the remaining time of the study (15 minutes). At the end of the exposure period 
DQGHYHU\ÀYHPLQXWHVGXULQJWKHSRVWH[SRVXUHSHULRGZHFROOHFWHGHQGH[KDOHG
air samples. During each of these three periods, the time-weighted average D5 
concentration in ambient air was measured, separately (Figure 6.1). 
In addition to the collection of end-exhaled air and ambient air samples, we 
measured the temperature and relative humidity in the bathroom using a 
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thermohygrometer (HMI41 Vaisala, Helsinki, Finland) during the pre-exposure 
and exposure periods. Directly after the end of the study, the air exchange rate 
of the bathroom was determined, using CO2 as a tracer. A large quantity of CO2 
ZDVGLVSHUVHGLQWKHEDWKURRPXVLQJDÀUHH[WLQJXLVKHUDQGPL[HGKRPRJHQRXVO\
using a hand-held ventilator. A CO2 monitor (aq-510 Metrosonics Inc., Rochester, 
NY, United States) coupled to a single channel BD 40 recorder (Kipp & Zonen, 
Delft, The Netherlands) recorded the decrease in CO2 concentration over time. 
From the decrease of CO2 concentration over time, we calculated the air exchange 
rate (hour -1). Finally, we measured the dimensions of the bathroom to calculate 
the volume. 
Sample collection
For the end-exhaled air samples, the volunteers exhaled completely into a 
GLVSRVDEOHFDUGERDUGPRXWKSLHFHWKDWZDVÀWWHGWRDP/%LR92&FRQWDLQHU
(Markes International, Llantrisant, United Kingdom). In total, we collected 5 end-
exhaled air samples in duplicate for each volunteer. Immediately, after sample 
collection, the organic compound was transferred to a 1/4” x 3.5” Stainless Steel 
WXEHÀOOHGZLWK&DUERJUDSK7'DQG&DUERJUDSK7'&$06&2
Houston TX, United States).
Ambient air samples were collected using a headset (Fenix Environmental, Umeå, 
Sweden) with two sampling heads that were placed in the breathing zone slightly 
above the nose (16). The sampling heads were equipped with mini automatic 
thermal desorption (ATD) tubes loaded with Tenax TA (Fenix Environmental, Umeå, 
Sweden) that were connected to personal air sampling pumps (Buck, A.P., Buck 
,QF2UODQGR )ORULGD8QLWHG6WDWHV YLD D ÁH[LEOH KRVH $LUZDV FROOHFWHGDW D
ÁRZRIPOPLQ%DVHGRQWKHDQDO\VLVRIWKHDEVRUEHGDPRXQWRI'DQGWKH
Legend: * Collection of end-exhaled air samples;               Collection of ambient air samples  
 0            5            10          15           20          25           30          35    Time (min)         
        Pre-exposure             Exposure                       Post-exposure             
             *                               *              *              *               *        
Figure 6.1 Overview of the time points used for the collection of end-exhaled air and 
ambient air samples.
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sampled air volume, time-weighted average concentrations of D5 in ambient air 
were calculated over the different study periods. 
Sample analysis
We prepared an internal standard solution of 5 ng/μL 13C-labelled D5 in methanol 
to quantify the end-exhaled and ambient air samples. Prior to analysis, 2.5 ng 
of 13C-labelled D5 (0.5 μL) was loaded on each of the ATD and mini ATD tubes 
using a loading rig (Markes International, Llantrisant, United Kingdom). The ATD 
or mini ATD tube was connected to the loading rig, the internal standard solution 
ZDVLQMHFWHGYLDDV\ULQJHDQGWKHWXEHZDVÁXVKHGZLWKKHOLXP/LQGH*DV
6FKLHGDP7KH1HWKHUODQGVDWDÁRZRIP/PLQIRUWKUHHPLQXWHVWRUHPRYHWKH
methanol. The samples were analyzed by thermal desorption gas chromatography 
mass spectrometry (TD-GC-MS). The analytical instrument consisted of a thermal 
desorption unit and an auto sampler (Unity 2 and Ultra 2, Markes) coupled to a 
gas chromatograph mass spectrometer (Focus and ISQ, Thermo) using electron 
impact ionization (EI). Both the ATD and the mini ATD tubes were positioned in 
the auto sampler and subsequently desorbed at 275 °C for 15 minutes. Tubesplit 
of 150 mL/min and trapsplit of 25 mL/min were applied. The analytical column 
ZDVDP5[L06PPLGPÀOPWKLFNQHVV5HVWHNZLWKKHOLXP
5.0 as carrier gas. The GC oven temperature was 50 °C; hold 5 min; 10 °C/min 
to 150 °C; 30 °C/min to 250 °C, hold 2 min. The transfer line was kept at 250 
°C and the ion source at 250 °C. The ions monitored were m/z 355 and 360 for 
D5 and 13C-labelled D5, respectively and the dwell time was 0.4 sec. The limit 
RITXDQWLÀFDWLRQ /24 LQHQGH[KDOHGDLUZDVQJ/ IRU'7KHFDOLEUDWLRQ
curve included eight standard solutions with a concentration range of 0-200 ng/
μL (ATD tubes) or 0-350 ng/μL (mini ATD tubes). A more detailed description of the 
analytical method can be found elsewhere (17).
Modelling
7KHGDWDREWDLQHG LQ WKHÀHOGVWXG\ZHUHXVHGWRFRQVWUXFWD OLQHDUUHJUHVVLRQ
model to identify important environmental variables that may predict internal 
exposure due to the application of deodorant. Subsequently, the data were used 
to modify an existing physiologically based pharmacokinetic (PBPK) model to 
identify important personal variables that predict the internal exposure. In both 
models, the concentration of D5 in end-exhaled air served as a proxy for internal 
exposure to D5. 
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Linear regression model
7KHLQWHUQDOH[SRVXUHWR3&3VZDVGHÀQHGDVWKHOQWUDQVIRUPHG'FRQFHQWUDWLRQ
in end-exhaled air at the end of the exposure period (t=20 min) and entered into 
the linear regression model as the dependent variable. As potential determinants 
for internal consumer exposure to PCPs were considered: (1) the ln-transformed 
time-weighted average D5 concentration in ambient air during the exposure 
period, (2) the ln-transformed D5 concentration in end-exhaled air at the end of 
the pre-exposure period (t=10 min) (3) the ln-transformed amount of D5 applied, 
(4) the ln-transformed air exchange rate of the bathroom, (5) the temperature in 
the bathroom,  (6) the relative humidity in the bathroom,  (7) the volume of the 
bathroom, and (8) the height and (9) body weight of the volunteer (Table 6.1). 
8VLQJ D VWHSZLVH IRUZDUG SURFHGXUH WKH VWDWLVWLFDOO\ VLJQLÀFDQW GHWHUPLQDQWV
(P<0.05) were selected. How much of the variability in the internal exposure to 
'ZDVH[SODLQHGE\ WKHYDULDEOHVHQWHUHG LQWR WKHPRGHOZDV UHÁHFWHG LQ WKH
FRHIÀFLHQWRIGHWHUPLQDWLRQ52.
PBPK model
In 2008, Reddy and co-workers developed a PBPK model for inhaled D5 in rats 
and humans (18). Their goal was to estimate free blood and tissue concentrations 
of D5 under various exposure conditions. In the present study, the PBPK model 
developed by Reddy and co-workers was used as a starting point. We adjusted the 
LQSXWSDUDPHWHUV7DEOHWRUHÁHFWRXUEDWKURRPH[SRVXUHVWXG\:HXVHGWKH
model to simulate two different scenarios.
Table 6.1 Overview of the independent variables included in the linear regression model.
Independent variable Explanation 
1. The ambient air D5 concentration 
during the exposure period (μg/m3) 
The ln-transformed time-weighted average D5 
concentration in ambient air during the exposure period  
2. The D5 concentration in end-exhaled 
air at the end of the pre-exposure period 
(ng/L) 
The ln-transformed D5 concentration in end-exhaled air at 
the end of the pre-exposure period (t=10 min) 
3. Amount of D5 applied (g) The ln-transformed amount of deodorant applied times 0.3, 
as the deodorant contains approximately 30% D5  
4. Air exchange rate of the bathroom 
(1/hour) 
The ln-transformed mean of two air exchange rate 
measurements 
5. Temperature in the bathroom (°C) The mean of the temperature during the pre-exposure 
period and the exposure period 
6. Relative humidity in the bathroom (%) The mean of the relative humidity during the pre-exposure 
and exposure period 
7. Volume of the bathroom (m3) Measurements of length, width, and height  
8. Length of the volunteer (cm) Provided by volunteer 
9. Weight of the volunteer (kg) Provided by volunteer 
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Scenario 1 (individual level)
In this scenario, the performance of the PBPK model for individual volunteers was 
tested by inserting physiological parameters as exact values. Body weight (BW) and 
age (AGE) of the volunteers were self-reported, whereas the minute volume (MINV) 
DQGDOYHRODU YHQWLODWLRQ 43ZHUHPHDVXUHGRYHUDÀYHPLQXWHV UHVWLQJSHULRG
XVLQJ4XDUN&3(7&260('5RPH,WDO\&RPSDUWPHQWVSHFLÀFSDUDPHWHUVZHUH
inserted as log-normal distributions using the values from the original model as 
reported by Reddy and co-workers (18). The measured time-weighted average 
ambient D5 concentration served as input for the D5 concentration in inhaled 
air. Initially, we simulated the internal D5 concentration for four volunteers, as 
the minute volume and alveolar ventilation rate were only measured in these 
four volunteers. The preliminary results showed, however, that minute volume 
and alveolar ventilation rate were no sensitive model parameters. Therefore, we 
decided to simulate the internal D5 concentration for all remaining volunteers 
as well, using the mean minute volume and mean alveolar ventilation rate of the 
volunteers for which measured data were available. Finally, we simulated the D5 
concentration in end-exhaled air for each individual separately using Monte Carlo 
simulation (N=1000).
Scenario 2 (population level)
,Q WKLV VFHQDULR WKH LQÁXHQFH RI LQWHULQGLYLGXDO YDULDELOLW\ LQ SK\VLRORJLFDO
parameters was assessed. All parameters were inserted as log-normal 
distributions, except age. This parameter was inserted as uniform distribution, 
based on data from the study participants. Minute volume correlated positively 
with alveolar ventilation (r2=0.83), which was incorporated in this scenario. Just 
DV LQ VFHQDULR  WKH YDOXHV UHODWHG WR WKH FRPSDUWPHQWVSHFLÀF SDUDPHWHUV
were obtained from the original model by Reddy and co-workers. The mean time-
ZHLJKWHGDYHUDJH'FRQFHQWUDWLRQLQDPELHQWDLUIRUDOOSDUWLFLSDQWVLQWKHÀHOG
study served as input for the D5 concentration in inhaled air. Taking all these data 
together, we simulated population inhalation exposure to D5, using Monte Carlo 
simulation (N=1000). 
Statistical analysis 
The linear regression model was developed using IBM SPSS Statistics (version 
20), while the software package Berkeley Madonna (Version 8.3.18, University 
of California, Berkeley, CA, United States) was used to solve the PBPK model 
equations. The PBPK model code is available in the supplementary information 
(SI 1). A sensitivity analysis was performed on the basis of Spearman rank 
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FRUUHODWLRQ FRHIÀFLHQWVDQGSDUWLDO FRUUHODWLRQ FRHIÀFLHQWV (19) using Microsoft 
2IÀFH([FHO0LFURVRIW5HGPRQG:$8QLWHG6WDWHV)LQDOO\ZHFRPSDUHG
the measured D5 concentration in end-exhaled air at the end of the exposure 
period (t=20 min) and the predicted concentrations using the linear regression 
model and the PBPK model. In addition, we assumed that the time-weighted 
average D5 concentration in ambient air is equal to the D5 concentration in end-
exhaled air at the end of the exposure period (t=20).  As a third comparison, this 
was added to evaluate the performance of the prediction methods (Table 6.3). 
 
Table 6.3 Overview of the comparisons made between the measured and the predicted D5 
concentration in end-exhaled air using three prediction methods.
Measured 
(true) value 
The measured D5 concentration in end-exhaled air during the field study at the end 
of exposure (t=20 min) 
Predicted 
values 
1. D5 concentration in end-exhaled air resulting from the linear regression 
model at the end of exposure (t=20 min) 
2. D5 concentration in end-exhaled air resulting from the PBPK model at the 
end of exposure (t=20 min) 
3. D5 concentration in end-exhaled air resulting from the measured time-
weighted average D5 concentration in ambient air at the end of the 
exposure (t=20 min) 
Results
Field study
In total, 34 participants were included in the study, of which 33 completed the 
study. Due to practical circumstances, we were unable to perform the study with the 
one participant. Furthermore, we lost data on the end-exhaled air concentrations 
and ambient air concentrations of two participants due to failure of the analytical 
equipment. As this rendered the data of these participants incomplete, they 
ZHUH H[FOXGHG IURP WKH DQDO\VLV )LQDOO\ WKH GDWD RI  SDUWLFLSDQWV ÀYH
men, 26 women) were included. Table 6.4 provides an overview of participant 
characteristics and the variables measured during the experiment. The raw data 
are available in the supplementary information (SI 2). As the study included only 
ÀYHPHQDQGQRGLIIHUHQFHV LQ'FRQFHQWUDWLRQ LQH[KDOHGDLUZHUHREVHUYHG
between men and women previously (20), we did not differentiate between male 
and female participants.   
Some participants applied a very small amount of deodorant (minimum 0.02 g), 
whereas a few others applied more than 100 times that much (maximum 3.39 g). 
The temperature and relative humidity in the bathrooms hardly changed during 
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the pre-exposure and exposure periods. In most cases, the air exchange rate 
varied between 1 and 5 times per hour, but we measured substantially higher 
air exchange rates of 13.9 and 17.5 times per hour in two bathrooms. On all 
occasions, the D5 concentrations in end-exhaled and ambient air during the 
pre-exposure period were lower compared to the D5 concentrations during the 
exposure and post-exposure periods. The median D5 concentration in ambient air 
during the exposure period in the bathroom was higher than the D5 concentration 
in ambient air in the “non-contaminated” room. However, in a few individual 
cases, the ambient air concentration during the post-exposure period was higher 
than the D5 concentration during the exposure period in the bathroom. The D5 
FRQFHQWUDWLRQVLQHQGH[KDOHGDLUGXULQJWKHSRVWH[SRVXUHSHULRGÁXFWXDWHG,Q
approximately 50% of the experiments, the D5 concentration in end-exhaled air 
increased compared to the D5 concentration in end-exhaled air at the end of the 
exposure period.
  
Linear regression model
2XU OLQHDU UHJUHVVLRQ PRGHO LGHQWLÀHG WKUHH VWDWLVWLFDOO\ VLJQLÀFDQW S
independent variables: the time-weighted average D5 concentration in ambient 
air during the exposure period (Camb exp), the D5 concentration in end-exhaled 
Table 6.4 Characteristics of the participants (N=31) and variables measured during the 
ÀHOGVWXG\
 Median Min Max 
Age (years) 56 22 79 
Length (cm) 172 155 195 
Body weight (kg) 66 50 98 
Amount of deodorant applied (g) 0.34 0.02 3.39 
Temperature in bathroom (°C) 19.6 15.0 24.3 
Relative Humidity in bathroom (%) 55.0 36.1 73.7 
Volume of bathroom (m3) 11 5 22 
Air exchange rate in bathroom (n/hour) 2.2 0.2 17.5 
D5 concentration in end-exhaled air (ng/L)    
T=10 min 10 3 284 
T=20 min 248 15 1544 
T=25 min 192 20 1172 
T=30 min 142 10 1618 
T=35 min 150 10 1820 
D5 concentration in ambient air (μg/m3)    
Pre-exposure 21 8 247 
Exposure 773 234 2211 
Post-exposure 420 56 1657 
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air at the end of the pre-exposure period (Cex pexp), and the air exchange rate (Air 
rate). Together, these variables explained 70% (Table 6.5) of the variation in the 
ratio of the D5 concentration in end-exhaled air at the end of exposure (Cex exp) 
and is represented by the following formula:
ln(Cex exp) = -5.465 + 1.533 ln(Camb exp) + 0.349 ln(Cex pexp) – 0.229 ln(Air rate)
Table 6.5 Results of the linear regression model.
 B-coefficient (S.E) 
 Model 1 Model 2 Model 3 
Intercept -3.744 -5.137 -5.465 
Camb exp 1.381 (0.252) 1.468 (0.219) 1.533 (0.207) 
Cex pexp - 0.333 (0.101) 0.349 (0.094) 
Air rate - - -0.229 (0.102) 
R2 0.509 0.647 0.702 
PBPK model
Figure 6.2 shows the modelling results of scenario 1, on the individual level of 
volunteer 1, 2, 3 and 4. The results of the remaining volunteers are available in the 
supplementary information (SI 3). In general, the measured D5 concentrations in 
HQGH[KDOHGDLUZHUHZHOOUHÁHFWHGE\WKHSUHGLFWHGYDOXHV:KHQORRNLQJLQPRUH
GHWDLOWKHVSHFLÀFUHVXOWVIRUYROXQWHHUVKRZHGDJRRGUHVHPEODQFHEHWZHHQ
modelled and measured values. The modelled internal D5 concentrations for 
volunteers 3 and 4 showed similar patterns as the accompanying measured 
values, but the latter were almost all lower than the modelled values. In contrast, 
we observed a deviation from the modelled pattern in the post-exposure period 
for volunteer 2. The measured internal D5 concentration increased at the end of 
the post-exposure period, whereas the model predicted a decrease in internal D5 
concentration. In all four cases, the measured D5 concentrations in ambient air 
were in the same range as the modelled D5 concentrations in end-exhaled air. 
The result for scenario 2, the population level, is similar to the results for scenario 
1 (SI 4).
The results of the sensitivity analysis of both scenarios of the PBPK model showed 
WKDWWKHSDUDPHWHUV./8'PDVVWUDQVIHUFRHIÀFLHQWIRUWUDQVSRUWLQWRGHHSOXQJ
DQG3%EORRGDLUSDUWLWLRQFRHIÀFLHQWZHUHWKHPRVW LPSRUWDQWSDUDPHWHUVIRU
an accurate prediction of the D5 concentration in end-exhaled air (SI 5). Large 
ÁXFWXDWLRQV LQ VHQVLWLYLW\ RYHU WLPH ZHUH QRW REVHUYHG EXW DW WKH HQG RI WKH
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simulation (t=29 and t=34 min), the D5 concentration in end-exhaled air tended 
to become less sensitive to the parameter PB and more sensitive to the parameter 
.'/8PDVVWUDQVIHUFRHIÀFLHQWIRUWUDQVSRUWRXWRIGHHSOXQJ
In Figure 6.3, the differences between the measured and predicted D5 
concentration in end-exhaled air at the end of the exposure period (t=20 min) 
are presented. The linear regression model predicts the internal exposure best, 
whereas the PBPK model and the time-weighted average ambient air concentration 
tend to overestimate the internal D5 concentration.
Chapter 6
236
Fi
gu
re
 6
.2
 S
ce
na
rio
 1
 (
in
di
vi
du
al
 le
ve
l):
 t
he
 m
od
el
le
d 
an
d 
m
ea
su
re
d 
D
5
 c
on
ce
nt
ra
tio
n 
in
 e
nd
-e
xh
al
ed
 a
ir 
an
d 
th
e 
m
ea
su
re
d 
tim
e 
w
ei
gh
te
d 
av
er
ag
e 
D
5
 c
on
ce
nt
ra
tio
n 
in
 a
m
bi
en
t a
ir 
of
 v
ol
un
te
er
s 
1,
 2
, 3
 a
nd
 4
.
Measuring and modelling of D5 inhalation exposure
6
237
Figure 6.3 The residual analysis of the D5 concentration in end-exhaled air at the end of 
exposure (t=20 min). The measured D5 concentration was compared to the predicted D5 
concentration using our linear regression model, our PBPK model and the measured time-
weighted ambient air concentration.
Discussion
:H FRQGXFWHG D ÀHOG VWXG\ DQG LQYHVWLJDWHG UHDOLVWLF FRQVXPHU LQKDODWLRQ
H[SRVXUHWRD3&3LHDGHRGRUDQWFRQWDLQLQJ',PSRUWDQWIDFWRUVLQÁXHQFLQJ
internal D5 exposure resulting from the application of the deodorant were the 
D5 concentration in ambient air, the D5 concentration in end-exhaled air before 
application, and the air exchange rate of the bathroom. The data obtained during 
WKHÀHOGVWXG\ZHUHXVHGWRFRQVWUXFWDOLQHDUUHJUHVVLRQPRGHODQGWRDSSO\DQ
existing PBPK model to predict internal exposure. The linear regression model 
predicted internal D5 exposure best.  
Field study
7RWKHEHVWRIRXUNQRZOHGJHZHZHUHWKHÀUVWWRPRQLWRUFRQVXPHULQKDODWLRQ
exposure to D5 present in a PCP under realistic exposure conditions. In 2012, 
Lefebvre and colleagues measured inhalation exposure to formaldehyde released 
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from PCPs under both stringent and realistic conditions (21), but no similar 
studies are available. Recently, it was suggested that inhalation of PCPs might 
have a small adverse effect on lung function (22).  
As the current study started in the winter of 2014 and ended in the spring of 2014, 
WKHZHDWKHU FRQGLWLRQV GXULQJ WKH ÀHOG VWXG\ GLIIHUHGZKLOH KXPDQ EHKDYLRXU
LV LQÁXHQFHG E\ WKH ZHDWKHU :KHQ LW LV FROG DQG ZHW RXWVLGH WKH KHDWLQJ LV
turned up and the windows are generally closed, but when it is warm and sunny 
outside, windows are opened and the heating is turned down. As the temperature 
and the presence of natural or mechanical ventilation in the bathroom were 
not standardized in this study, the variation in measured temperatures and air 
exchange rates - partly due to variation in weather conditions - mimics  intra-
individual variation in human behaviour and preferences. In addition, no two 
EDWKURRPVZHUHVLPLODUDVHYHU\EDWKURRPKDGLWVVSHFLÀFFKDUDFWHULVWLFVZKLFK
led to inter-individual variation. Together, these two sources of variation provide a 
realistic exposure scenario.  
The D5 concentrations in end-exhaled and ambient air were higher in the exposure 
period compared to the pre-exposure period. The only difference between the pre-
exposure and exposure periods was the application of deodorant, which explains 
the increase in D5 concentrations. The median amount of deodorant applied was 
0.35 g, which is less compared to the 0.79 g reported by Loretz and co-workers 
(23), but more than triple the amount of 0.1 g described by our research group 
previously (1). As the participants were removed from the bathroom after the end 
of the exposure period without washing off the deodorant, and were seated in a 
‘non-contaminated’ room, actual exposure did not end but was reduced. When 
the participant provided an end-exhaled air sample during the post-exposure 
period, possible movement of the arms may have released D5 vapour that was 
LQKDOHGGLUHFWO\EHIRUHVDPSOHFROOHFWLRQ7KLVPLJKWH[SODLQ WKHÁXFWXDWLQJ'
concentrations in end-exhaled air during the post-exposure period (Figure 2). 
8QIRUWXQDWHO\ WKLVK\SRWKHVLV FRXOGQRWEHFRQÀUPHGDV WKH'FRQFHQWUDWLRQ
LQDPELHQWDLUZDVUHÁHFWHGE\WLPHZHLJKWHGDYHUDJHPHDVXUHPHQWV,QIXWXUH
research, direct and continuous measurement of the ambient air concentration 
FRXOGSURYLGHLQVLJKWLQÁXFWXDWLRQVLQWKH'FRQFHQWUDWLRQLQDPELHQWDLUGXHWR
movement by the consumer.     
Modelling
Linear regression model
In the linear regression model, the time-weighted average D5 concentration in 
ambient air during the exposure period provided the largest contribution to the 
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increase in D5 concentration in end-exhaled air after exposure to a PCP. Smaller, 
EXWVWLOOVWDWLVWLFDOO\VLJQLÀFDQWFRQWULEXWLRQVWRWKHPRGHOZHUHREVHUYHGIRUWKH'
concentration in end-exhaled air before the start of exposure and the air exchange 
rate. In preparation for this study, we assessed the number of participants needed 
to construct a valid model to be 75 (i.e., 15 participants per independent variable). 
For practical reasons, however, we could only collect data from 34 volunteers in 
WKHÀHOGVWXG\DQGLQFRUSRUDWHWKHGDWDIURPSDUWLFLSDQWVLQWKHGHYHORSPHQW
RI WKH OLQHDU UHJUHVVLRQPRGHO %HFDXVHRI RYHUÀWWLQJ WKHPRGHO FRXOG EH WRR
optimistic for prediction. Therefore, validation of this model should be addressed 
LQWKHIXWXUH3RVVLEO\ZHLGHQWLÀHGIHZHULQGHSHQGHQWSDUDPHWHUVWKDWSURYLGHG
a relevant contribution to the increase in D5 concentration in end-exhaled air 
than we could have if data from more volunteers would have been available. The 
linear regression model developed in this study is only applicable in situations 
UHÁHFWLQJWKHFRQGLWLRQVLQRXUÀHOGVWXG\$GGLWLRQDOÀHOGVWXGLHVLQYHVWLJDWLQJ'
inhalation exposure are needed to develop and validate other linear regression 
models as well. Eventually this might lead to a generic formula predicting internal 
D5 consumer exposure. 
PBPK model
We modelled realistic inhalation exposure to D5 present in a deodorant and 
predicted the D5 concentration in end-exhaled air on an individual and a population 
EDVLVXVLQJDPRGLÀHGYHUVLRQRIWKH3%3.PRGHOE\5HGG\DQGFRZRUNHUV(18). 
The predicted D5 concentrations in end-exhaled air in both the individual and the 
population models were substantially lower than the NOAEL (150 ppm, based 
on chronic inhalation studies in rats) established by the European Committee on 
Consumer Safety (SCCS) (4). 
Both scenarios (individual and population levels) were the most sensitive to 
ÁXFWXDWLRQV LQ WZR SDUDPHWHUV WKH EORRGDLU SDUWLWLRQLQJ 3% DQG WKH PDVV
WUDQVIHUFRHIÀFLHQWIRUWUDQVSRUWLQWRWKHGHHSOXQJ./8'&RQWUDU\WRZKDWZH
H[SHFWHGSHUVRQVSHFLÀFFKDUDFWHULVWLFV VXFKDVPLQXWH YROXPHERG\ZHLJKW
age and alveolar ventilation rate contributed only minor to the variation in internal 
D5 exposure. 
The sensitivity of PB, KLUD and other parameters did not change over time. In a 
study with 2-propanol, Huizer and co-workers (24) demonstrated that the impact 
of physiological and metabolic parameters can change over time, e.g. when fast 
processes dominate during the exposure phase and slow and deeper processes 
become more important after exposure ends. Our results seem to indicate that 
the processes involved in D5 exposure are relatively fast. However, considering 
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the high lipophilicity of D5, storage in deep fat compartments and a subsequent 
slow release might be expected. We did not observe this phenomenon, which on 
the one hand might be explained by a rather short follow-up time after the end of 
exposure (15 minutes), and on the other hand by the fact that most inhaled D5 is 
almost immediately exhaled and does not reach other compartments in the body 
(18). 
Environmental and personal variables 
Figure 6.4 provides a schematic overview of the comparisons made between 
the D5 concentration in end-exhaled air (Cex) resulting from the linear regression 
model, the PBPK model, and the direct translation from the time-weighted average 
D5 concentration in ambient air (Camb). 
After comparing the measured D5 concentrations at the end of exposure (t=20 
PLQLQHQGH[KDOHGDLUGXULQJWKHÀHOGVWXG\WRWKHPRGHOOHG'FRQFHQWUDWLRQV
in end-exhaled air, we concluded that the best method to predict the internal D5 
concentration may be using our linear regression model. Compared to the PBPK 
model and the D5 time-weighted average ambient air concentration, our linear 
regression model produced the lowest residual values on average. The linear 
regression model was constructed using the D5 concentration in end-exhaled air 
En
vi
ro
nm
en
ta
l v
ar
ia
bl
es
 
P
ersonal variables 
 
Linear regression 
model 
 
PBPK model 
Camb Camb Camb 
Cex Cex 
Cex 
Figure 6.4 Schematic overview of the comparisons made between the D5 concentration in 
end-exhaled air (Cex) resulting from the linear regression model, the PBPK model, and the 
direct translation from the time-weighted average D5 concentration in ambient air (Camb). 
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at the end of the exposure period (t=20 min). Therefore, we only estimated the 
D5 concentration in end-exhaled air at this time point and used it as input for the 
residual analysis. As end-exhaled air data were collected during the post-exposure 
period (t=25, t=30, t=35 min) as well, we also estimated the D5 concentrations 
in end-exhaled air at these time points using both models and the time-weighted 
average ambient air concentration. Subsequently, these were incorporated in a 
root mean square error (RMSE) analysis (SI 6). The predicted D5 concentration in 
end-exhaled air using the linear regression model was based on the measured D5 
concentration in ambient air, the measured D5 concentration in end-exhaled prior 
to exposure and the air exchange rate in the bathroom. The air exchange rate of 
the “non-contaminated” room was not measured, however, making it impossible to 
adjust the linear regression model to the post-exposure situation. Despite the fact 
that the air exchange rates were not representative for the “non-contaminated” 
room, the D5 concentration in end-exhaled air was still best predicted on average 
by the linear regression model.    
The linear regression model consists solely of environmental variables (i.e., 
D5 concentration in ambient air, D5 concentration in end-exhaled air prior to 
exposure and air exchange rate), whereas the PBPK model almost solely consists 
of personal variables (e.g., age and body weight). In the PBPK model the D5 
concentration in ambient air was used as input. As the linear regression model 
performed best in the residual analysis during the exposure period (t=20) and in 
the RMSE analysis during the exposure and post-exposure periods (t=20, t=25, 
t=30 and t=35 min), the best method to predict internal exposure to D5 resulting 
from application of a deodorant is by measuring environmental variables. In risk 
DVVHVVPHQWZLWKOLPLWHGWLPHDQGUHVRXUFHVVXIÀFLHQWDQGGHWDLOHGLQIRUPDWLRQ
on D5 exposure can therefore be obtained by measuring environmental variables. 
,QDÀUVWWLHUH[SRVXUHDVVHVVPHQWLWPLJKWHYHQEHVXIÀFLHQWWRPHDVXUHWKH'
FRQFHQWUDWLRQ LQ DPELHQW DLU ,I UHÀQHPHQW LV QHHGHG WKHRWKHU HQYLURQPHQWDO
variables could be measured or estimated with little effort. 
Finally, should be kept in mind that the thoughts and considerations presented 
in this paper are restricted to consumer exposure to PCPs containing D5. As 
PCPs consist of a wide variety of ingredients with a possibly even wider variety of 
physical and chemical properties, the routes of uptake, the distribution throughout 
the body, the possible biotransformation, or the metabolism may differ for each 
component and eventually alter internal exposure. In risk assessment of consumer 
exposure to PCPs, there might be no need for complicated models including 
personal variables, as less complex model represented by a few environmental 
YDULDEOHVPLJKWSUHGLFWWKHLQWHUQDOH[SRVXUHZLWKVXIÀFLHQWGHWDLO
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Conclusion
When predicting the internal exposure to ingredients of PCPs in consumer exposure 
assessment, it is important to understand whether modelling of environmental 
or personal variables leads to the best prediction. The D5 concentration in end-
exhaled air – as a proxy for internal exposure to D5 – was measured during a 
realistic inhalation exposure study. The measured internal D5 concentration was 
compared to the predicted internal D5 concentration using a linear regression 
model and a PBPK model, and the time-weighted average D5 ambient air 
concentration. The linear regression model, consisting of solely environmental 
variables, predicted the internal D5 concentration best. Therefore, it might not 
be meaningful to improve values of the personal variables in a PBPK model 
SUHGLFWLQJ LQWHUQDO'H[SRVXUH)RU LQLWLDO ULVNDVVHVVPHQW LWPD\EHVXIÀFLHQW
to measure only one environmental variable, the ambient D5 concentration. If 
IXUWKHUUHÀQHPHQW LVQHHGHGRWKHUHQYLURQPHQWDOYDULDEOHVFRXOGEH LQFOXGHG
the D5 concentration in end-exhaled air prior to exposure and air exchange rate 
of room. Although, this study was limited to D5 as ingredient of PCPs, the general 
principle of the application of a simple model is applicable to the risk assessment 
of consumer exposure to PCPs. 
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Supplementary Information 
The following information is presented:
SI 1. Berkeley Madonna modeling code
6,5HVXOWVRIWKHÀHOGVWXG\
SI 3. Scenario 1: Modelling results of the other 29 individual participants
SI 4. Scenario 2: Modelling results
SI 5. Scenario 2: Results of the sensitivity analysis
SI 6. Results of the RMSE analysis
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SI 1. Berkeley Madonna modeling code
^'KXPDQPRGHOÀQDOBDGMXVWHGPPGPRGLÀHGODVWE\-%`
{PBPK model simulates decamethylcyclopentasiloxane (D5) disposition in humans. The 
original model by M.B. Reddy was used and re-parameterized to simulate the following 
experimental setup: Human volunteers were seated their bathroom at home for 
approximately 10 minutes (pre exposure period). After this, they applied a deodorant to 
their axillae, put on a sweater and stayed seated in their bathroom for another 10 minutes 
(exposure period). Finally, they left the bathroom and were seated in another room were no 
personal care products were used, e.g. living room (post exposure period). During the study 
D5 concentration in end-exhaled air and ambient air was measured. The D5 concentration 
in ambient air during the different exposure periods was used as input for this model. The 
D5 concentration measured in end-exhaled air was used as an imported dataset in this 
PRGHO`
{The minute volume (MINV) and alveolar ventilation (QP) of the volunteer were not measured 
in this experiment. However, as part of another experiment we monitored the minute 
YROXPHDQGDOYHRODUYHQWLODWLRQGXULQJDÀYHPLQXWHUHVWLQJSHULRGRIKHDOWK\YROXQWHHUV
also participating in this study. The mean and standard deviation of these values were 
incorporated as a log normal distribution in this model. Reddy parameterized her model 
IRU HDFK VXEMHFW VHSDUDWHO\ XVLQJ EHVWÀW YDOXHV IRU VHYHUDO SDUDPHWHUV ./8' .'/8
KLD, KDL, Kmlp and CLmlp). In this model, we used these values to obtain log normal 
distributions for the parameters. Similar to the model of Reddy, this model incorporates a 
mobile lipid pool containing unavailable D5 in the blood, and deep compartments in the 
OXQJDQGOLYHUWLVVXHV`
{Description of datasets:
Cex ;conc. of D5 in exhaled breath during the pre exposure, exposure and post exposure 
SHULRGSSP`
METHOD STIFF; Rosenbrock variable step size integration method
DTOUT = 0.1; setting reporting interval
MW = 370.8; molecular weight, g/mol
{Setting the different modeling scenario’s, in combination with the data available for the 
subjects:
6FHQDULRÀ[HGSK\VLRORJLFDOSDUDPHWHUVIRUVXEMHFWDQG
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6FHQDULRK\SRWKHWLFDOH[SRVXUHVFHQDULRYDULDWLRQLQDOOSDUDPHWHUVIRUVXEMHFW`
SUB = 1; number of experimental subjects - 1 through 34 are the subjects of the D5 
inhalation exposure experiment, 35 is the average of all volunteers. Data for subject 2, 10 
and 32 are not available due to an error in the analysis.
6&(1$5,2 WKHPRGHOLQJVFHQDULR·V À[HGYDOXHVIRU0,1943$*(%:DQGYDULDWLRQ
in KLUD, KDLU, KLD, KDL, Kmlp and CLmlp, 2= variation in MINV, QP, KLUD, KDLU, KLD, 
KDL, Kmlp, CLmlp, AGE and BW).
{Setting D5 concentration in inhaled air for subject SUB, during the pre exposure, exposure 
DQGSRVWH[SRVXUHSHULRGSSP`
CONC = IF (TIME>=0 AND TIME<T1) THEN CONCPREEXPS[SUB] ELSE
 IF (TIME>=T1 AND TIME<T2) THEN CONCEXPS[SUB] ELSE
 IF (TIME>=T2 AND TIME<T3) THEN CONCPOSTEXPS[SUB] ELSE 
CONCPOSTEXPS[SUB]
CONCPREEXPS[1] = 0.00928/15.2; D5 concentration in inhaled air for subject 1 during 
pre exposure period, ppm
CONCPREEXPS[3] = 0.00764/15.2; D5 concentration in inhaled air for subject 3 during pre 
exposure period, ppm
CONCPREEXPS[4] = 0.02420/15.2; D5 concentration in inhaled air for subject 4 during 
pre exposure period, ppm
CONCPREEXPS[5] = 0.05062/15.2; D5 concentration in inhaled air for subject 5 during 
pre exposure period, ppm
CONCPREEXPS[6] = 0.01860/15.2; D5 concentration in inhaled air for subject 6 during 
pre exposure period, ppm
CONCPREEXPS[7] = 0.02601/15.2; D5 concentration in inhaled air for subject 7 during 
pre exposure period, ppm
CONCPREEXPS[8] = 0.01664/15.2; D5 concentration in inhaled air for subject 8 during 
pre exposure period, ppm
CONCPREEXPS[9] = 0.08343/15.2; D5 concentration in inhaled air for subject 9 during 
pre exposure period, ppm
CONCPREEXPS[11] = 0.06682/15.2; D5 concentration in inhaled air for subject 11 during 
pre exposure period, ppm
CONCPREEXPS[12] = 0.01218/15.2; D5 concentration in inhaled air for subject 12 during 
pre exposure period, ppm
CONCPREEXPS[13] = 0.01691/15.2; D5 concentration in inhaled air for subject 13 during 
pre exposure period, ppm
CONCPREEXPS[14] = 0.24660/15.2; D5 concentration in inhaled air for subject 14 during 
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pre exposure period, ppm
CONCPREEXPS[15] = 0.03096/15.2; D5 concentration in inhaled air for subject 15 during 
pre exposure period, ppm
CONCPREEXPS[16] = 0.06897/15.2; D5 concentration in inhaled air for subject 16 during 
pre exposure period, ppm
CONCPREEXPS[17] = 0.01708/15.2; D5 concentration in inhaled air for subject 17 during 
pre exposure period, ppm
CONCPREEXPS[18] = 0.05208/15.2; D5 concentration in inhaled air for subject 18 during 
pre exposure period, ppm
CONCPREEXPS[19] = 0.01457/15.2; D5 concentration in inhaled air for subject 19 during 
pre exposure period, ppm
CONCPREEXPS[20] = 0.06497/15.2; D5 concentration in inhaled air for subject 20 during 
pre exposure period, ppm
CONCPREEXPS[21] = 0.01357/15.2; D5 concentration in inhaled air for subject 21 during 
pre exposure period, ppm
CONCPREEXPS[22] = 0.03867/15.2; D5 concentration in inhaled air for subject 22 during 
pre exposure period, ppm
CONCPREEXPS[23] = 0.01767/15.2; D5 concentration in inhaled air for subject 23 during 
pre exposure period, ppm
CONCPREEXPS[24] = 0.19158/15.2; D5 concentration in inhaled air for subject 24 during 
pre exposure period, ppm
CONCPREEXPS[25] = 0.04340/15.2; D5 concentration in inhaled air for subject 25 during 
pre exposure period, ppm
CONCPREEXPS[26] = 0.01098/15.2; D5 concentration in inhaled air for subject 26 during 
pre exposure period, ppm
CONCPREEXPS[27] = 0.01956/15.2; D5 concentration in inhaled air for subject 27 during 
pre exposure period, ppm
CONCPREEXPS[28] = 0.01719/15.2; D5 concentration in inhaled air for subject 28 during 
pre exposure period, ppm
CONCPREEXPS[29] = 0.02044/15.2; D5 concentration in inhaled air for subject 29 during 
pre exposure period, ppm
CONCPREEXPS[30] = 0.03470/15.2; D5 concentration in inhaled air for subject 30 during 
pre exposure period, ppm
CONCPREEXPS[31] = 0.01233/15.2; D5 concentration in inhaled air for subject 31 during 
pre exposure period, ppm
CONCPREEXPS[33] = 0.02116/15.2; D5 concentration in inhaled air for subject 33 during 
pre exposure period, ppm
CONCPREEXPS[34] = 0.04244/15.2; D5 concentration in inhaled air for subject 34 during 
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pre exposure period, ppm
CONCPREEXPS[35] = 0.04230/15.2; mean D5 concentration in inhaled air for all subjects 
during pre exposure period, ppm
CONCEXPS[1] = 2.21135/15.2; D5 concentration in inhaled air for subject 1 during the 
exposure period, ppm
CONCEXPS[3] = 0.56920/15.2; D5 concentration in inhaled air for subject 3 during the 
exposure period, ppm
CONCEXPS[4] = 1.30850/15.2; D5 concentration in inhaled air for subject 4 during the 
exposure period, ppm
CONCEXPS[5] = 0.90348/15.2; D5 concentration in inhaled air for subject 5 during the 
exposure period, ppm
CONCEXPS[6] = 0.88195/15.2; D5 concentration in inhaled air for subject 6 during the 
exposure period, ppm
CONCEXPS[7] = 0.52258/15.2; D5 concentration in inhaled air for subject 7 during the 
exposure period, ppm
CONCEXPS[8] = 0.51493/15.2; D5 concentration in inhaled air for subject 8 during the 
exposure period, ppm
CONCEXPS[9] = 0.51825/15.2; D5 concentration in inhaled air for subject 9 during the 
exposure period, ppm
CONCEXPS[11] = 0.77255/15.2; D5 concentration in inhaled air for subject 11 during the 
exposure period, ppm
CONCEXPS[12] = 0.59837/15.2; D5 concentration in inhaled air for subject 12 during the 
exposure period, ppm
CONCEXPS[13] = 0.23445/15.2; D5 concentration in inhaled air for subject 13 during the 
exposure period, ppm
CONCEXPS[14] = 0.66764/15.2; D5 concentration in inhaled air for subject 14 during the 
exposure period, ppm
CONCEXPS[15] = 1.06645/15.2; D5 concentration in inhaled air for subject 15 during the 
exposure period, ppm
CONCEXPS[16] = 0.87859/15.2; D5 concentration in inhaled air for subject 16 during the 
exposure period, ppm
CONCEXPS[17] = 0.73720/15.2; D5 concentration in inhaled air for subject 17 during the 
exposure period, ppm
CONCEXPS[18] = 0.71295/15.2; D5 concentration in inhaled air for subject 18 during the 
exposure period, ppm
CONCEXPS[19] = 0.86048/15.2; D5 concentration in inhaled air for subject 19 during the 
exposure period, ppm
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CONCEXPS[20] = 0.55826/15.2; D5 concentration in inhaled air for subject 20 during the 
exposure period, ppm
CONCEXPS[21] = 0.56095/15.2; D5 concentration in inhaled air for subject 21 during the 
exposure period, ppm
CONCEXPS[22] = 0.57643/15.2; D5 concentration in inhaled air for subject 22 during the 
exposure period, ppm
CONCEXPS[23] = 0.31203/15.2; D5 concentration in inhaled air for subject 23 during the 
exposure period, ppm
CONCEXPS[24] = 0.89640/15.2; D5 concentration in inhaled air for subject 24 during the 
exposure period, ppm
CONCEXPS[25] = 0.73926/15.2; D5 concentration in inhaled air for subject 25 during the 
exposure period, ppm
CONCEXPS[26] = 0.95092/15.2; D5 concentration in inhaled air for subject 26 during the 
exposure period, ppm
CONCEXPS[27] = 0.38525/15.2; D5 concentration in inhaled air for subject 27 during the 
exposure period, ppm
CONCEXPS[28] = 1.02672/15.2; D5 concentration in inhaled air for subject 28 during the 
exposure period, ppm
CONCEXPS[29] = 0.86244/15.2; D5 concentration in inhaled air for subject 29 during the 
exposure period, ppm
CONCEXPS[30] = 1.90039/15.2; D5 concentration in inhaled air for subject 30 during the 
exposure period, ppm
CONCEXPS[31] = 1.41966/15.2; D5 concentration in inhaled air for subject 31 during the 
exposure period, ppm
CONCEXPS[33] = 1.32937/15.2; D5 concentration in inhaled air for subject 33 during the 
exposure period, ppm
CONCEXPS[34] = 1.27404/15.2; D5 concentration in inhaled air for subject 34 during the 
exposure period, ppm
CONCEXPS[35] = 0.86273/15.2; mean D5 concentration in inhaled air for all subjects 
during the exposure period, ppm
CONCPOSTEXPS[1] = 1.65724/15.2; D5 concentration in inhaled air for subject 1 during 
the post exposure period, ppm
CONCPOSTEXPS[3] = 0.47277/15.2; D5 concentration in inhaled air for subject 3 during 
the post exposure period, ppm
CONCPOSTEXPS[4] = 1.39270/15.2; D5 concentration in inhaled air for subject 4 during 
the post exposure period, ppm
CONCPOSTEXPS[5] = 0.27322/15.2; D5 concentration in inhaled air for subject 5 during 
Measuring and modelling of D5 inhalation exposure
6
251
the post exposure period, ppm
CONCPOSTEXPS[6] = 0.90942/15.2; D5 concentration in inhaled air for subject 6 during 
the post exposure period, ppm
CONCPOSTEXPS[7] = 0.28029/15.2; D5 concentration in inhaled air for subject 7 during 
the post exposure period, ppm
CONCPOSTEXPS[8] = 0.29066/15.2; D5 concentration in inhaled air for subject 8 during 
the post exposure period, ppm
CONCPOSTEXPS[9] = 0.27033/15.2; D5 concentration in inhaled air for subject 9 during 
the post exposure period, ppm
CONCPOSTEXPS[11] = 0.67178/15.2; D5 concentration in inhaled air for subject 11 during 
the post exposure period, ppm
CONCPOSTEXPS[12] = 0.30969/15.2; D5 concentration in inhaled air for subject 12 
during the post exposure period, ppm
CONCPOSTEXPS[13] = 0.07694/15.2; D5 concentration in inhaled air for subject 13 during 
the post exposure period, ppm
CONCPOSTEXPS[14] = 0.28085/15.2; D5 concentration in inhaled air for subject 14 
during the post exposure period, ppm
CONCPOSTEXPS[15] = 0.60568/15.2; D5 concentration in inhaled air for subject 15 
during the post exposure period, ppm
CONCPOSTEXPS[16] = 0.72524/15.2; D5 concentration in inhaled air for subject 16 during 
the post exposure period, ppm
CONCPOSTEXPS[17] = 0.16932/15.2; D5 concentration in inhaled air for subject 17 during 
the post exposure period, ppm
CONCPOSTEXPS[18] = 0.39160/15.2; D5 concentration in inhaled air for subject 18 during 
the post exposure period, ppm
CONCPOSTEXPS[19] = 1.46468/15.2; D5 concentration in inhaled air for subject 19 
during the post exposure period, ppm
CONCPOSTEXPS[20] = 0.34121/15.2; D5 concentration in inhaled air for subject 20 during 
the post exposure period, ppm
CONCPOSTEXPS[21] = 0.60921/15.2; D5 concentration in inhaled air for subject 21 during 
the post exposure period, ppm
CONCPOSTEXPS[22] = 0.41982/15.2; D5 concentration in inhaled air for subject 22 
during the post exposure period, ppm
CONCPOSTEXPS[23] = 0.05641/15.2; D5 concentration in inhaled air for subject 23 
during the post exposure period, ppm
CONCPOSTEXPS[24] = 0.20622/15.2; D5 concentration in inhaled air for subject 24 during 
the post exposure period, ppm
CONCPOSTEXPS[25] = 1.09067/15.2; D5 concentration in inhaled air for subject 25 
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during the post exposure period, ppm
CONCPOSTEXPS[26] = 0.12978/15.2; D5 concentration in inhaled air for subject 26 during 
the post exposure period, ppm
CONCPOSTEXPS[27] = 0.28043/15.2; D5 concentration in inhaled air for subject 27 during 
the post exposure period, ppm
CONCPOSTEXPS[28] = 0.28735/15.2; D5 concentration in inhaled air for subject 28 
during the post exposure period, ppm
CONCPOSTEXPS[29] = 0.79699/15.2; D5 concentration in inhaled air for subject 29 
during the post exposure period, ppm
CONCPOSTEXPS[30] = 1.20252/15.2; D5 concentration in inhaled air for subject 30 
during the post exposure period, ppm
CONCPOSTEXPS[31] = 0.83548/15.2; D5 concentration in inhaled air for subject 31 during 
the post exposure period, ppm
CONCPOSTEXPS[33] = 0.43883/15.2; D5 concentration in inhaled air for subject 33 
during the post exposure period, ppm
CONCPOSTEXPS[34] = 0.87803/15.2; D5 concentration in inhaled air for subject 34 
during the post exposure period, ppm
CONCPOSTEXPS[35] = 0.57469/15.2; mean D5 concentration in inhaled air for all subjects 
during the post exposure period, ppm
;**********Subjects’ Ages**********
INIT AGE = IF SCENARIO=2 THEN RANDOM(22,79) ELSE AGES[SUB]; age of subject 
VSHFLÀHGE\YDULDEOH68%
NEXT AGE = AGE
AGES[1] = 65; age of subject 1, years
AGES[3] = 29; age of subject 3, years
AGES[4] = 41; age of subject 4, years
AGES[5] = 59; age of subject 5, years
AGES[6] = 56; age of subject 6, years
AGES[7] = 68; age of subject 7, years
AGES[8] = 27; age of subject 8, years
AGES[9] = 26; age of subject 9, years
AGES[11] = 34; age of subject 11, years
AGES[12] = 46; age of subject 12, years
AGES[13] = 56; age of subject 13, years
AGES[14] = 22; age of subject 14, years
AGES[15] = 28; age of subject 15, years
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AGES[16] = 50; age of subject 16, years
AGES[17] = 54; age of subject 17, years
AGES[18] = 69; age of subject 18, years
AGES[19] = 64; age of subject 19, years
AGES[20] = 25; age of subject 20, years
AGES[21] = 56; age of subject 21, years
AGES[22] = 60; age of subject 22, years
AGES[23] = 58; age of subject 23, years
AGES[24] = 78; age of subject 24, years
AGES[25] = 28; age of subject 25, years
AGES[26] = 66; age of subject 26, years
AGES[27] = 79; age of subject 27, years
AGES[28] = 66; age of subject 28, years
AGES[29] = 59; age of subject 29, years
AGES[30] = 71; age of subject 30, years
AGES[31] = 42; age of subject 31, years
AGES[33] = 44; age of subject 33, years
AGES[34] = 31; age of subject 34, years
AGES[35] = 50; mean age of all subjects, years
;**********Physiological Parameters**********
T1 = 10; time of start of exposure, min
INIT T2 = IF SCENARIO=2 THEN T1+10 ELSE T1+T2S[SUB]; time of start post exposure 
period for subject SUB, min
NEXT T2 = T2
T3 = T2+15; time of end of post exposure period for subject SUB, min
T2S[1] = 10; time of exposure for subject 1, min
T2S[3] = 10; time of exposure for subject 3, min
T2S[4] = 12; time of exposure for subject 4, min
T2S[5] = 11; time of exposure for subject 5, min
T2S[6] = 10; time of exposure for subject 6, min
T2S[7] = 11; time of exposure for subject 7, min
T2S[8] = 11; time of exposure for subject 8, min
T2S[9] = 11; time of exposure for subject 9, min
T2S[11] = 11; time of exposure for subject 11, min
T2S[12] = 12; time of exposure for subject 12, min
T2S[13] = 10; time of exposure for subject 13, min
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T2S[14] = 10; time of exposure for subject 14, min
T2S[15] = 13; time of exposure for subject 15, min
T2S[16] = 13; time of exposure for subject 16, min
T2S[17] = 12; time of exposure for subject 17, min
T2S[18] = 10; time of exposure for subject 18, min
T2S[19] = 12; time of exposure for subject 19, min
T2S[20] = 11; time of exposure for subject 20, min
T2S[21] = 11; time of exposure for subject 21, min
T2S[22] = 13; time of exposure for subject 22, min
T2S[23] = 9; time of exposure for subject 23, min
T2S[24] = 11; time of exposure for subject 24, min
T2S[25] = 10; time of exposure for subject 25, min
T2S[26] = 11; time of exposure for subject 26, min
T2S[27] = 11; time of exposure for subject 27, min
T2S[28] = 11; time of exposure for subject 28, min
T2S[29] = 12; time of exposure for subject 29, min
T2S[30] = 12; time of exposure for subject 30, min
T2S[31] = 11; time of exposure for subject 31, min
T2S[33] = 11; time of exposure for subject 33, min
T2S[34] = 11; time of exposure for subject 34, min
T2S[35] = 11; mean time of exposure for all subjects, min
{Setting minute volume and alveolar ventilation as a function of time for subject SUB, L/
PLQ8VLQJDFRUUHODWLRQEHWZHHQPLQXWHYROXPHDQGDOYHRODUYHQWLODWLRQ`
0,19PHDQ PHDQPLQXWHYROXPHYROXQWHHUVIURPÀHOGVWXG\1 
MINVsd = 0.29; standard deviation of natural logarithm minute volume volunteers from 
volunteer study
43PHDQ PHDQDOYHRODUYHQWLODWLRQYROXQWHHUVIURPÀHOGVWXG\1 
QPsd = 0.31; standard deviation of natural logarithm alveolar ventilation volunteers from 
volunteer study
UKR VTUWFRUUHODWLRQFRHIÀFLHQW
zMINV = normal(0,1); normal distribution
zQP = normal(0,1); normal distribution
INIT MINV = IF SCENARIO=2 THEN MINVmean*exp(zMINV*MINVsd) ELSE MINVS[SUB]   
NEXT MINV = MINV
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INIT QP = IF SCENARIO=2 THEN QPmean*exp((rho*zMINV+sqrt(1-rho*rho)*zQP)*QPsd) 
ELSE QPS[SUB]
NEXT QP = QP
MINVS[1] =14.34; minute volume of subject 1, L/min
MINVS[15] = 10.00; minute volume of subject 15, L/min
MINVS[26] = 10.15; minute volume of subject 26, L/min
MINVS[33] = 11.62; minute volume of subject 33, L/min
QPS[1] = 9.32; alveolar ventilation as function of time for subject 1, L/min
QPS[15] = 7.74; alveolar ventilation as function of time for subject 15, L/min
QPS[26] = 7.16; alveolar ventilation as function of time for subject 26, L/min
QPS[33] = 7.48; alveolar ventilation as function of time for subject 33, L/min
QC = -6.85*LOG10(AGE)+16.8; cardiac output for sub. SUB, L/min
QLC = 0.227; fraction of cardiac output to liver comp.
QFC = 0.052; fraction of cardiac output to fat comp.
QSC = 0.249; fraction of cardiac output to slowly perf. tissues
QRC = 1.0 - QLC - QFC - QSC; fraction of cardiac output to rapidly perf. tissues
3(50) FRHIÀFLHQWIRUPDVVWUDQVSRUWLQWRIDW
^3DUDPHWHUVIRUGHHSOXQJFRPSDUWPHQW`
KLUDmean = 0.12; mean mass trans. coeff. for transport into lung, 1/min
KLUDsd = 0.573; natural logarithm standard deviation mass trans. coeff. for transport into 
lung, 1/min
INIT KLUD = KLUDmean * exp(normal(0,KLUDsd))
NEXT KLUD = KLUD
KDLUmean = 0.0036; mean mass trans. coeff. for transport out of lung, 1/min
KDLUsd = 1.008; natural logarithm standard deviation mass trans. coeff. for transport out 
of lung, 1/min
INIT KDLU = KDLUmean * exp(normal(0,KDLUsd))
NEXT KDLU = KDLU
^3DUDPHWHUVIRUGHHSOLYHUFRPSDUWPHQW`
KLDmean = 0.072; mean mass trans. coeff. for transport into deep liver, 1/min
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KLDsd = 1.126; natural logarithm standard deviation mass trans. coeff. for transport into 
deep liver, 1/min
INIT KLD = KLDmean * exp(normal(0,KLDsd))
NEXT KLD = KLD
KDLmean = 0.0031; mean mass trans. coeff. for transport out of deep liver, 1/min
KDLsd = 0.832; natural logarithm standard deviation mass trans. coeff. for transport out 
of deep liver, 1/min
INIT KDL = KDLmean * exp(normal(0,KDLsd)) 
NEXT KDL = KDL
^9ROXPHSDUDPHWHUV`
%:PHDQ PHDQERG\ZHLJKWIURPYROXQWHHUVIURPÀHOGVWXG\1 NJ
%:VG QDWXUDOORJDULWKPVWDQGDUGGHYLDWLRQERG\ZHLJKWIURPYROXQWHHUVIURPÀHOG
study, kg
INIT BW = IF SCENARIO=2 THEN BWmean * exp(normal(0,BWsd)) ELSE BWS[SUB]; body 
weight for the subject designated by SUB, kg
NEXT BW = BW
BWS[1] = 72; body weight of subject 1, kg
BWS[3] = 71; body weight of subject 3, kg
BWS[4] = 98; body weight of subject 4, kg
BWS[5] = 61; body weight of subject 5, kg
BWS[6] = 79; body weight of subject 6, kg
BWS[7] = 64; body weight of subject 7, kg
BWS[8] = 54; body weight of subject 8, kg
BWS[9] = 90; body weight of subject 9, kg
BWS[11] = 63; body weight of subject 11, kg
BWS[12] = 74; body weight of subject 12, kg
BWS[13] = 64; body weight of subject 13, kg
BWS[14] = 80; body weight of subject 14, kg
BWS[15] = 71; body weight of subject 15, kg
BWS[16] = 85; body weight of subject 16, kg
BWS[17] = 66; body weight of subject 17, kg
BWS[18] = 71; body weight of subject 18, kg
BWS[19] = 57; body weight of subject 19, kg
BWS[20] = 75; body weight of subject 20, kg
BWS[21] = 73; body weight of subject 21, kg
BWS[22] = 63; body weight of subject 22, kg
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BWS[23] = 52.5; body weight of subject 23, kg
BWS[24] = 61; body weight of subject 24, kg
BWS[25] = 58; body weight of subject 25, kg
BWS[26] = 65; body weight of subject 26, kg
BWS[27] = 84; body weight of subject 27, kg
BWS[28] = 50; body weight of subject 28, kg
BWS[29] = 62; body weight of subject 29, kg
BWS[30] = 64; body weight of subject 30, kg
BWS[31] = 85; body weight of subject 31, kg
BWS[33] = 83; body weight of subject 33, kg
BWS[34] = 61; body weight of subject 34, kg
BWS[35] = 69; mean body weight of all subjects, kg
VLUC = 0.0076; fraction of BW that is lung
VLC = 0.0314; fraction of BW that is liver
VBLC = 0.059; fraction of BW that is blood
VFC = IF (SUB=32) THEN VFCall ELSE
IF (SUB=1 OR SUB=4 OR SUB=18 OR SUB=20 OR SUB=31) THEN VFCmale ELSE VFCfemale
VFCall = 0.25;fraction of BW that is in fat compartment of all subjects, kg
VFCmale = 0.23;fraction of BW that is in fat compartment of all male subjects, kg
VFCfemale = 0.27; fraction of BW that is in fat compartment of all female subjects, kg
VRC = 0.0424; fraction of BW that is rapidly perfused
VSC = 0.91 - VLC - VBLC - VFC - VRC - VLUC; fraction of BW in slowly perf. comp.
&KHPLFDOVSHFLÀFSDUDPHWHUV
^3DUWLWLRQ&RHIÀFLHQWV`
3/8 OXQJEORRGSDUWLWLRQFRHIÀFLHQW
3/ OLYHUEORRGSDUWLWLRQFRHIÀFLHQW
3) IDWFRPSDUWPHQWEORRGSDUWLWLRQFRHIÀFLHQW
36 VORZO\SHUIXVHGWLVVXHVEORRGSDUWLWLRQFRHIÀFLHQW
35 UDSLGO\SHUIXVHGWLVVXHVEORRGSDUWLWLRQFRHIÀFLHQW
3%PHDQ PHDQEORRGDLUSDUWLWLRQFRHIÀFLHQW
3%VG QDWXUDOORJDULWKPVWDQGDUGGHYLDWLRQEORRGDLUSDUWLWLRQFRHIÀFLHQW
INIT PB = PBmean * exp(normal(0,PBsd))
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NEXT PB = PB
^3DUDPHWHUVUHODWLQJWRPHWDEROLVPRUPHWDEROLWH`
.)& DOORPHWULFFRQVWDQWIRUÀUVWRUGHUUDWHFRQVWDQWIRUPHWDEROLVP/PLQNJA
.) .)&%:AÀUVWRUGHUUDWHFRQVWDQWIRUPHWDEROLVP/PLQ
^3DUDPHWHUVUHODWLQJWRPRELOHOLSLGSRRO`
.POSPHDQ PHDQÀUVWRUGHUUDWHFRQVWDQWIRUSURGXFWLRQRIPRELOHOLSLGSRRO
min
.POSVG    QDWXUDO ORJDULWKP VWDQGDUG GHYLDWLRQ ÀUVWRUGHU UDWH FRQVWDQW IRU
production of mobile lipid pool, 1/min
INIT Kmlp = Kmlpmean * exp(normal(0,Kmlpsd))
NEXT Kmlp = Kmlp
CLmlpmean = 0.046; mean clearance of unavailable D5 from mobile lipid pool, 1/min
CLmlpsd = 0.605; natural logarithm standard deviation clearance of unavailable D5 from 
mobile lipid pool, 1/min
INIT CLmlp = CLmlpmean * exp(normal(0,CLmlpsd))
NEXT CLmlp = CLmlp
;**********Parameters of the exposure***********
STARTTIME = 0.0; setting the start time of the simulation, min
TEXP = T3; duration of total experiment for subject SUB, min
STOPTIME = 35.0; setting the time the simulation ends, min
CONCC = CONC*15.2; exposure concentration, ug/L
^&RQYHUWLQJ%:IUDFWLRQVWRYROXPHV`
VLU = VLUC * BW; liver volume, L
VL = VLC * BW; liver volume, L
VBLA = 0.35*VBLC * BW; arterial blood volume, L
VBLV = 0.65*VBLC * BW; venous blood  volume, L
VF = VFC * BW; fat comp. volume, L
VR = VRC * BW; rapidly perfused comp. volume, L
VS = VSC * BW; slowly perfused comp. volume, L
^&DOFXODWLQJÁRZUDWHVIURPIUDFWLRQDOEORRGÁRZV`
4/ 4/&4&EORRGÁRZUDWHWRWKHOLYHU/PLQ
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4) 4)&4&EORRGÁRZUDWHWRWKHIDWFRPS/PLQ
46 46&4&EORRGÁRZUDWHWRVORZO\SHUIFRPS/PLQ
45 45&4&EORRGÁRZUDWHWRWKHUDSLGO\SHUIFRPS/PLQ
;**********Mass balances***********
Cin = CONCC * (1.0 - SQUAREPULSE(TEXP, STOPTIME)); inhaled D5 conc., ug/L
^&LQLV&21&&IRUW7(;3DQG]HURRWKHUZLVH`
^,QLWLDO&RQGLWLRQV`
INIT ABLA = 0.0; amount free D5 in arterial blood, ug
INIT AX = 0.0; amount D5 exhaled, ug
INIT AX2 = 0.0; amount D5 exhaled after exposure stops, ug
INIT ABLV = 0.0; amount free D5 in venous blood, ug
INIT AF = 0.0; amount D5 in fat comp., ug
INIT AL = 0.0; amount D5 in liver comp., ug
INIT ALD = 0.0; amount D5 in deep liver comp., ug
INIT ALU = 0.0; amount D5 in lung comp., ug
INIT ALUD = 0.0; amount D5 in deep lung comp., ug
INIT AS = 0.0; amount D5 in slowly perfused tissue comp., ug
INIT AR = 0.0; amount D5 in rapidly perfused tissue compartment, ug
INIT AMET = 0.0; amount D5 metabolite produced, ug
INIT AI = 0.0; amount D5 entering the region of lungs capable of gas exchange by inhalation, 
ug
INIT AII = 0.0; amount D5 entering the total lung volume by inhalation route, ug
INIT AmlpV = 0.0; amount D5 in the mobile lipid pool of venous blood, ug
INIT AmlpA = 0.0; amount D5 in the mobile lipid pool of arterial blood, ug
INIT AABS = 0.0; amount D5 systemically absorbed by inhalation, ug
^0DVV%DODQFHIRUWKHOXQJVGHHSFRPSDUWPHQW`
CX = CA / PB; exhaled conc. not considering dead space, ug/L
ALU’ = QP*(Cin-CA/Pb) - QC*(CA-CBLV) - KLUD*ALU + KDLU*ALUD
CA = ALU/VLU/PLU; D5 concentration in blood exiting lung tissue, ug/L
FNDS = QP/MINV; fraction of lungs where gas exchange occurs
FDS = 1.0 - QP/MINV; fraction of lungs that is dead space
CEX = (FNDS*CX + FDS*Cin)/15.2; exhaled conc. adjusted for dead space, ppm
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^0DVV%DODQFHIRUWKHGHHSOXQJFRPSDUWPHQW`
ALUD’ = KLUD * ALU - KDLU * ALUD
^0DVVEDODQFHIRUDUWHULDOEORRGFRPSDUWPHQW`
ABLA’ = QC * (CA - CBLA)
CBLA = ABLA / VBLA; D5 concentration in arterial blood, ug/L
^0DVV%DODQFHVIRU'H[KDOHGEHIRUHDQGDIWHUH[SRVXUHHQGV`
AX’ = QP * CX; before and after exposure ends
AX2’ = QP * CX * SQUAREPULSE(TEXP, STOPTIME); after exposure ends
^0DVVEDODQFHIRUIUHH'LQYHQRXVEORRG`
ABLV’ = (QF*CEXF+QL*CVL+QR*CVR+QS*CVS)-QC*CBLV
;ABLV’ = (QF*CVF+QL*CVL+QR*CVR+QS*CVS)-QC*CBLV
CBLV = ABLV / VBLV; D5 concentration in venous blood compartment, ug/L
^0DVVEDODQFHIRUIDWFRPSDUWPHQW`
;AF’ = QF * (CBLA-CVF) + QF*CLmlp/(QF+CLmlp)*AmlpA/VBLA
AF’ = PERMF * QF * (CBLA-CVF) + QF*CLmlp/(QF+CLmlp)*AmlpA/VBLA
CEXF = CBLA - PERMF * (CBLA - CF/PF); D5 conc. exiting fat
CVF = AF / (VF * PF)
CF = AF / VF; concentration in fat, ug/l
^0DVV%DODQFHIRUWKHOLYHUFRPSDUWPHQW`
AL’ = QL*(CBLA - CVL) - KF*CVL - Kmlp*VL*CVL - KLD*AL + KDL*ALD
CVL = AL / (VL * PL)
CL = AL / VL; D5 concentration in liver, ug/L
AMET’ =  KF*CVL
^0DVV%DODQFHIRUWKHGHHSOLYHUFRPSDUWPHQW`
ALD’ = KLD * AL - KDL * ALD
^0DVV%DODQFHIRUWKHVORZO\SHUIXVHGWLVVXHV`
;AS’ = PAS * (CBLA - AS/VS/PS)
;CEXSR = CBLA - PAS / QS * (CBLA - AS/VS/PS)
AS’ = QS * (CBLA - CVS)
CVS = AS / (VS * PS); D5 concentration exiting the slowly perfused tissue, ug/L
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^0DVV%DODQFHIRUWKHUDSLGO\SHUIXVHGWLVVXHV`
AR’ = QR * (CBLA - CVR)
CR = AR / VR
CVR = AR / (VR * PR); D5 concentration exiting the rapidly perfused tissue, ug/L
^0DVVEDODQFHIRUWKHDPRXQW'LQKDOHGLQWROXQJV`
AI’ = QP * Cin
AII’ = MINV * Cin
^&DOFXODWLRQIRUWKHDPRXQWRI'DEVRUEHGV\VWHPLFDOO\`
AABS’= IF TIME<TEXP THEN QP*(Cin-CX) ELSE 0
^0DVVEDODQFHIRUDPRXQW'LQYHQRXVEORRGPRELOHOLSLGSRRO`
AMLPV’ = Kmlp*VL*CVL - QC * (AMLPV / VBLV - AMLPA / VBLA)
^0DVVEDODQFHIRUDPRXQW'LQDUWHULDOEORRGPRELOHOLSLGSRRO`
AMLPA’ = QC * (AMLPV/VBLV - AMLPA/VBLA) - QF*CLmlp/(QF+CLmlp)*AMLPA/VBLA
^'FRQFLQYHQRXVUHWXUQLQFOXGLQJXQDYDLODEOH'`
CVMIX = (ABLV+AMLPV) / VBLV; ave. conc. in the venous blood, ug/L
FUNAV = AMLPV / (ABLV+AMLPV+0.00001)
CRAT = CVMIX/(CEX*15.2); ratio of D5 concentration in venous blood to exhaled breath
^&DOFXODWLQJWKHIUDFWLRQRI'HQWHULQJWKHOXQJVWKDWJHWVUHWDLQHG`
FA = IF TIME<TEXP THEN 1.0 - CEX / CONC ELSE 0; fraction absorbed
^2YHUDOOPDVVEDODQFH`
MB=(AI-(ABLA+AMLPA+AMLPV+AF+AL+ALD+AS+AR+ABLV+AMET+AX+ALU+ALUD))/
(AI+0.0001)*100.
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SI 3. Scenario 1: Modeling results of the other 29 individual participants
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SI 4. Scenario 2: Modelling results
Figure 4.3. The results of population modelling of the D5 concentration in end-exhaled air 
(μg/L). (Scenario 2, N=1000) 
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SI 5. Scenario 2: Results of the sensitivity analysis 
Table 5.1. Results of the sensitivity analysis for volunteer 1, 2, 3 and 4 (scenario 1). 
Volunteer 1 
Parameter T=9 min  T=19 min T=29 min T=34 min 
CLmlp 0.01 0.00 0.01 0.11 
KDL 0.16 0.37 0.24 0.66 
KDLU 0.19 0.17 1.88 4.07 
KLD 0.38 0.74 0.18 0.05 
KLUD 47.13 75.51 55.48 56.31 
Kmlp 0.02 0.05 0.02 1.78 
PB 52.10 23.15 42.17 37.02 
SUM 100 100 100 100 
Volunteer 2 
Parameter T=9 min  T=19 min T=29 min T=34 min 
CLmlp 0.92 0.92 0.92 0.94 
KDL 0.27 0.27 0.30 0.31 
KDLU 0.14 0.15 1.81 2.83 
KLD 0.13 0.13 0.01 0.05 
KLUD 35.67 35.89 53.99 45.99 
Kmlp 0.60 0.60 0.49 0.60 
PB 62.27 62.05 42.48 49.27 
SUM 100,00 100,00 100,00 100,00 
Volunteer 3 
Parameter T=9 min  T=19 min T=29 min T=34 min 
CLmlp 0.07 0.06 0.00 0.01 
KDL 0.01 0.01 0.03 0.09 
KDLU 0.44 0.51 20.53 26.17 
KLD 0.11 0.10 0.87 0.92 
KLUD 41.25 42.48 75.65 58.29 
Kmlp 0.09 0.09 0.26 0.26 
PB 58.04 56.75 2.66 14.26 
SUM 100,00 100,00 100,00 100,00 
Volunteer 4 
Parameter T=9 min  T=19 min T=29 min T=34 min 
CLmlp 0.14 0.14 0.08 0.11 
KDL 0.00 0.00 0.00 0.00 
KDLU 0.13 0.16 4.73 6.43 
KLD 0.25 0.26 1.45 1.50 
KLUD 39.43 40.38 63.89 52.86 
Kmlp 0.02 0.02 0.05 0.02 
PB 60.03 59.04 29.80 39.08 
SUM 100.00 100.00 100.00 100.00 
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Table 5.2. Results of the sensitivity analysis of scenario 2, population level. 
Parameter t=9 min t=19 min t=29 min t=34 min 
AGE 4.55 4.83 4.49 5.04 
BW 7.64 6.96 6.10 5.70 
CLmlp 0.01 0.01 0.03 0.03 
KDL 0.03 0.08 0.08 0.10 
KDLU 0.02 0.02 1.22 1.80 
KLD 0.03 0.04 0.26 0.33 
KLUD 29.19 31.02 38.83 37.68 
Kmlp 0.05 0.02 0.07 0.07 
MINV 9.72 8.82 7.06 6.99 
PB 48.73 48.19 41.85 42.27 
QP 0.02 0.01 0.00 0.01 
SUM 100.00 100.00 100.00 100.00 
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SI 6. Results of the RMSE analysis 
Table 6.1. Results of the RMSE analysis, including the D5 concentration in end-exhaled air 
at t=20, t=25, t=30 and t=35 min.
Volunteer Measurement vs. statistical linear regression model 
Measurement vs. PBPK 
model 
Measurement vs. Ambient air 
measurement 
1 1.33 0.75 0.87 
2 0.66 0.69 0.89 
3 0.91 0.93 1.17 
4 0.99 1.40 1.52 
5 0.43 0.35 0.54 
6 0.65 0.77 0.85 
7 0.46 1.02 1.19 
8 0.46 1.28 1.46 
9 0.95 1.22 1.42 
10 0.56 0.98 1.09 
11 0.85 1.70 2.12 
12 0.32 1.08 1.29 
13 0.70 1.23 1.39 
14 0.41 0.74 0.64 
15 0.67 1.57 1.63 
16 0.73 0.62 0.66 
17 1.57 1.34 1.34 
18 0.54 1.11 1.30 
19 1.34 1.98 2.17 
20 0.82 0.52 0.63 
21 1.05 0.70 0.95 
22 0.72 1.39 1.49 
23 0.91 0.78 1.01 
24 1.17 1.26 1.30 
25 1.09 1.56 1.57 
26 0.83 1.39 1.39 
27 0.47 0.50 0.65 
28 1.22 0.48 0.62 
29 0.78 0.73 0.89 
30 1.30 1.84 1.97 
31 1.37 1.37 1.55 
Mean 0.85 1.07 1.21 
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The aim of this thesis was to obtain better insight into consumer exposure to 
personal care products (PCPs) in order to improve human health risk assessment. 
7KLVRYHUDOODLPZDVWUDQVODWHGLQWRWKUHHUHVHDUFKREMHFWLYHV7KHÀUVWREMHFWLYH
pertained to the construction of a database consisting of exposure factors related 
to the use of PCPs by Dutch consumers. The second objective comprised the 
investigation of internal exposure to PCPs after dermal application of a single 
product and the combined use of two products (aggregate exposure). And the 
WKLUGREMHFWLYHLQYROYHGWKHUHÀQHPHQWDQGDSSOLFDWLRQRIDSK\VLRORJLFDOO\EDVHG
pharmacokinetic (PBPK) model, and the subsequent simulation of aggregate 
consumer exposure to PCPs. In this general discussion, each of these objectives 
and the accompanying chapters in this thesis describing the results will be 
discussed in the context of consumer exposure assessment. The discussion starts 
by considering the generalizability of the studies included in this thesis, followed 
by an evaluation of the model substances and the use of end-exhaled air analysis 
in consumer exposure assessment, and concludes with recommendations for 
future research. 
Generalizability 
The database presented in Chapter 2 comprises data on PCP usage patterns 
and circumstances of use from 516 Dutch adult consumers. Despite the small 
sample size, the information obtained is fairly representative for the Dutch 
general population. Consumers living in small villages and large cities throughout 
the Netherlands participated. No selective non-response was observed and the 
usage patterns and circumstances of use described by the respondents are 
logical and as would be expected. The information present in the database cannot 
be extrapolated beyond the Dutch population, however, as consumer behaviour is 
varies between cultures (1, 2). Within the context of the current PhD study, it was 
not feasible to address all ingredients of PCPs available on the market. Therefore, 
two cyclic siloxanes (octamethylcyclosiloxane, D4 and decamethylcyclosiloxane, 
D5) were selected as model substances to provide answers to objectives 2 and 
7KHUHVXOWVSUHVHQWHGLQ&KDSWHUVDQGDUHYDOLGIRUWKHVHVSHFLÀFPRGHO
substances. To some extent, the results can be extrapolated to more general 
FRQFOXVLRQVDSSOLFDEOH WR WKHHQWLUH ÀHOGRI FRQVXPHUKHDOWK ULVNDVVHVVPHQW
First, the suggestion that dermal absorption is not always the main route of uptake 
of ingredients present in PCPs and second, the notion that simple exposure 
PRGHOVPLJKW EH VXIÀFLHQW WR SUHGLFW LQWHUQDO H[SRVXUH WR 3&3 LQJUHGLHQWV DUH
conclusions that are not restricted to D4 and D5 as ingredients of PCPs. These 
conclusions are likely also applicable to other PCP ingredients with similar 
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substance characteristics, i.e. a relative high vapour pressure and poor dermal 
absorption. 
    
Choice of model substances
In collaboration with the other research partners in the European project, 
'DQG'ZHUHFKRVHQDVPRGHOVXEVWDQFHVDV WKH\ IXOÀOOHGDOOFULWHULD IRUD
suitable model substance. The main reason for selecting D4 and D5 was that 
these compounds are considered safe as an ingredient of PCPs (3, 4), which is 
a prerequisite for conducting a human exposure study. Similar exposure studies 
showed that D4 and D5 were detectable in exhaled air (5, 6). Furthermore, a 
human physiologically based pharmacokinetic (PBPK) model was available (7, 8). 
In hindsight, the choice for D4 and D5 as modelling compounds was probably not 
the best to investigate aggregate dermal consumer exposure. The combination 
of a considerable vapour pressure (124.5 Pa for D4 and 20.4 Pa for D5) and 
limited skin absorption resulted in inhalation being the dominant route of uptake 
and negligible dermal uptake (Chapter 5). As a consequence, we were unable 
to demonstrate the relevance of the dermal uptake route for aggregate PCP 
exposure. However, this does not mean that the dermal route is irrelevant for all 
PCP ingredients; it may still be relevant for PCP ingredients that have lower vapour 
pressure and/or higher skin absorption, such as parabens (i.e. ethyl-, methyl-, 
butyl-, propylparaben), phthalates (i.e. diethyl phthalate), and triclosan. When 
UHÁHFWLQJRQSDUDEHQVSKWKDODWHVDQGWULFORVDQLQOLJKWRIRXUOLVWRIUHTXLUHPHQWV
for a model substance, we observe the following: (1) consumer exposure to these 
substances through the use of PCPs in generally considered safe, despite possible 
endocrine disrupting properties (9-11); (2) skin absorption is the major route of 
uptake as the vapour pressure of these compounds is low; and (3) the parent 
compounds or metabolites are detectable in urine (12, 13). Therefore, we suggest 
that parabens, phthalates, or triclosan should be used as model substance in 
future human exposure studies investigating aggregate dermal uptake of PCP 
ingredients. 
End-exhaled air analysis in consumer exposure assessment 
Uptake of a PCP ingredient via all routes (dermal absorption, inhalation, and 
LQJHVWLRQLVUHÁHFWHGE\WKHFRQFHQWUDWLRQRIWKLVLQJUHGLHQWLQELRORJLFDOPHGLD
of a consumer, such as blood, urine or exhaled air (14). In this thesis, the 
concentrations of D4 and D5 in end-exhaled air were used as chemical markers 
for internal exposure to substances present in PCPs. End-exhaled air analysis 
is an easy and non-invasive way to collect biological samples. In contrast to the 
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collection of blood or urine, repeated samples are collected in a limited period of 
time without much effort and burden to the consumer. Therefore, we consider it to 
be the method of choice for consumer exposure assessment. The literature review 
(Chapter 3) showed that in order to increase the use of end-exhaled air analysis in 
consumer exposure assessment, more research is needed to improve awareness 
among exposure scientists, to develop standardized protocols, to obtain guidance 
YDOXHVDQGWRVWUHVVWKHEHQHÀWVRIWKLVPHWKRG ,QSUDFWLFHWKHYDOXHRIHQG
H[KDOHG DLU DQDO\VLV KDV QRW \HW EHHQ DFNQRZOHGJHG LQ WKH ÀHOG RI H[SRVXUH
sciences. In the US, for example, the Centers for Disease Control and Prevention 
(CDC) perform the National Health and Nutrition Examination Survey (NHANES), an 
ongoing project which includes monitoring exposure to environmental chemicals 
in the general US population. So far, only blood and urine samples are collected 
as biological media (15), but participants as well as exposure scientist involved in 
WKH1+$1(6VWXG\ZRXOGEHQHÀWIURPWKHFROOHFWLRQRIHQGH[KDOHGDLUVDPSOHV
The large amount of data collected with this non-invasive method provides ample 
opportunities to obtain guidance values and to develop standardized protocols 
for collection and analysis. For these reasons, we recommend to include the 
collection of end-exhaled air samples in the NHANES and other large population 
studies. The use of end-exhaled air analysis has already been widely adopted in 
WKHÀHOGRIRFFXSDWLRQDOH[SRVXUHDVVHVVPHQWEXWHQGH[KDOHGDLUDQDO\VLVFRXOG
also be used in other exposure settings, such as in the detection of drugs or triage 
following chemical, biological, and radionuclear incidents (CBRN-incidents).
Discussion of the objectives of this thesis
1. Construction of an exposure factors database
At the beginning of this PhD project, we developed a questionnaire and investigated 
PCP usage patterns and circumstances of use among Dutch consumers. The 
collected data were analyzed and compiled in an exposure factors database 
(Chapter 2). Recently, the data were included in the European Expo-Facts database, 
that is developed by the European Commission Joint Research Centre and contains 
data from 30 European Union countries (16). In addition, the data have been used 
by other researchers to develop a probabilistic aggregate consumer exposure 
model (PACEM) and to model aggregate consumer exposure to parabens, diethyl 
phthalate, and D5 (17-19). The US Environmental Protection Agency (US EPA) was 
WKH ÀUVW WR FROOHFW IDFWRUV UHODWHG WR KXPDQEHKDYLRXU DQG FKDUDFWHULVWLFV WKDW
help to determine an individual’s exposure to an agent (i.e. exposure factors). The 
Exposure Factors Handbook (20) became and still is an important reference for 
General Discussion
7
281
exposure assessment, although the underlying data are only representative for 
children and adults in the US. Next to our database, representing Dutch adults, 
RWKHU GDWDEDVHV KDYH EHHQ HVWDEOLVKHG FRYHULQJ VSHFLÀF SRSXODWLRQV VXFK DV
Korean adults and Swiss-German children, adolescents, and adults (21, 22). In 
future research, it is important to investigate exposure patterns and circumstances 
of PCP use in different populations worldwide as consumer behaviour (i.e. the use 
RI3&3VLVLQÁXHQFHGE\SHUVRQDOVRFLRFXOWXUDODQGPDUNHWLQJSDUDPHWHUV(1, 2). 
2. Investigation of internal exposure to PCPs after dermal administration of a 
single product and the combined use of two products (aggregate exposure)
Using D4 and D5 as model substances, internal exposure to PCPs was studied 
following dermal application. The concentrations of D4 and D5 in end-exhaled 
air served as chemical markers for internal exposure. After our human exposure 
study, we concluded that inhalation and not dermal absorption was the major 
route of uptake responsible for internal exposure to D4 and D5 (Chapter 5). This 
PHDQVWKDWZHZHUHQRWDEOHWRIXOÀOWKHVHFRQGREMHFWLYHEXWWKHVWXG\GLGSURYLGH
informative and essential information for future aggregate exposure assessment. 
The biomonitoring data collected in this study (i.e. D4 and D5 concentration in 
end-exhaled air) were used to validate the new higher tier Probabilistic Aggregate 
Consumer Exposure Model (PACEM) (19). PACEM also included our questionnaire 
data on PCP use and co-use, which were essential for realistic aggregate exposure 
estimation at the individual level. The authors concluded that PACEM is reasonably 
conservative and can be used for risk assessment of cosmetic ingredients. The 
development and validation of the PACEM model is the result of the work of several 
UHVHDUFKJURXSVLQFOXGLQJWKLV3K'SURMHFWZKLFKZDVPHUJHGLQDÀQDOFRQVXPHU
aggregate exposure model.
Next to the development of the PACEM model, other researchers have predicted 
aggregate consumer exposure to ingredients of PCPs using other tools and 
simulation techniques. A deterministic approach (Tier 1) and a probabilistic 
approach (Tier 2) were evaluated in predicting aggregate exposure to parabens 
in PCPs (18), which led to the conclusion that a deterministic approach is a good 
starting point for aggregate consumer exposure assessment. A probabilistic, 
SHUVRQRULHQWHG DSSURDFK FDQ EH DSSOLHG ZKHQ PRUH UHÀQHPHQW LV QHHGHG
leading to more informative exposure assessment as the input of more data and 
the complexity of the model resemble realistic exposures. Recently, a probabilistic 
approach was used to predict aggregate consumer exposure to ethylhexyl 
PHWKR[\FLQQDPDWH(+0&D89ÀOWHULQ3&3VZLWKSRWHQWLDOO\HQGRFULQHGLVUXSWLQJ
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effects (23). In general, the calculated internal exposure estimates were below 
the derived no effect level (DNEL) for EHMC. The same authors also investigated 
DJJUHJDWH FRQVXPHU H[SRVXUH WR RFWRFU\OHQH 2&7 DQ 89 ÀOWHU LQ 3&3V ZLWK
possible skin sensitizing properties (24). In this study, a probabilistic approach 
was used and the authors concluded that sunscreens were the most important 
source of exposure to OCT. The prediction of aggregate consumer exposure to 
PCPs is often partly based on assumptions. One of these assumptions in the 
recent studies discussed above is that a consumer is primarily exposed via the 
skin (dermal absorption). Often, dermal absorption data provided by in vitro and 
in vivo experiments are used as input. In practice, dermal exposure might not 
always be the most important exposure route for consumers, as can be seen 
in the conclusion of Chapter 5. Therefore, additional realistic human exposure 
studies are needed to evaluate aggregate dermal, inhalation, and oral consumer 
exposure to PCPs. Data obtained from these studies can, among others, be used 
WRYDOLGDWHDQGUHÀQHDJJUHJDWHH[SRVXUHPRGHOV
 
5HÀQHPHQWRID3%3.PRGHODQGVXEVHTXHQWPRGHOOLQJRIDJJUHJDWHFRQVXPHU
exposure to PCPs
7KH LQLWLDO JRDO ZDV WR UHÀQH DQG DSSO\ DQ H[LVWLQJ 3%3. PRGHO WR SUHGLFW
aggregate consumer exposure to PCPs, with the intention to use the results from 
the human exposure study (Chapter 5) for D5 as input. This was not possible, 
as the results from the human exposure study did not yield data on aggregate 
dermal absorption. Inhalation instead of dermal absorption turned out to be the 
primary route of uptake, which offered a new perspective and the opportunity 
to change the focus to inhalation uptake of D5 resulting from PCP use. To this 
end, an additional human exposure study was performed, and realistic inhalation 
exposure to a PCP studied in bathrooms at the residences of volunteers was 
estimated. The data collected were used to model internal exposure to D5 using 
several prediction methods. So, the third objective of this thesis was rephrased as: 
´7RGHYHORSQHZDQGUHÀQHH[LVWLQJH[SRVXUHPRGHOVWRSUHGLFWLQWHUQDOFRQVXPHU
inhalation exposure to PCPs”.  
For the prediction of internal consumer exposure to D5, a linear regression 
PRGHOZDVGHYHORSHGDQGDQH[LVWLQJ3%3.PRGHOZDVUHÀQHG7KLVUHVXOWHGLQ
the conclusion that internal exposure was best predicted using a simple linear 
regression model with only a few environmental parameters (Chapter 6). In 
WKLVSDUWLFXODUFDVHDVLPSOHPRGHOZDVVXIÀFLHQWWRSUHGLFWLQWHUQDOFRQVXPHU
exposure to D5. In current consumer exposure modelling, however, a tiered 
approach is used. Especially in the higher tiers, sophisticated and more complex 
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models are applied. Acknowledging the results of Chapter 6, researchers and risk 
DVVHVVRUVRU UHJXODWRUVDUHHQFRXUDJHGWRÀQGDEDODQFH LQ WKHQHHGVRIERWK
SDUWLHVZKHQGHYHORSLQJDQGUHÀQLQJH[SRVXUHPRGHOV
Future perspectives
Traditionally, hazard characterization based on dose-response relationships forms 
the basis for human health risk assessment. However, the increasing number of 
chemicals that need to be evaluated and the restrictions on the use of animals for 
WR[LFLW\WHVWLQJPDNHLWLQFUHDVLQJO\GLIÀFXOWWRJDWKHUWKHWR[LFRORJLFDOGDWDQHHGHG
for hazard characterization. The European Commission as well as the RISK21 
project employed by the Health and Environmental Sciences Institute (HESI) in 
the US propose a paradigm shift in human health risk assessment, i.e. a shift 
in primacy from hazard to exposure assessment (25, 26). By making exposure 
DVVHVVPHQW WKH ÀUVW VWHS LQ WKH ULVN DVVHVVPHQW SURFHVV UHOHYDQW H[SRVXUH
VFHQDULRVLGHQWLÀHGZLOOOLPLWWKHQXPEHURIWR[LFRORJLFDOGDWDQHHGHGIRUKD]DUG
characterization. To establish this paradigm shift, the development of exposure 
assessment is crucial as it has been the weakest part of human risk assessment 
VRIDU7RLPSURYHH[SRVXUHDVVHVVPHQWWKH6FLHQWLÀF&RPPLWWHHRQ(PHUJLQJDQG
1HZO\ ,GHQWLÀHG+HDOWK5LVN 6&(1,+5 WKH6FLHQWLÀF&RPPLWWHHRQ&RQVXPHU
6DIHW\6&&6DQGWKH6FLHQWLÀF&RPPLWWHHRQ+HDOWKDQG(QYLURQPHQWDO5LVNV
(SCHER) of the European Commission (25) proposed the following actions:
x The development of an academic discipline at major universities;
x The improvement of methodology;
x Shifting the focus from single to multiple exposures;
x Giving more attention to biotransformation and transport of chemicals 
in the body. 
Following their proposal to shift from hazard to exposure, the European Commission 
should practice what they preach. At the moment, we believe that this paradigm 
shift does not receive the attention it deserves. The European Commission could 
facilitate the actual shift, by implementing an addendum to the REACH legislation 
and providing funds to support exposure research. This addendum should 
state that the risk assessment  required for the REACH registration must start 
ZLWK H[SRVXUH DVVHVVPHQW LQVWHDG RI KD]DUG DVVHVVPHQW 6FLHQWLÀF UHVHDUFK
IRFXVVLQJRQWKHEHQHÀWVRIWKHSDUDGLJPVKLIWFRXOGVXSSRUWWKHLPSOHPHQWDWLRQ
RIWKLVQHZOHJDOIUDPHZRUN)XUWKHUPRUHDVVWDWHGDERYHWKHIRFXVRIVFLHQWLÀF
research should be on the improvement of exposure assessment in general.  
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The development of the US EPA Exposure Factors Handbook, the ExpoFacts 
database in Europe, and similar documents in Australia, Canada, Japan, Korea, 
and Taiwan have led to a large collection of exposure factors. Recently, all available 
UHVRXUFHVZHUHH[DPLQHGDQGVHYHUDOJDSVZHUHLGHQWLÀHG(27):
x Reporting on inter-individual variation is inconsistent;
x Information on intra-individual variation is limited;
x Information on infants and pregnant and lactating women is limited;
x Not all databases are available online.
To close these gaps, more intense international collaboration between researchers 
is required, as protocols need to be developed to collect and report exposure 
factors in a standardized manner. At the moment, differences in collected 
exposure factors among individuals are studied. In addition to these differences, 
exposure factors may differ within an individual over time, for example, due to 
VHDVRQDOLQÁXHQFHVRQWKHXVHRIWDQQLQJSURGXFWVRUVRFLDOLQÁXHQFHVRQWKHXVH
of cosmetics (e.g., a day at work versus a night out). In the future, when collecting 
data on exposure factors, research should focus on the collection of longitudinal 
data to investigate the intra-individual variation. Compared to adults, children are 
often more sensitive to the potential adverse effects of exposure to chemicals 
and may be higher exposed. In combination with more or less unpredictable 
behaviour of children, the collection of exposure factors representing this group is 
especially important. Furthermore, the collection of exposure factors representing 
pregnant and lactating women is of interest, as some chemicals reach the unborn 
or newborn infant via the placenta or the breast milk.    
During the 7th International Conference on the Science of Exposure Assessment 
(X2012), the statement was made that consumer exposure research receives 
increased attention initiated by industry, and motivated by the REACH legislation. 
However, it was also emphasized that current consumer exposure research 
JHQHUDOO\IRFXVHVRQDVPDOOQXPEHURIVSHFLÀFSURGXFWVRULQJUHGLHQWVZKHUHDV
many other potentially harmful chemicals are present in common household 
products and PCPs (28). Therefore, future research should focus on a wider 
range of chemicals or chemical classes, e.g., nanomaterials. A growing number of 
PCPs contain nanomaterials, which are added to improve stability and enhance 
penetration of cosmetic ingredients (e.g., vitamins or antioxidants), and to make 
products more aesthetically appealing (29). In 2008, Hansen and co-workers 
ZHUHWKHÀUVWWRSHUIRUPDFRQVXPHUH[SRVXUHDVVHVVPHQWIRUFRVPHWLFSURGXFWV
containing nanomaterials (30)7KHDXWKRUVLGHQWLÀHGLPSRUWDQWSRLQWVKDPSHULQJ
this exposure assessment, such as the characterization and the concentration of 
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nanomaterials in cosmetics. To aid risk assessment, the SCCS provided guidance 
on the safety assessment of nanomaterials in cosmetics (31). Although worker’s 
exposure to nanomaterials has been investigated widely, information on consumer 
exposure scenarios and exposure measurements is still scarce (32). In future 
UHVHDUFK WKH ÀUVW VWHSZRXOG EH WR LGHQWLI\ DQG FKDUDFWHUL]H QDQRPDWHULDOV LQ
cosmetics and subsequently to use this information in a human exposure study to 
investigate realistic consumer exposure. 
The research described in this thesis did not provide more data on the determinants 
of aggregate consumer exposure to PCPs that can be used in further development 
of exposure models. Fortunately, other researchers investigated this issue as well. 
In 2013, members of the TAGS (Tiered Aggregate Exposure Assessment) project 
proposed an aggregate exposure assessment method, which was divided into 
three tiers (33): 
x Tier 0, preliminary information on the substance is collected and 
interpreted to decide whether aggregate exposure assessment could be 
relevant;
x Tier 1, a screening-level aggregate assessment is performed based on 
the information obtained in Tier 0, using simple deterministic exposure 
calculations to decide whether a potential risk exists and how routes and 
exposure pathways contribute;
x Tier 2, a full quantitative aggregate assessment is performed to determine 
human exposure using complex deterministic or probabilistic modelling.
Evaluating their proposed method, the TAGS team used consumer exposure to 
bisphenol A (BPA) as an example. Instead of the proposed Tier 2 analysis, a two-
step Tier 2 analysis was conducted by including toxicokinetic modelling. This 
example shows that there is still a need for guidance on how to perform aggregate 
consumer exposure assessment, especially in the higher Tiers. The results in this 
thesis, however, indicate that the possibilities of lower Tier aggregate consumer 
exposure assessment  deserve attention as well.  
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To realize a high protection level for human health and the environment, 
the European Union established legislation on the Registration, Evaluation, 
Authorisation and Restriction of chemicals (REACH). Within this legislation, 
manufacturers are responsible to provide all possible information about the safety 
of chemicals that are produced and marketed. Human health risk assessment, 
FRQVLVWLQJRIKD]DUGLGHQWLÀFDWLRQKD]DUGFKDUDFWHUL]DWLRQH[SRVXUHDVVHVVPHQW
and risk characterization is required for chemicals that are imported or 
manufactured in a quantity over 10 tonnes per year.
Consumers are exposed to a wide variety of consumer products, such as personal 
care products (PCPs), possibly leading to aggregate exposure of common chemical 
LQJUHGLHQWV$JJUHJDWHH[SRVXUHLVGHÀQHGDVH[SRVXUHWRDVLQJOHFKHPLFDOYLD
all exposure routes and from different sources. Consumer exposure assessment 
is an important aspect of the risk assessment process. Currently, the preferred 
method to estimate consumer exposure is based on a tiered (stepwise) modelling 
DSSURDFK %RWK WKH (XURSHDQ &KHPLFDO $JHQF\ (&+$ DQG WKH 6FLHQWLÀF
Committee on Consumer Safety (SCCS) have stressed the importance of including 
aggregate exposure in consumer exposure assessment. However, current higher 
tier exposure models do not account for aggregate exposure. Thus, more data 
are needed to further develop consumer exposure models and improve the risk 
assessment of PCPs.
To improve risk assessment of PCPs, this thesis aims at obtaining better insight into 
consumer exposure to PCPs. This primary aim is subdivided into three objectives:
1. To construct a database consisting of exposure factors related to the use 
of PCPs by Dutch consumers.
2. To investigate internal exposure to substances in PCPs after dermal 
administration of a single product and the combined use of two products 
(aggregate exposure). 
3. 7R UHÀQH DQG DSSO\ D SK\VLRORJLFDOO\ EDVHG SKDUPDFRNLQHWLF 3%3.
model to simulate aggregate consumer exposure to substances in PCPs. 
This thesis starts with a general introduction to human health risk assessment, 
and in particular consumer exposure assessment (Chapter 1). Subsequently, in 
Chapter 2 a database is presented with PCP exposure factors, such as usage 
patterns and circumstances of use, collected from Dutch consumers. The 
collection of end-exhaled air is a person-friendly, non-invasive and rapid way to 
collect biological samples. Compared to blood and urine, exhaled air is more 
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easily accessible and its collection will cause less discomfort and embarrassment 
for the study participants. The use of end-exhaled air analysis in human exposure 
assessment is described in a literature review (Chapter 3). Wide-spread use 
of end-exhaled air analysis is currently hampered by a lack of background and 
guidance values, especially if the parent compound or metabolite is also produced 
endogenously. Nevertheless, the method has great potential to be widely used, 
e.g. in sample collection by self-administration, on-line sampling, and real-time 
analysis. 
PCPs consist of many different substituents, which complicate the analysis 
of internal exposure to the different compounds and the interpretation of 
the results. Therefore, this thesis was focussed on two compounds that 
were used as model substances, i.e., octamethylcyclotetrasiloxane (D4) and 
decamethylcyclopentasiloxane (D5). Chapter 4 describes the development of an 
analytical method to quantify D4 and D5 in end-exhaled air by thermal desorption 
gas chromatography mass spectrometry (TD-GC-MS). Using this sensitive 
technique, aggregate dermal exposure to D4 and D5 was investigated (Chapter 
5). D4 and D5, as pure substances and as ingredients of a deodorant and a night 
cream, were both applied to the skin of human volunteers. The concentration 
of D4 and D5 in end-exhaled air was used as a proxy for internal exposure. The 
results indicated that dermal absorption of D4 and D5 contributes only marginally 
to internal exposure following dermal application. Instead, inhalation appeared 
WR EH WKHPDMRU SDWKZD\ UHVSRQVLEOH IRU LQWHUQDO H[SRVXUH ,Q D VHSDUDWH ÀHOG
study, realistic inhalation exposure to D5 after application of a deodorant was 
investigated (Chapter 6). The data obtained were used to develop a linear 
UHJUHVVLRQPRGHO DQG UHÀQHDQH[LVWLQJSK\VLRORJLFDOO\ EDVHGSKDUPDFRNLQHWLF
(PBPK) model for the prediction of internal exposure. The linear regression model 
performed best. As this model only consisted of environmental variables, we 
concluded that these variables are more important than personal characteristics 
to predict internal exposure to D5 from the use of a deodorant. 
This thesis concludes with a general discussion, which considers among others 
the generalizability of the results and the appropriateness of the selected model 
substances. In collaboration with the other research partners in the European 
project (CEFIC-LRI), D4 and D5 were chosen as model substances. In hindsight, 
this choice was probably not the best to investigate aggregate dermal consumer 
exposure. Nonetheless, some of the insights presented in Chapters 5 and 6 can 
EH H[WUDSRODWHG WR PRUH JHQHUDO FRQFOXVLRQV DSSOLFDEOH WR WKH HQWLUH ÀHOG RI
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consumer health risk assessment, such as the suggestion that dermal absorption 
is not always the main route of uptake of ingredients present in PCPs (Chapter 5) 
DQGWKHQRWLRQWKDWVLPSOHH[SRVXUHPRGHOVPLJKWEHVXIÀFLHQWWRSUHGLFWLQWHUQDO
exposure to PCP ingredients (Chapter 6). 
$VDUHVXOWRIWKHÀUVWREMHFWLYHRIWKLVWKHVLVZHFRQVWUXFWHGDQH[SRVXUHIDFWRUV
database representing the PCP usage pattern and circumstances of use among 
'XWFKFRQVXPHUV:HZHUHXQDEOHWRIXOÀOWKHVHFRQGREMHFWLYHDVZHFRQFOXGHG
that inhalation and not dermal absorption was the major route of uptake 
responsible for internal exposure to D4 and D5. The third objective was rephrased, 
as we shifted the focus from dermal absorption to inhalation exposure, into: “To 
GHYHORSQHZDQGUHÀQHH[LVWLQJPRGHOVWRSUHGLFWLQWHUQDOFRQVXPHULQKDODWLRQ
exposure to PCPs”. This resulted in the development of a linear regression model 
DQGWKHUHÀQHPHQWRIDQH[LVWLQJ3%3.PRGHODQGZHFRQFOXGHGWKDW LQWHUQDO
exposure was best predicted using a simple linear regression model with only a 
few environmental parameters.
The general discussion concludes with recommendations for future research. The 
most important recommendation is a proposed paradigm shift in human health 
risk assessment, i.e. a shift in primacy from hazard to exposure assessment. 
This paradigm shift has also been proposed by the European Commission as 
ZHOODVWKH5,6.SURMHFW%\PDNLQJH[SRVXUHDVVHVVPHQWWKHÀUVWVWHSLQWKH
ULVN DVVHVVPHQW SURFHVV UHOHYDQW H[SRVXUH VFHQDULRV LGHQWLÀHG ZLOO OLPLW WKH
number of toxicological data needed for hazard characterization. The European 
Commission could facilitate the actual shift by implementing an addendum to the 
REACH legislation and providing funds to support exposure research, particularly 
on aggregate exposure. The addendum should state that the REACH risk 
assessments must start with exposure assessment instead of hazard assessment.
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Om zowel de mens als het milieu te beschermen, heeft de Europese Unie wetgeving 
geïmplementeerd rond de Registratie, Evaluatie, Autorisatie en restrictie van 
Chemische stoffen (REACH). Krachtens deze wet is het de verantwoordelijkheid 
van de producent om aan te tonen dat de chemische stoffen die worden 
geproduceerd en op de markt worden gebracht geen schade aanrichten aan 
de mens of het milieu. Producenten zijn in dit kader verplicht om een humane 
risicobeoordeling uit te voeren voor chemische stoffen die in hoeveelheden van 
meer dan tien ton worden geïmporteerd of op de markt worden gebracht. Deze 
ULVLFREHRRUGHOLQJEHVWDDWXLWYLHUVWDSSHQJHYDDULGHQWLÀFDWLHDDQGHKDQGYDQ
de intrinsieke eigenschappen van de stof, (2) beschrijving van de relatie tussen 
blootstelling en effect (effectkarakterisering), (3) schatting van de blootstelling en 
(4) karakterisering van het risico. 
Door het gebruik van een breed scala aan consumentenproducten, waaronder 
persoonlijke verzorgingsproducten, wordt de consument blootgesteld aan 
verschillende chemische stoffen. Het gebruik van deze producten leidt mogelijk tot 
geaggregeerde blootstelling. Geaggregeerde blootstelling is de totale blootstelling 
aan één chemische stof via alle bronnen en blootstellingsroutes gezamenlijk. Het 
bepalen van de blootstelling is een belangrijk aspect van de risicobeoordeling. De 
beoordeling is een stapsgewijs proces waarbij veelal modellen worden gebruikt. 
In eerste instantie wordt gebruik gemaakt van een relatief simpel model, terwijl 
bij eventuele vervolgstappen complexere modellen worden toegepast. Zowel het 
Europees Agentschap voor chemische stoffen (ECHA) als de wetenschappelijke 
commissie voor consumentenveiligheid (SCCS) van de Europese Unie 
benadrukken dat geaggregeerde blootstelling onderdeel moet zijn van het 
inschatten van consumentenblootstelling. Op dit moment houden de meeste 
bestaande modellen geen rekening met geaggregeerde blootstelling. Om deze 
modellen verder te ontwikkelen is meer informatie nodig over de determinanten 
die geaggregeerde consumentenblootstelling bepalen. 
Dit proefschrift heeft als doel om inzicht te verwerven in de consumenten-
blootstelling aan persoonlijke verzorgingsproducten ten einde de risicobeoordeling 
van deze producten verder te optimaliseren. Dit primaire doel is opgedeeld in drie 
onderzoeksvragen:
1. Het verzamelen en registreren van gegevens over de factoren die de 
blootstelling aan persoonlijke verzorgingsproducten bij Nederlandse 
consumenten bepalen.
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2. Het onderzoeken van de inwendige blootstelling aan ingrediënten van 
persoonlijke verzorgingsproducten nadat in eerste instantie één product 
op de huid is aangebracht, en in een later stadium twee producten 
(geaggregeerde blootstelling). 
3. Het verbeteren en toepassen van een semifysiologisch farmacokinetisch 
model om met behulp van dit model geaggregeerde interne blootstelling 
aan ingrediënten van persoonlijke verzorgingsproducten te simuleren. 
Dit proefschrift begint met een algemene introductie over humane risicobeoordeling, 
waarbij het accent ligt op het inschatten van de consumentenblootstelling 
(Hoofdstuk 1). Hoofdstuk 2 presenteert een database met gegevens over factoren 
die de blootstelling aan persoonlijke verzorgingsproducten bij Nederlandse 
consumenten bepalen, zoals gebruikspatronen en –omstandigheden. 
Het verzamelen van ademlucht is een snelle, niet invasieve en daardoor weinig 
belastende manier om een biologisch monster bij een proefpersoon te nemen. 
Ademlucht is, in vergelijking met bloed en urine, beter toegankelijk, comfortabeler 
en zorgt daardoor voor minder onbehagen bij de proefpersoon. Hoofdstuk 
3 beschrijft het gebruik van ademluchtanalyse voor de inschatting van de 
blootstelling. Tot op heden wordt grootschalige toepassing van ademluchtanalyse 
beperkt door een gebrek aan referentiewaarden. Dit is vooral een knelpunt 
wanneer chemische stoffen en/of metabolieten in het lichaam worden gevormd. 
Desondanks heeft ademluchtanalyse de potentie om breed te worden ingezet, 
bijvoorbeeld bij monstername door de proefpersonen zelf en het direct verzamelen 
en analyseren van monsters op locatie. 
Persoonlijke verzorgingsproducten bestaan uit vele verschillende ingrediënten. 
Het is praktisch niet haalbaar om de inwendige blootstelling aan al deze stoffen 
te analyseren en de resultaten te interpreteren. Daarom richt dit proefschrift zich 
RSWZHHVSHFLÀHNHLQJUHGLsQWHQYDQSHUVRRQOLMNHYHU]RUJLQJVSURGXFWHQQDPHOLMN
octamethylcyclotetrasiloxaan (D4) en decamethylcyclopentasiloxaan (D5). Deze 
stoffen zijn gebruikt als modelstof. Hoofdstuk 4 beschrijft de ontwikkeling van een 
analysemethode om D4 en D5 in uitgeademde lucht met behulp van thermische 
GHVRUSWLHJDVFKURPDWRJUDÀHPDVVDVSHFWURPHWULH 7'*&06 WH NZDQWLÀFHUHQ
Met deze gevoelige analysemethode is de geaggregeerde blootstelling aan D4 
en D5 via de huid onderzocht (Hoofdstuk 5). Daartoe is D4 en D5 op de huid 
van vrijwilligers aangebracht; als pure stof en als ingrediënt van een deodorant 
en nachtcrème. De concentratie D4 en D5 in uitgeademde lucht diende als 
benadering van de inwendige blootstelling. De huidopname van D4 en D5 
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bleek marginaal bij te dragen aan de inwendige blootstelling. Daarentegen 
bleek inhalatie de belangrijkste opnameroute te zijn. Gebaseerd op deze 
resultaten is de inhalatoire blootstelling aan D5 in een aparte studie gemeten 
na het aanbrengen van een deodorant onder realistische omstandigheden 
in de badkamer bij de proefpersoon thuis (Hoofdstuk 6). De verkregen data 
zijn gebruikt om een lineair regressiemodel te ontwikkelen en een bestaand 
VHPLI\VLRORJLVFKIDUPDFRNLQHWLVFKPRGHOWHYHUÀMQHQ0HWEHLGHPRGHOOHQLVGH
inwendige blootstelling voorspeld. Het lineair regressiemodel, bestaande uit alleen 
omgevingsvariabelen, voorspelde de inwendige blootstelling het beste. Daarom 
concludeerden wij dat omgevingsvariabelen belangrijker zijn dan persoonlijke 
variabelen voor het voorspellen van de inwendige blootstelling aan D5 na het 
gebruik van een deodorant. 
Dit proefschrift eindigt met een algemene discussie. In deze discussie wordt 
onder andere de generaliseerbaarheid van de studies in dit proefschrift en de 
keuze voor de modelstoffen besproken. De resultaten uit hoofdstuk 5 en 6 kunnen 
naar meer algemene conclusies worden vertaald die van toepassing zijn op het 
volledige veld van risicobeoordeling voor de consument. Dit geldt bijvoorbeeld 
voor de constatering dat huidopname niet altijd de belangrijkste opnameroute 
is voor ingrediënten van persoonlijke verzorgingsproducten (Hoofdstuk 5) en 
dat eenvoudige blootstellingsmodellen de inwendige blootstelling voldoende 
voorspellen (Hoofdstuk 6). D4 en D5 zijn als modelstoffen gekozen, omdat deze 
stoffen voldeden aan een aantal selectiecriteria dat we vooraf samen met onze 
partners uit het Europese onderzoeksproject (CEFIC-LRI) hadden opgesteld. 
Terugkijkend was deze keuze misschien niet optimaal om de geaggregeerde 
consumentenblootstelling via de huid te onderzoeken. 
De eerste onderzoeksvraag van dit proefschrift resulteerde in een database met 
factoren die het gebruik van persoonlijke verzorgingsproducten bij Nederlandse 
consumenten verklaren. Het was niet mogelijk om de tweede onderzoeksvraag 
te beantwoorden, omdat wij concludeerden dat de inwendige blootstelling aan 
D4 en D5 voornamelijk door inhalatie, en niet door huidopname, wordt bepaald. 
Doordat de focus van blootstelling via huidopname naar blootstelling via inhalatie 
verschoof, is de derde onderzoeksvraag geherformuleerd: “Het ontwikkelen van 
QLHXZH HQ KHW YHUÀMQHQ YDQ EHVWDDQGH PRGHOOHQ RP LQZHQGLJH EORRWVWHOOLQJ
na inhalatie te voorspellen”. Dit heeft geresulteerd in de ontwikkeling van een 
OLQHDLU UHJUHVVLHPRGHO HQ GH YHUÀMQLQJ YDQ HHQ EHVWDDQG VHPLI\VLRORJLVFK
farmacokinetisch model. Inwendige blootstelling werd het best voorspeld door 
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een simpel lineair regressiemodel bestaande uit alleen omgevingsvariabelen. 
De algemene discussie eindigt met verschillende aanbevelingen voor verder 
onderzoek. De belangrijkste aanbeveling is een verschuiving in het humane 
risicobeoordelingsparadigma, namelijk van effectkarakterisering naar 
blootstellingsschatting. Deze verschuiving is voorgesteld door zowel de Europese 
Commissie als door leden van het RISK21-project in de Verenigde Staten. 
Door de blootstellingsinschatting te prevaleren boven de effectkarakterisering 
ZRUGHQ DOOHHQ UHOHYDQWH EORRWVWHOOLQJVFHQDULR·V JHwGHQWLÀFHHUG 'H EHQRGLJGH
toxicologische data voor effectkarakterisering worden hiermee verkleind. De 
Europese Commissie kan deze verschuiving faciliteren door een addendum toe 
te voegen aan de REACH-wetgeving en extra fondsen beschikbaar te stellen voor 
wetenschappelijk onderzoek. In het addendum moet worden vastgelegd dat bij 
het uitvoeren van een humane risicobeoordeling de blootstellingsinschatting 
prevaleert boven de effectkarakterisering. 
Chapter 10
Dankwoord
About the author
List of publications
PhD portfolio
Chapter 10
300
Dankwoord
Misschien is het dankwoord wel het moeilijkste gedeelte van het proefschrift om 
te schrijven. Krijg ik de juiste woorden op papier? Ben ik niemand vergeten? Dit 
zijn moeilijke vragen zo aan het eind van dit promotietraject. In ieder geval is het 
dankwoord wel het meest gelezen gedeelte van elk proefschrift. Een extra reden 
om mijn best te doen.
Allereerst wil ik mijn vrijwilligers bedanken. Alle vrouwen en mannen die zich op 
het lab hebben laten insmeren, die geduldig vele ademlucht- en urinemonsters 
afstonden en uren onder de ‘droogkap’ doorbrachten. En natuurlijk alle vrouwen 
en mannen die mij verwelkomden in hun badkamer thuis. Dank voor alle leuke 
gesprekken met kopjes thee en koekjes.   
Frans, Ad, Paul en Nel. Als mijn begeleidingsteam vormden jullie met ieder zijn/
haar eigen expertise een dynamisch vierspan. Saai waren onze overleggen nooit. 
Frans, bedankt voor het feit dat je mij als promovendus aangenomen hebt zonder 
mij te ontmoeten. Ik weet niet wat Paul, Nel en Ad gezegd hebben na mijn sollicitatie, 
maar dat spreekt van vertrouwen! Ad, je bent een echte docent. Met veel toewijding 
en geduld heb je mij het programmeren/modelleren bijgebracht. Dank hiervoor. 
Paul, in het begin moesten wij beiden wennen aan de samenwerking maar 
uiteindelijk zijn we een geolied team geworden. Je gedrevenheid met betrekking 
tot wetenschappelijk onderzoek en je enthousiasme voor biomonitoring hebben 
mij geïnspireerd. Ik wil je enorm bedanken voor alles wat je mij de afgelopen jaren 
hebt geleerd. Nel, het feit dat jouw deur altijd open stond zodat ik even plaats kon 
nemen op ‘de bank’ om mijn hart te luchten heeft ervoor gezorgd dat ik elke keer 
weer de moed vond om door te gaan. 
Thanks to all the members of the CEFIC project team, Natalie, Tanya, Christiaan, 
Bas and Martine! We had wonderful times in Nijmegen, Bilthoven, Zürich and 
Cincinnati. 
Rob en Gwendolyn, mijn collega’s op het lab. Rob, jij zorgde altijd voor een 
vrolijke noot en wist mij vaak te verrassen met een truc uit de scheikundedoos. 
Gezelligheid ten top! Gwendolyn, wat moest ik zonder jou? Ik heb geprobeerd uit 
te rekenen hoe vaak wij de buizen in onze handen hebben gehad tijdens mijn 
onderzoek. Op een gegeven moment ben ik maar gestopt met tellen… Het was 
niet te doen. Ik bewonder jouw inzet en passie voor het lab. Bij nacht en ontij 
stond jij te werken. Wat hebben wij ook samen staan vloeken toen de TD het weer 
eens niet deed en staan juichen toen de uitstook unit geïnstalleerd werd. Het was 
onmogelijk geweest dit project zonder jou tot een goed einde te brengen. Je bent 
super!
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Speciaal gekocht voor mijn promotietraject, een gloednieuwe TD-GC-MS. Groot 
was dan ook de frustratie toen gaandeweg bleek dat de TD niet altijd even 
betrouwbaar was. Gelukkig konden wij rekenen op Rini! Rini, ik hoefde maar 
naar Interscience te bellen en je stond diezelfde week en soms aan het eind van 
diezelfde dag op de stoep. Een strakke planning zorgde ervoor dat de TD niet stil 
kon staan. Door jouw kennis en kunde hebben we het altijd gered om de buizen 
geanalyseerd en schoongemaakt te krijgen voordat de volgende vrijwilliger weer 
kwam. 
Nelleke en Jeroen, jullie waren mijn eerste kamergenoten. Nelleke, bedankt voor 
het voorbereidende werk rond de CMO-aanvraag, je hulp bij het ontwikkelen van 
de vragenlijst en het eindeloos veranderen van het SNAP-bestand. Jeroen, ik heb 
enorm genoten van de gesprekken die wij hadden over echt van alles en nog wat. 
Het was gezellig, soms misschien iets te gezellig en moest ik moeite doen om 
toch nog iets gedaan te krijgen die dag… Luuk, naast mijn kamergenoot was je 
ook mijn maatje bij het uitvoeren van de badkamerstudie. We hebben heel wat 
ritjes gemaakt in het rode autootje volgeladen met apparatuur. Op een gegeven 
moment waren we net twee “kneuzen” op pad. De een met een dikke buik en de 
ander met slechte knieën. Gelukkig hebben we alle metingen weten te volbrengen 
door het zware werk te verdelen. Trouwens wel frappant dat zodra de meetperiode 
afgelopen was het koekblik aan de kant werd gedaan en er een dikke Volvo voor 
in de plaats kwam... Dank voor je hulp en succes met je eigen promotietraject. 
Na mijn verhuizing naar de derde verdieping werd ik losgekoppeld van het lab. 
Gelukkig werd ik boven goed opgevangen door Kevin en Sophie. Dank voor alle 
gesprekken over de zin en onzin van het leven, het promoveren en het kopen en/
of verbouwen van een huis.  
De laatste van een generatie promovendi op de afdeling Health Evidence die 
promoveert. Al mijn medepromovendi wil ik graag bedanken voor de etentjes, 
avonden met spelletjes en karaoke. Even de zinnen verzetten en lachen om 
het leed dat promoveren heet. Ook de andere collega’s van de afdeling HEV 
EHGDQNWYRRUGHJH]HOOLJKHLGWLMGHQVGHNRIÀHSDX]HVDOGDQQLHWPHWFDNHGH
bowlingavonden, dagjes uit, etc.
BMW for life! Carolien, Nicolien, Mariska, Rianne, Mireille, Mieke en Linda. In 2005 
zijn we allemaal begonnen aan de studie biomedische wetenschappen. Inmiddels 
zijn we uitgevlogen en gaan we allemaal onze eigen weg. Samen met jullie kon ik 
onder het genot van eindeloze kopjes thee praten over de ups en downs van een 
promotietraject. Mijn belangrijkste bevindingen…. Ieder traject heeft zijn eigen 
problemen en het kan altijd erger. Ik hoop dat wij in de toekomst nog vaak bij 
elkaar mogen komen om spelletjes te spelen, sinterkerst te vieren of weekendjes 
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weg te gaan. Wie vergeet het hostel in Milaan, de kou in Krakau of Koos Konijn in 
Bad Bentheim?!
Meiden van het Gym. Suzanne, Esther, Sietske, Monique en Marieke. Ook jullie 
bedankt voor de kopjes thee en de etentjes om even te ontspannen!
Ik ben bijna aan het eind van het dankwoord. Dus is het tijd voor de (schoon)
IDPLOLH-RNHHQ)UHHN0DULsOOHHQ)UDQNKHW LVÀMQ WHZHWHQGDWGHGHXUDOWLMG
open staat en dat Geeke en Robbe bij jullie in goede handen zijn. Ontspanning 
door middel van een spelletje, een gekookte maaltijd of een nachtje doorslapen. 
Bedankt!
Syl, zusje. Samen met Matthijs had je de eer om zowel bij Geeke als bij Robbe de 
eerste te zijn waar zij logeerden. Fijn om even ontlast te worden. Dank voor de lol 
die je samen met Matthijs en Robert brengt, ook al ben ik dan vaak het lijdend 
voorwerp. Dat we nog vaak onder de bank mogen rollen van het lachen!
Lieve pap en mam. Bedankt voor jullie onvoorwaardelijke steun. De ontelbare ritjes 
met de auto, handbal, dansles of een feestje. Geen probleem. De avonden met 
goede raad, daar waar ik het huilend niet meer zag zitten (die meneer van Latijn…). 
Het leven gaat verder en de rol van ouder veranderd, maar de onvoorwaardelijke 
VWHXQEOLMIW+HWLVÀMQRPWHZHWHQGDW5REHUW*HHNH5REEHHQLNDOWLMGELMMXOOLH
terecht kunnen, wat er ook gebeurt. 
Als laatste is Robert. Lief, het is inmiddels 12,5 jaar geleden dat wij na een zomer 
YDQÀHWVHQDDQGH,-VVHO]LWWHQHQRPHONDDUKHHQGUDDLHQEHVORWHQHHQVWHOWH
worden. Met je positiviteit, humor en relaxedheid zorg je ervoor dat ik het leven 
niet te serieus neem. De afgelopen jaren waren niet altijd even gemakkelijk, maar 
zoals wij altijd zeggen: “Samen kunnen wij de wereld aan”. Ik hoop dat wij samen 
met Geeke en Robbe nog vele jaren van het leven kunnen genieten. Ik houd van 
jullie!
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